tokens,ner_tags,id,nct_id,text,ner_manual_ct_target
"['Modafinil', 'for', 'Treatment', 'of', 'Cognitive', 'Dysfunction', 'in', 'Schizophrenia', '|', 'Patients', 'with', 'schizophrenia', 'have', 'problems', 'in', 'thinking', ',', 'known', 'as', 'cognitive', 'dysfunction', '.', 'This', 'appears', 'to', 'be', 'responsible', 'for', 'their', 'difficulties', 'in', 'social', 'and', 'occupational', 'functioning', '.', 'One', 'particular', 'cognitive', 'function', 'that', 'may', 'be', 'important', 'for', 'schizophrenia', 'is', 'called', 'context', 'processing', '.', 'This', 'refers', 'to', 'the', 'ability', 'to', 'properly', 'use', 'information', 'in', 'the', 'environment', 'to', 'guide', 'thinking', 'and', 'behavior', 'so', 'that', 'it', 'is', 'appropriate', 'to', 'the', 'present', 'circumstance', '.', 'Problems', 'with', 'this', 'function', 'may', 'explain', 'why', 'patients', 'with', 'schizophrenia', 'think', 'and', 'act', 'in', 'unusual', 'ways', ',', 'and', 'often', 'have', 'problems', 'managing', 'aspects', 'of', 'their', 'lives', 'that', 'healthy', 'adults', 'take', 'for', 'granted', '.', 'This', 'cognitive', 'function', 'depends', 'on', 'a', 'region', 'of', 'the', 'brain', 'called', 'the', 'prefrontal', 'cortex', ',', 'which', 'shows', 'impaired', 'function', 'in', 'schizophrenia', 'as', 'well', '.', 'Unfortunately', ',', 'the', 'biochemical', 'aspects', 'of', 'this', 'dysfunction', 'are', 'presently', 'unknown', ',', 'and', 'it', 'is', 'not', 'clear', 'whether', 'current', 'psychiatric', 'medications', 'can', 'improve', 'this', 'function', '.', 'A', 'recent', 'FDA', '-', 'approved', 'medication', 'that', 'may', 'improve', 'this', 'function', 'is', 'modafinil', '.', 'Studies', 'in', 'animals', 'and', 'healthy', 'adults', 'show', 'that', 'this', 'medication', 'can', 'improve', 'cognitive', 'functions', 'which', 'are', 'related', 'to', 'context', 'processing', '.', 'We', 'plan', 'to', 'study', 'the', 'effects', 'of', 'modafinil', 'on', 'context', 'processing', 'and', 'the', 'brain', 'activity', 'that', 'underlies', 'this', 'function', '.', 'We', 'will', 'use', 'functional', 'MRI', 'and', 'electrophysiology', 'to', 'examine', 'the', 'effects', 'of', 'modafinil', ',', 'both', 'after', 'a', 'single', 'dose', 'and', 'after', 'sustained', '(', '4', 'week', ')', 'treatment', '.', 'We', 'predict', 'that', 'when', 'patients', 'receive', 'modafinil', 'they', 'will', 'perform', 'better', 'on', 'cognitive', 'tests', 'and', 'have', 'improved', 'activity', 'in', 'the', 'regions', 'of', 'the', 'brain', 'that', 'are', 'responsible', 'for', 'these', 'cognitive', 'processes', '.']","['B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00423943,NCT00423943,"Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia | Patients with schizophrenia have problems in thinking, known as cognitive dysfunction. This appears to be responsible for their difficulties in social and occupational functioning. One particular cognitive function that may be important for schizophrenia is called context processing. This refers to the ability to properly use information in the environment to guide thinking and behavior so that it is appropriate to the present circumstance. Problems with this function may explain why patients with schizophrenia think and act in unusual ways, and often have problems managing aspects of their lives that healthy adults take for granted. This cognitive function depends on a region of the brain called the prefrontal cortex, which shows impaired function in schizophrenia as well. Unfortunately, the biochemical aspects of this dysfunction are presently unknown, and it is not clear whether current psychiatric medications can improve this function. A recent FDA-approved medication that may improve this function is modafinil. Studies in animals and healthy adults show that this medication can improve cognitive functions which are related to context processing. We plan to study the effects of modafinil on context processing and the brain activity that underlies this function. We will use functional MRI and electrophysiology to examine the effects of modafinil, both after a single dose and after sustained (4 week) treatment. We predict that when patients receive modafinil they will perform better on cognitive tests and have improved activity in the regions of the brain that are responsible for these cognitive processes.","[(0, 9, 'DRUG', 'Modafinil'), (27, 48, 'CONDITION', 'Cognitive Dysfunction'), (52, 65, 'CONDITION', 'Schizophrenia'), (82, 95, 'CONDITION', 'schizophrenia'), (132, 153, 'CONDITION', 'cognitive dysfunction'), (309, 322, 'CONDITION', 'schizophrenia'), (571, 584, 'CONDITION', 'schizophrenia'), (1089, 1098, 'DRUG', 'modafinil'), (1269, 1278, 'DRUG', 'modafinil'), (1429, 1438, 'DRUG', 'modafinil'), (1543, 1552, 'DRUG', 'modafinil')]"
"['Task', 'Specific', 'Training', 'for', 'Stroke', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'see', 'if', 'providing', 'training', 'using', 'a', 'Sit', '-', 'to', '-', 'Stand', 'protocol', 'for', 'residents', 'of', 'Long', '-', 'Term', 'Care', 'Facilities', 'who', 'have', 'had', 'a', 'stroke', 'will', 'increase', 'their', 'independence', 'in', 'performing', 'Sit', '-', 'to', '-', 'Stand', '.']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O']",NCT00197509,NCT00197509,Task Specific Training for Stroke Patients | The purpose of this study is to see if providing training using a Sit-to-Stand protocol for residents of Long-Term Care Facilities who have had a stroke will increase their independence in performing Sit-to-Stand.,"[(0, 22, 'PHYSICAL', 'Task Specific Training'), (27, 33, 'CONDITION', 'Stroke'), (111, 132, 'PHYSICAL', 'Sit-to-Stand protocol'), (191, 197, 'CONDITION', 'stroke'), (245, 257, 'PHYSICAL', 'Sit-to-Stand')]"
"['We', 'Walk', 'Plus', 'Study', ':', 'A', 'Walking', 'Program', 'Using', 'Physical', 'Activity', 'Monitors', 'and', 'Social', 'Networking', 'for', 'Older', 'Adults', 'With', 'Intellectual', 'Disabilities', '|', 'Determine', 'the', 'feasibility', 'and', 'acceptability', 'of', 'We', 'Walk', 'Plus', 'intervention', 'to', 'promote', 'physical', 'activity', 'and', 'improve', 'cognition', 'for', 'older', 'adults', 'with', 'intellectual', 'disabilities', '(', 'ID', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT04573530,NCT04573530,We Walk Plus Study: A Walking Program Using Physical Activity Monitors and Social Networking for Older Adults With Intellectual Disabilities | Determine the feasibility and acceptability of We Walk Plus intervention to promote physical activity and improve cognition for older adults with intellectual disabilities (ID).,"[(22, 92, 'OTHER', 'Walking Program Using Physical Activity Monitors and Social Networking'), (115, 140, 'CONDITION', 'Intellectual Disabilities'), (190, 215, 'OTHER', 'We Walk Plus intervention'), (289, 314, 'CONDITION', 'intellectual disabilities'), (316, 318, 'CONDITION', 'ID')]"
"['Mechanism', 'of', 'Amantadine', 'and', 'Functional', 'Improvement', 'Following', 'Acquired', 'Brain', 'Injury', 'as', 'Measured', 'by', 'MRI', 'Tractography', ';', 'A', 'Pilot', 'Study', '|', 'This', 'is', 'a', 'pilot', 'study', '.', 'The', 'objective', 'is', 'to', 'further', 'understand', 'the', 'mechanism', 'by', 'which', 'amantadine', 'improves', 'function', 'in', 'patients', 'with', 'persistent', 'vegetative', 'state', 'and', 'minimally', 'conscious', 'state', '.', 'Specifically', ',', 'the', 'investigators', 'will', 'measure', 'the', 'size', 'of', 'the', 'nerve', 'fibers', 'that', 'mediate', 'arousal', '(', 'reticular', 'activating', 'system', ',', 'or', 'RAS', ')', 'pre', 'and', 'post', 'treatment', 'on', 'MRI', 'tractography', '.', 'MRI', 'findings', 'will', 'be', 'correlated', 'with', 'the', 'Disability', 'Rating', 'Scale', '(', 'DRS', ')', 'score', '.', 'The', 'information', 'gathered', 'from', 'this', 'study', 'will', 'be', 'used', 'to', 'formulate', 'a', 'larger', 'clinical', 'trial', '.']","['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02566720,NCT02566720,"Mechanism of Amantadine and Functional Improvement Following Acquired Brain Injury as Measured by MRI Tractography; A Pilot Study | This is a pilot study. The objective is to further understand the mechanism by which amantadine improves function in patients with persistent vegetative state and minimally conscious state. Specifically, the investigators will measure the size of the nerve fibers that mediate arousal (reticular activating system, or RAS) pre and post treatment on MRI tractography. MRI findings will be correlated with the Disability Rating Scale (DRS) score. The information gathered from this study will be used to formulate a larger clinical trial.","[(13, 23, 'DRUG', 'Amantadine'), (61, 82, 'CONDITION', 'Acquired Brain Injury'), (217, 227, 'DRUG', 'amantadine'), (263, 290, 'CONDITION', 'persistent vegetative state'), (295, 320, 'CONDITION', 'minimally conscious state')]"
"['Open', 'Trial', 'of', 'Median', 'Nerve', 'Stimulation', 'for', 'Treatment', 'of', 'Tourette', 'Syndrome', '|', 'A', 'recent', 'report', '(', 'Morera', 'Maiquez', 'et', 'al', '2020', ')', 'described', 'reduced', 'tic', 'severity', 'in', 'people', 'with', 'Tourette', 'syndrome', 'during', '1', '-', 'minute', 'epochs', 'of', 'median', 'nerve', 'stimulation', '(', 'MNS', ')', 'at', '10', 'Hz', '.', 'Among', 'the', 'various', 'questions', 'still', 'to', 'be', 'answered', 'is', 'the', 'question', 'of', 'whether', 'a', 'device', 'to', 'administer', 'MNS', 'is', 'practical', 'for', 'use', 'in', 'a', 'chronic', ',', 'real', '-', 'world', 'setting', '.', 'This', 'study', 'will', 'recruit', 'participants', 'who', 'complete', 'the', 'clinic', '-', 'based', ',', 'blinded', ',', 'randomized', 'controlled', 'trial', ',', 'https://clinicaltrials.gov/ct2/show/NCT04731714', ',', 'to', 'determine', 'the', 'real', '-', 'world', 'usage', 'and', 'apparent', 'utility', 'of', 'median', 'nerve', 'stimulation', 'in', 'people', 'with', 'chronic', 'tics', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT05016765,NCT05016765,"Open Trial of Median Nerve Stimulation for Treatment of Tourette Syndrome | A recent report (Morera Maiquez et al 2020) described reduced tic severity in people with Tourette syndrome during 1-minute epochs of median nerve stimulation (MNS) at 10 Hz. Among the various questions still to be answered is the question of whether a device to administer MNS is practical for use in a chronic, real-world setting. This study will recruit participants who complete the clinic-based, blinded, randomized controlled trial, https://clinicaltrials.gov/ct2/show/NCT04731714, to determine the real-world usage and apparent utility of median nerve stimulation in people with chronic tics.","[(14, 38, 'OTHER', 'Median Nerve Stimulation'), (56, 73, 'CONDITION', 'Tourette Syndrome'), (166, 183, 'CONDITION', 'Tourette syndrome'), (210, 234, 'OTHER', 'median nerve stimulation'), (236, 239, 'OTHER', 'MNS'), (350, 353, 'OTHER', 'MNS'), (622, 646, 'OTHER', 'median nerve stimulation'), (662, 674, 'CONDITION', 'chronic tics')]"
"['Effects', 'of', 'Hydrotherapy', 'on', 'Neuropathic', 'Pain', 'and', 'Pain', 'Catastrophization', 'in', 'Spinal', 'Cord', 'Injury', ':', 'Study', 'Protocol', 'for', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'Spinal', 'Cord', 'Injury', '(', 'SCI', ')', 'is', 'a', 'spinal', 'cord', 'injury', 'of', 'traumatic', 'origin', 'with', 'its', 'main', 'etiology', 'being', 'violence', ',', 'which', 'constitutes', 'one', 'of', 'the', 'greatest', 'social', 'and', 'health', 'problems', 'worldwide', '.', 'One', 'of', 'the', 'complications', 'with', 'the', 'greatest', 'impact', 'in', 'people', 'with', 'SCI', 'is', 'Neuropathic', 'Pain', '(', 'NP', ')', '.', 'Pain', ',', 'mainly', 'chronic', 'pain', ',', 'has', 'an', 'effect', 'on', 'emotional', 'states', ',', 'cognition', 'regarding', 'pain', 'and', 'anticipation', 'which', 'leads', 'to', 'the', 'catastrophization', 'of', 'the', 'pain', '.', 'This', 'form', 'of', 'pain', 'is', 'related', 'to', 'chronic', 'diseases', 'that', 'develop', 'with', 'pain', 'of', 'poor', 'prognosis', 'and', 'are', 'detrimental', 'to', 'quality', 'of', 'life', 'therefore', 'having', 'enormous', 'impacts', 'on', 'health', 'systems', '.', 'The', 'physiological', 'mechanisms', 'of', 'Hydrotherapy', 'on', 'pain', 'are', 'clear', 'and', 'there', 'is', 'evidence', 'of', 'its', 'use', 'in', 'the', 'management', 'of', 'painful', 'syndromes', 'of', 'difficult', 'treatments', 'such', 'as', 'that', 'for', 'fibromyalgia', 'and', 'chronic', 'lumbar', 'pain', ',', 'as', 'well', 'as', 'its', 'positive', 'effect', 'on', 'pain', 'perception', '.', 'However', ',', 'the', 'effects', 'of', 'hydrotherapy', 'on', 'the', 'NP', 'of', 'patients', 'with', 'SCI', 'are', 'unknown', '.', '\n\n', 'Randomized', ',', 'controlled', 'clinical', 'trial', 'of', 'parallel', 'groups', '.', 'A', 'randomized', 'sequence', 'will', 'be', 'carried', 'out', 'in', 'balanced', 'blocks', 'to', 'assign', 'the', 'intervention', '(', 'Hydrotherapy', ')', 'or', 'the', 'control', '(', 'Standard', 'Physical', 'Therapy', ')', ',', 'to', 'a', 'sample', 'of', '28', 'participants', ',', '14', 'for', 'each', 'group', '.', 'Each', 'of', 'the', 'interventions', '(', 'hydrotherapy', 'and', 'physical', 'therapy', ')', 'will', 'last', '9', 'weeks', ',', 'for', 'a', 'total', 'of', '18', 'sessions', '(', '2', 'weekly', 'sessions', ')', '.', 'Two', 'measurements', 'will', 'be', 'made', ',', 'baseline', '(', 'pre', '-', 'intervention', ')', 'and', 'a', 'second', 'time', 'one', 'month', 'after', 'the', 'end', 'of', 'the', 'intervention', '.', 'The', 'validated', 'Spanish', 'scales', 'will', 'be', 'used', ':', 'NP-4', '(', 'NP', 'Screening', ')', ',', 'Numerical', 'Pain', 'Scale', '(', 'END', ')', ',', 'PCS', '(', 'Pain', 'Catastrophization', ')', ',', 'SF-36', '(', 'Health', '-', 'related', 'quality', 'of', 'life', ')', 'and', 'WHODAS', '2.0', '(', 'Disability', ')', '.', 'The', 'primary', 'outcome', 'is', 'the', 'level', 'of', 'NP', 'and', 'its', 'catastrophization', ',', 'and', 'the', 'secondary', 'outcomes', 'are', 'level', 'of', 'disability', 'and', 'quality', 'of', 'life', '.', 'With', '28', 'participants', 'fully', 'measured', ',', 'it', 'is', 'possible', 'to', 'have', '80', '%', 'power', 'to', 'find', 'differences', 'between', 'the', 'groups', 'with', 'respect', 'to', 'the', 'primary', 'outcomes', '.', 'All', 'information', 'will', 'be', 'analyzed', 'using', 'average', 'comparisons', 'with', '95', '%', 'confidence', '.', 'The', 'analysis', 'will', 'be', 'carried', 'out', 'by', 'Intention', 'to', 'Treat', '(', 'ITT', ')', 'taking', 'all', 'the', 'randomized', 'participants', '.', 'Missing', 'data', 'will', 'be', 'processed', 'through', 'multiple', 'imputation', 'chains', '.', 'Generalized', 'mixed', 'linear', 'models', 'will', 'be', 'used', 'comparing', 'the', 'standardized', 'baseline', 'and', 'post', '-', 'intervention', 'averages', 'of', 'each', 'group', 'and', 'between', 'each', 'group', ',', 'obtaining', '95', '%', 'confidence', 'intervals', 'and', 'p', '-', 'values', '.', 'Subgroup', 'analysis', 'will', 'be', 'performed', 'adjusting', 'confounders', 'and', 'interactions', '.', 'A', 'significant', 'difference', 'will', 'be', 'considered', 'when', 'the', 'value', 'of', 'p', 'is', 'less', 'than', '0.05', '.', 'Cohen´s', 'D', 'will', 'be', 'calculated', 'to', 'identify', 'the', 'size', 'of', 'the', 'intervention', 'effect', '.', '\n\n', 'Discussion', ':', 'The', 'results', 'will', 'reflect', 'the', 'effect', 'of', 'the', 'hydrotherapy', 'on', 'NP', 'in', 'patients', 'with', 'SCI', '.', 'They', 'will', 'also', 'permit', 'the', 'identification', 'of', 'potential', 'changes', 'in', 'functionality', 'levels', 'or', 'quality', 'of', 'life', 'in', 'the', 'intervened', 'population', '.']","['O', 'O', 'B-PHYS', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04164810,NCT04164810,"Effects of Hydrotherapy on Neuropathic Pain and Pain Catastrophization in Spinal Cord Injury: Study Protocol for a Randomized Controlled Trial | Spinal Cord Injury (SCI) is a spinal cord injury of traumatic origin with its main etiology being violence, which constitutes one of the greatest social and health problems worldwide. One of the complications with the greatest impact in people with SCI is Neuropathic Pain (NP). Pain, mainly chronic pain, has an effect on emotional states, cognition regarding pain and anticipation which leads to the catastrophization of the pain. This form of pain is related to chronic diseases that develop with pain of poor prognosis and are detrimental to quality of life therefore having enormous impacts on health systems. The physiological mechanisms of Hydrotherapy on pain are clear and there is evidence of its use in the management of painful syndromes of difficult treatments such as that for fibromyalgia and chronic lumbar pain, as well as its positive effect on pain perception. However, the effects of hydrotherapy on the NP of patients with SCI are unknown.

Randomized, controlled clinical trial of parallel groups. A randomized sequence will be carried out in balanced blocks to assign the intervention (Hydrotherapy) or the control (Standard Physical Therapy), to a sample of 28 participants, 14 for each group. Each of the interventions (hydrotherapy and physical therapy) will last 9 weeks, for a total of 18 sessions (2 weekly sessions). Two measurements will be made, baseline (pre-intervention) and a second time one month after the end of the intervention. The validated Spanish scales will be used: NP-4 (NP Screening), Numerical Pain Scale (END), PCS (Pain Catastrophization), SF-36 (Health-related quality of life) and WHODAS 2.0 (Disability). The primary outcome is the level of NP and its catastrophization, and the secondary outcomes are level of disability and quality of life. With 28 participants fully measured, it is possible to have 80% power to find differences between the groups with respect to the primary outcomes. All information will be analyzed using average comparisons with 95% confidence. The analysis will be carried out by Intention to Treat (ITT) taking all the randomized participants. Missing data will be processed through multiple imputation chains. Generalized mixed linear models will be used comparing the standardized baseline and post-intervention averages of each group and between each group, obtaining 95% confidence intervals and p-values. Subgroup analysis will be performed adjusting confounders and interactions. A significant difference will be considered when the value of p is less than 0.05. Cohen´s D will be calculated to identify the size of the intervention effect.

Discussion: The results will reflect the effect of the hydrotherapy on NP in patients with SCI. They will also permit the identification of potential changes in functionality levels or quality of life in the intervened population.","[(11, 23, 'PHYSICAL', 'Hydrotherapy'), (27, 43, 'CONDITION', 'Neuropathic Pain'), (48, 70, 'CONDITION', 'Pain Catastrophization'), (74, 92, 'CONDITION', 'Spinal Cord Injury'), (145, 163, 'CONDITION', 'Spinal Cord Injury'), (165, 168, 'CONDITION', 'SCI'), (175, 193, 'CONDITION', 'spinal cord injury'), (394, 397, 'CONDITION', 'SCI'), (401, 417, 'CONDITION', 'Neuropathic Pain'), (419, 421, 'CONDITION', 'NP'), (424, 428, 'CONDITION', 'Pain'), (437, 449, 'CONDITION', 'chronic pain'), (506, 510, 'CONDITION', 'pain'), (572, 576, 'CONDITION', 'pain'), (591, 595, 'CONDITION', 'pain'), (645, 649, 'CONDITION', 'pain'), (792, 804, 'PHYSICAL', 'Hydrotherapy'), (808, 812, 'CONDITION', 'pain'), (968, 972, 'CONDITION', 'pain'), (1008, 1012, 'CONDITION', 'pain'), (1049, 1061, 'PHYSICAL', 'hydrotherapy'), (1069, 1071, 'CONDITION', 'NP'), (1089, 1092, 'CONDITION', 'SCI'), (1254, 1266, 'PHYSICAL', 'Hydrotherapy'), (1284, 1309, 'CONTROL', 'Standard Physical Therapy'), (1390, 1402, 'PHYSICAL', 'hydrotherapy'), (1407, 1423, 'CONTROL', 'physical therapy'), (1706, 1709, 'CONDITION', 'PCS'), (1711, 1733, 'CONDITION', 'Pain Catastrophization'), (1840, 1842, 'CONDITION', 'NP'), (2829, 2841, 'PHYSICAL', 'hydrotherapy'), (2845, 2847, 'CONDITION', 'NP'), (2865, 2868, 'CONDITION', 'SCI')]"
"['To', 'Evaluate', 'the', 'Activity', 'and', 'the', 'Efficacy', 'of', 'Traditional', 'Swallowing', 'Therapy', '(', 'TST', ')', 'Plus', 'Neuromuscular', 'Electrostimulation', '(', 'NMES', ')', 'vs', 'TST', 'Plus', 'Sham-', 'NMES', 'in', 'Multiple', 'Sclerosis', 'People', 'With', 'Dysphagia', '|', 'Dysphagia', 'is', 'a', 'disabling', ',', 'life', '-', 'threatening', 'symptom', 'that', 'can', 'cause', 'death', 'in', 'Multiple', 'Sclerosis', 'people', '(', 'pwMS', ')', 'through', 'aspiration', 'pneumonia', '.', 'Speech', 'therapists', 'use', 'behavioural', 'therapies', '(', 'compensatory', 'and', 'rehabilitative', ')', 'to', 'alleviate', 'such', 'swallowing', 'problems', ',', 'with', 'limited', 'benefit', '.', 'Compensatory', 'strategies', 'such', 'as', 'postural', 'changes', 'and', 'changes', 'in', 'food', 'consistency', ',', 'have', 'been', 'found', 'to', 'be', 'partially', 'effective', ',', 'especially', 'in', 'patients', 'with', 'mild', 'dysphagia', 'and', 'may', 'be', 'ineffective', 'in', 'patients', 'with', 'more', 'severe', 'dysphagia', '.', 'The', 'rehabilitative', 'strategies', 'include', '""', 'no', 'swallow', 'exercises', '""', 'which', 'aim', 'to', 'strengthen', 'isolated', 'muscles', 'used', 'in', 'swallowing', '(', 'such', 'as', 'tongue', 'strengthening', ')', 'and', '""', 'swallowing', 'exercises', '""', 'that', 'aim', 'at', 'strengthening', 'all', 'the', 'muscles', 'used', 'in', 'swallowing', 'while', 'executing', 'a', 'hard', ',', 'effortful', ',', 'or', 'prolonged', 'swallow', '.', 'To', 'date', ',', 'no', 'randomized', 'clinical', 'trials', 'have', 'shown', 'that', 'rehabilitative', 'strategies', 'are', 'effective', '.', 'Neuromuscular', 'electrical', 'stimulation', '(', 'NMES', ')', ',', 'often', 'referred', 'to', 'as', 'electrical', 'stimulation', ',', 'was', 'introduced', 'as', 'a', 'novel', 'therapy', 'for', 'dysphagia', 'in', 'the', 'late', '2001', '.', 'The', 'principles', 'of', 'NMES', 'in', 'the', 'limb', 'rehabilitation', 'literature', 'are', 'well', 'established', '.', 'However', 'published', 'protocols', 'applying', 'NMES', 'to', 'swallowing', 'function', 'have', 'shown', 'mixed', 'results', 'in', 'people', 'with', 'stroke', 'and', 'only', 'one', 'study', 'was', 'published', 'on', 'MS', 'people', '.', 'This', 'will', 'be', 'a', 'double', 'blinded', ',', 'randomized', 'clinical', 'trial', '(', 'patients', 'and', 'research', 'staff', 'blinded', ')', 'with', 'two', 'arms', ':', 'standard', 'speech', 'therapy', 'plus', 'Active', 'NMES', 'vs', 'speech', 'therapy', 'with', 'Sham', 'NMES', '.', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'NMES', 'added', 'benefit', 'to', 'a', 'therapy', 'program', 'comprised', 'of', 'standard', 'swallowing', 'exercises', 'in', 'dysphagic', 'pwMS', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT05063708,NCT05063708,"To Evaluate the Activity and the Efficacy of Traditional Swallowing Therapy (TST) Plus Neuromuscular Electrostimulation (NMES) vs TST Plus Sham- NMES in Multiple Sclerosis People With Dysphagia | Dysphagia is a disabling, life-threatening symptom that can cause death in Multiple Sclerosis people (pwMS) through aspiration pneumonia. Speech therapists use behavioural therapies (compensatory and rehabilitative) to alleviate such swallowing problems, with limited benefit. Compensatory strategies such as postural changes and changes in food consistency, have been found to be partially effective, especially in patients with mild dysphagia and may be ineffective in patients with more severe dysphagia. The rehabilitative strategies include ""no swallow exercises"" which aim to strengthen isolated muscles used in swallowing (such as tongue strengthening) and ""swallowing exercises"" that aim at strengthening all the muscles used in swallowing while executing a hard, effortful, or prolonged swallow. To date, no randomized clinical trials have shown that rehabilitative strategies are effective. Neuromuscular electrical stimulation (NMES), often referred to as electrical stimulation, was introduced as a novel therapy for dysphagia in the late 2001. The principles of NMES in the limb rehabilitation literature are well established. However published protocols applying NMES to swallowing function have shown mixed results in people with stroke and only one study was published on MS people. This will be a double blinded, randomized clinical trial (patients and research staff blinded) with two arms: standard speech therapy plus Active NMES vs speech therapy with Sham NMES. The aim of this study is to determine whether NMES added benefit to a therapy program comprised of standard swallowing exercises in dysphagic pwMS.","[(45, 75, 'OTHER', 'Traditional Swallowing Therapy'), (77, 80, 'OTHER', 'TST'), (87, 119, 'OTHER', 'Neuromuscular Electrostimulation'), (121, 125, 'OTHER', 'NMES'), (130, 133, 'CONTROL', 'TST'), (139, 149, 'CONTROL', 'Sham- NMES'), (153, 171, 'CONDITION', 'Multiple Sclerosis'), (184, 193, 'CONDITION', 'Dysphagia'), (196, 205, 'CONDITION', 'Dysphagia'), (271, 289, 'CONDITION', 'Multiple Sclerosis'), (626, 640, 'CONDITION', 'mild dysphagia'), (686, 702, 'CONDITION', 'severe dysphagia'), (743, 763, 'OTHER', 'no swallow exercises'), (861, 881, 'OTHER', 'swallowing exercises'), (1097, 1133, 'OTHER', 'Neuromuscular electrical stimulation'), (1135, 1139, 'OTHER', 'NMES'), (1163, 1185, 'OTHER', 'electrical stimulation'), (1225, 1234, 'CONDITION', 'dysphagia'), (1271, 1275, 'OTHER', 'NMES'), (1373, 1377, 'OTHER', 'NMES'), (1484, 1486, 'CONDITION', 'MS'), (1605, 1628, 'OTHER', 'standard speech therapy'), (1634, 1645, 'OTHER', 'Active NMES'), (1649, 1663, 'CONTROL', 'speech therapy'), (1669, 1678, 'CONTROL', 'Sham NMES'), (1726, 1730, 'OTHER', 'NMES'), (1812, 1821, 'CONDITION', 'dysphagic')]"
"['Effect', 'of', 'Nitric', 'Oxide', '(', 'NO', ')', 'Supplementation', 'on', 'Neurocognitive', 'Measures', 'in', 'Argininosuccinate', 'Lyase', 'Deficiency', '(', 'ASLD', ')', '|', 'This', 'is', 'a', 'study', 'involving', 'a', 'dietary', 'supplement', '.', 'Patients', 'with', 'argininosuccinate', 'lyase', 'deficiency', '(', 'ASLD', ')', 'will', 'be', 'randomly', 'assigned', 'to', 'receive', 'either', 'a', 'nitric', 'oxide', 'dietary', 'supplement', 'or', 'placebo', 'for', '24', 'weeks', ',', 'and', 'then', 'crossed', '-', 'over', 'to', 'receive', 'the', 'other', 'treatment', 'for', '24', 'weeks', '.', 'The', 'investigators', 'will', 'assess', 'the', 'effects', 'of', 'the', 'supplement', 'in', 'domains', 'of', 'general', 'cognition', ',', 'memory', ',', 'executive', 'functioning', ',', 'and', 'fine', 'motor', 'functioning', 'in', 'individuals', 'with', 'ASLD', '.']","['O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT03064048,NCT03064048,"Effect of Nitric Oxide (NO) Supplementation on Neurocognitive Measures in Argininosuccinate Lyase Deficiency (ASLD) | This is a study involving a dietary supplement. Patients with argininosuccinate lyase deficiency (ASLD) will be randomly assigned to receive either a nitric oxide dietary supplement or placebo for 24 weeks, and then crossed-over to receive the other treatment for 24 weeks. The investigators will assess the effects of the supplement in domains of general cognition, memory, executive functioning, and fine motor functioning in individuals with ASLD.","[(10, 22, 'DRUG', 'Nitric Oxide'), (24, 26, 'DRUG', 'NO'), (74, 108, 'CONDITION', 'Argininosuccinate Lyase Deficiency'), (110, 114, 'CONDITION', 'ASLD'), (180, 214, 'CONDITION', 'argininosuccinate lyase deficiency'), (216, 220, 'CONDITION', 'ASLD'), (268, 280, 'DRUG', 'nitric oxide'), (303, 310, 'CONTROL', 'placebo'), (563, 567, 'CONDITION', 'ASLD')]"
"['A', 'Pilot', 'Feasibility', 'Study', 'of', 'a', 'Co', '-', 'constructed', 'Program', '(', 'Patients', '-', 'Experts', ')', 'of', 'Mindfulness', 'Meditation', 'Adapted', 'to', 'Patients', 'With', 'Parkinson', ""'s"", 'Disease', '.', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'feasibility', '(', 'primary', 'objective', ')', 'and', 'the', 'effects', '(', 'secondary', 'objectives', ')', 'of', 'an', 'Mindfulness', 'Based', 'Stress', 'Reduction', '(', 'MBSR', ')', 'program', 'adapted', 'specifically', 'for', 'patients', 'with', 'Parkinson', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT05622396,NCT05622396,A Pilot Feasibility Study of a Co-constructed Program (Patients - Experts) of Mindfulness Meditation Adapted to Patients With Parkinson's Disease. | The objective of this study is to determine the feasibility (primary objective) and the effects (secondary objectives) of an Mindfulness Based Stress Reduction (MBSR) program adapted specifically for patients with Parkinson's disease.,"[(78, 100, 'BEHAVIOURAL', 'Mindfulness Meditation'), (126, 145, 'CONDITION', ""Parkinson's Disease""), (274, 308, 'BEHAVIOURAL', 'Mindfulness Based Stress Reduction'), (310, 314, 'BEHAVIOURAL', 'MBSR'), (363, 382, 'CONDITION', ""Parkinson's disease"")]"
"['Prospective', ',', 'Double', '-', 'blind', ',', 'Randomized', ',', 'Placebo', '-', 'Controlled', 'Phase', 'III', 'Study', 'Evaluating', 'Efficacy', 'and', 'Safety', 'of', 'Octagam', '10', '%', 'in', 'Patients', 'With', 'Dermatomyositis', '(', '""', 'ProDERM', 'Study', '""', ')', '|', 'Prospective', ',', 'Double', '-', 'blind', ',', 'Randomized', ',', 'Placebo', '-', 'Controlled', 'Phase', 'III', 'Study', 'Evaluating', 'Efficacy', 'and', 'Safety', 'of', 'Octagam', '10', '%', 'in', 'Patients', 'With', 'Dermatomyositis', '(', '""', 'ProDERM', 'study', '""', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02728752,NCT02728752,"Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (""ProDERM Study"") | Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (""ProDERM study"")","[(39, 46, 'CONTROL', 'Placebo'), (108, 115, 'DRUG', 'Octagam'), (137, 152, 'CONDITION', 'Dermatomyositis'), (212, 219, 'CONTROL', 'Placebo'), (281, 288, 'DRUG', 'Octagam'), (310, 325, 'CONDITION', 'Dermatomyositis')]"
"['Phase', 'II', 'Study', 'of', 'JNS024ER', 'in', 'Japanese', 'Subjects', 'With', 'Chronic', 'Pain', 'Due', 'to', 'Diabetic', 'Neuropathic', 'Pain', 'or', 'Postherpetic', 'Neuralgia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'efficacy', 'and', 'safety', 'of', 'tapentadol', 'extended', '-', 'release', '(', 'ER', ')', 'tablets', 'in', 'Japanese', 'participants', 'with', 'moderate', 'to', 'severe', 'chronic', '(', 'lasting', 'a', 'long', 'time', ')', 'pain', 'due', 'to', 'painful', 'diabetic', 'peripheral', 'neuropathy', '(', 'pain', 'in', 'the', 'extremities', 'related', 'to', 'diabetes', '-', 'induced', 'nerve', 'damage', ')', 'or', 'postherpetic', 'neuralgia', '(', 'pain', 'lasting', 'after', 'condition', 'has', 'healed', ')', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01124617,NCT01124617,Phase II Study of JNS024ER in Japanese Subjects With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia | The purpose of this study is to investigate the efficacy and safety of tapentadol extended-release (ER) tablets in Japanese participants with moderate to severe chronic (lasting a long time) pain due to painful diabetic peripheral neuropathy (pain in the extremities related to diabetes-induced nerve damage) or postherpetic neuralgia (pain lasting after condition has healed).,"[(18, 26, 'DRUG', 'JNS024ER'), (53, 65, 'CONDITION', 'Chronic Pain'), (73, 98, 'CONDITION', 'Diabetic Neuropathic Pain'), (102, 124, 'CONDITION', 'Postherpetic Neuralgia'), (198, 208, 'DRUG', 'tapentadol'), (269, 322, 'CONDITION', 'moderate to severe chronic (lasting a long time) pain'), (330, 368, 'CONDITION', 'painful diabetic peripheral neuropathy'), (370, 374, 'CONDITION', 'pain'), (405, 413, 'CONDITION', 'diabetes'), (439, 461, 'CONDITION', 'postherpetic neuralgia'), (463, 467, 'CONDITION', 'pain')]"
"['Understanding', 'the', 'Sleep', 'Apnea', '/', 'Insomnia', 'Interaction', ':', 'a', 'CPAP', '/', 'Sham', '-', 'CPAP', 'Trial', '|', 'Nearly', 'half', 'of', 'all', 'patients', 'with', 'obstructive', 'sleep', 'apnea', 'have', 'insomnia', 'symptoms', ',', 'and', 'in', 'some', ',', 'but', 'not', 'all', 'cases', ',', 'these', 'insomnia', 'symptoms', 'are', 'caused', 'by', 'the', 'obstructive', 'sleep', 'apnea', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'find', 'out', 'what', 'type', 'of', 'insomnia', 'symptoms', 'are', 'caused', 'by', 'obstructive', 'sleep', 'apnea', 'and', 'therefore', 'most', 'likely', 'to', 'respond', 'to', 'obstructive', 'sleep', 'apnea', 'treatment', 'with', 'continuous', 'positive', 'airway', 'pressure', '(', 'also', 'known', 'as', 'CPAP', ')', 'and', 'if', 'additional', 'treatment', 'with', 'cognitive', '-', 'behavioral', 'therapy', 'for', 'insomnia', 'is', 'beneficial', '.']","['O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O']",NCT01824472,NCT01824472,"Understanding the Sleep Apnea/Insomnia Interaction: a CPAP/Sham-CPAP Trial | Nearly half of all patients with obstructive sleep apnea have insomnia symptoms, and in some, but not all cases, these insomnia symptoms are caused by the obstructive sleep apnea. The purpose of this study is to find out what type of insomnia symptoms are caused by obstructive sleep apnea and therefore most likely to respond to obstructive sleep apnea treatment with continuous positive airway pressure (also known as CPAP) and if additional treatment with cognitive-behavioral therapy for insomnia is beneficial.","[(18, 29, 'CONDITION', 'Sleep Apnea'), (30, 38, 'CONDITION', 'Insomnia'), (54, 58, 'OTHER', 'CPAP'), (59, 68, 'CONTROL', 'Sham-CPAP'), (110, 133, 'CONDITION', 'obstructive sleep apnea'), (139, 147, 'CONDITION', 'insomnia'), (196, 204, 'CONDITION', 'insomnia'), (232, 255, 'CONDITION', 'obstructive sleep apnea'), (311, 319, 'CONDITION', 'insomnia'), (343, 366, 'CONDITION', 'obstructive sleep apnea'), (407, 430, 'CONDITION', 'obstructive sleep apnea'), (446, 481, 'OTHER', 'continuous positive airway pressure'), (497, 501, 'OTHER', 'CPAP'), (536, 564, 'BEHAVIOURAL', 'cognitive-behavioral therapy'), (569, 577, 'CONDITION', 'insomnia')]"
"['The', 'Effects', 'of', 'Neuromuscular', 'Electrical', 'Stimulation', 'on', 'Swallowing', 'Functions', 'in', 'Stroke', 'Patients', 'With', 'Dysphagia', ':', 'Randomized', 'Controlled', 'Trial', '|', 'In', 'our', 'study', ',', 'our', 'aim', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'neuromuscular', 'electrical', 'stimulation', 'added', 'to', 'traditional', 'dysphagia', 'therapy', 'in', 'stroke', 'patients', 'with', 'dysphagia', ',', 'on', 'functional', 'oral', 'intake', 'status', ',', 'dysphagia', '-', 'related', 'symptoms', ',', 'quality', 'of', 'life', ',', 'and', 'complications', 'related', 'to', 'dysphagia', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04421937,NCT04421937,"The Effects of Neuromuscular Electrical Stimulation on Swallowing Functions in Stroke Patients With Dysphagia: Randomized Controlled Trial | In our study, our aim is to evaluate the effect of neuromuscular electrical stimulation added to traditional dysphagia therapy in stroke patients with dysphagia, on functional oral intake status, dysphagia-related symptoms, quality of life, and complications related to dysphagia.","[(15, 51, 'OTHER', 'Neuromuscular Electrical Stimulation'), (79, 85, 'CONDITION', 'Stroke'), (100, 109, 'CONDITION', 'Dysphagia'), (192, 228, 'OTHER', 'neuromuscular electrical stimulation'), (238, 267, 'OTHER', 'traditional dysphagia therapy'), (271, 277, 'CONDITION', 'stroke'), (292, 301, 'CONDITION', 'dysphagia'), (337, 346, 'CONDITION', 'dysphagia'), (411, 420, 'CONDITION', 'dysphagia')]"
"['Combination', 'of', 'Alpelisib', 'and', 'Trametinib', 'in', 'Progressive', 'Refractory', 'Meningiomas', ':', 'Phase', '1', 'Study', '|', 'Aggressive', 'growing', 'meningiomas', 'resistant', 'to', 'multiple', 'surgeries', 'and', 'radiotherapy', 'constitute', 'an', 'unmet', 'pharmaceutical', 'need', 'in', 'neurooncology', ',', 'leading', 'to', 'a', 'fatal', 'issue', 'within', 'a', 'few', 'months', '.', 'Grade', 'II', '-', 'III', 'meningiomas', 'progression', '-', 'free', 'survival', '(', 'PFS', ')', '6', 'is', 'at', '10', '-', '15', '%', '.', 'Median', 'PFS', 'grade', 'III', 'meningioma', 'is', 'approximate', '3', 'years', '.', '\n\n', 'Alpelisib', 'is', 'a', 'well', '-', 'tolerated', 'Phosphoinositide', '3', '-', 'kinase', 'α', '(', 'Pi3Kα', ')', 'specific', 'inhibitor', '.', 'However', ',', 'phosphatidylinositol-3', '-', 'kinase', '(', 'PI3', 'K', ')', 'and', 'the', 'mammalian', 'target', 'of', 'rapamycin', '(', 'mTOR', ')', 'inhibition', 'does', 'not', 'induce', 'apoptosis', 'in', 'vitro', 'and', 'induces', 'an', 'antiproliferative', 'effect', 'without', 'any', 'radiologic', 'response', 'in', 'most', 'treated', 'patients', '.', '\n\n', 'Trametinib', ',', 'a', 'mekinist', '(', 'MEK', ')', 'inhibitor', 'is', 'currently', 'used', 'in', 'combined', 'treatment', 'for', 'recurrent', 'melanomas', 'in', 'clinical', 'practice', 'with', 'a', 'good', 'clinical', 'tolerance', 'at', '1', '-', '2', 'mg', 'daily', '.', 'In', 'vitro', ',', 'on', 'meningioma', 'primary', 'cell', 'culture', ',', 'Trametinib', 'induces', 'cell', 'apoptosis', 'via', 'caspase', 'activity', '.', '\n\n', 'These', 'results', 'strongly', 'suggest', 'the', 'relevance', 'to', 'combine', 'Alpelisib', 'and', 'Trametinib', 'in', 'aggressive', 'and', 'recurrent', 'meningiomas', '.', '\n\n', 'Alpelisib', 'and', 'Trametinib', 'combination', 'has', 'not', 'been', 'studied', 'to', 'date', ',', 'despite', 'each', 'drugs', 'have', 'been', 'separately', 'studied', 'in', 'phase', '3', '.', '\n\n', 'Multicenter', ',', 'open', 'label', ',', 'dose', '-', 'finding', 'phase', 'I', 'study', 'of', 'Alpelisib', 'in', 'combination', 'with', 'Trametinib', 'administered', 'at', 'a', 'fixed', 'dose', '(', '1.5', 'mg', 'daily', ')', ',', 'both', 'drugs', 'will', 'be', 'administered', 'daily', '.', 'Starting', 'dose', 'of', 'Alpelisib', 'will', 'be', '160mg', '/', 'day', 'and', 'will', 'be', 'increased', 'to', '200mg', '/', 'day', 'or', 'decreased', 'to', '120mg', '/', 'day', 'depending', 'of', 'grade', '3', '-', '4', 'adverse', 'events', 'occurrence', ',', 'to', 'determine', 'maximal', 'tolerated', 'dose', '(', 'MTD', ')', 'and', 'recommended', 'dose', '.', '\n\n', 'Primary', 'Objective', 'is', 'to', 'determine', 'the', 'safety', 'profile', 'and', 'tolerability', 'of', 'Alpelisib', 'and', 'Trametinib', 'given', 'in', 'combination', 'in', 'patients', 'with', 'aggressive', 'and', 'refractory', 'meningiomas', 'in', 'terms', 'of', 'Dose', '-', 'Limiting', 'Toxicities', '(', 'DLT', ',', 'assessed', 'during', 'cycle', '1', ')', '.']","['O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03631953,NCT03631953,"Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas: Phase 1 Study | Aggressive growing meningiomas resistant to multiple surgeries and radiotherapy constitute an unmet pharmaceutical need in neurooncology, leading to a fatal issue within a few months. Grade II-III meningiomas progression-free survival (PFS) 6 is at 10-15%. Median PFS grade III meningioma is approximate 3 years.

Alpelisib is a well-tolerated Phosphoinositide 3-kinase α (Pi3Kα) specific inhibitor. However, phosphatidylinositol-3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) inhibition does not induce apoptosis in vitro and induces an antiproliferative effect without any radiologic response in most treated patients.

Trametinib, a mekinist (MEK) inhibitor is currently used in combined treatment for recurrent melanomas in clinical practice with a good clinical tolerance at 1-2 mg daily. In vitro, on meningioma primary cell culture, Trametinib induces cell apoptosis via caspase activity.

These results strongly suggest the relevance to combine Alpelisib and Trametinib in aggressive and recurrent meningiomas.

Alpelisib and Trametinib combination has not been studied to date, despite each drugs have been separately studied in phase 3.

Multicenter, open label, dose-finding phase I study of Alpelisib in combination with Trametinib administered at a fixed dose (1.5 mg daily), both drugs will be administered daily. Starting dose of Alpelisib will be 160mg/day and will be increased to 200mg/day or decreased to 120mg/day depending of grade 3-4 adverse events occurrence, to determine maximal tolerated dose (MTD) and recommended dose.

Primary Objective is to determine the safety profile and tolerability of Alpelisib and Trametinib given in combination in patients with aggressive and refractory meningiomas in terms of Dose-Limiting Toxicities (DLT, assessed during cycle 1).","[(15, 24, 'DRUG', 'Alpelisib'), (29, 39, 'DRUG', 'Trametinib'), (43, 77, 'CONDITION', 'Progressive Refractory Meningiomas'), (95, 174, 'CONDITION', 'Aggressive growing meningiomas resistant to multiple surgeries and radiotherapy'), (279, 303, 'CONDITION', 'Grade II-III meningiomas'), (363, 383, 'CONDITION', 'grade III meningioma'), (409, 418, 'DRUG', 'Alpelisib'), (731, 741, 'DRUG', 'Trametinib'), (916, 926, 'CONDITION', 'meningioma'), (949, 959, 'DRUG', 'Trametinib'), (1062, 1071, 'DRUG', 'Alpelisib'), (1076, 1086, 'DRUG', 'Trametinib'), (1090, 1126, 'CONDITION', 'aggressive and recurrent meningiomas'), (1129, 1138, 'DRUG', 'Alpelisib'), (1143, 1153, 'DRUG', 'Trametinib'), (1312, 1321, 'DRUG', 'Alpelisib'), (1342, 1352, 'DRUG', 'Trametinib'), (1454, 1463, 'DRUG', 'Alpelisib'), (1731, 1740, 'DRUG', 'Alpelisib'), (1745, 1755, 'DRUG', 'Trametinib'), (1794, 1831, 'CONDITION', 'aggressive and refractory meningiomas')]"
"['The', 'Effectiveness', 'of', 'Tibial', 'Nerve', 'Mobilization', 'in', 'Patients', 'With', 'Tarsal', 'Tunnel', 'Syndrome', '|', 'This', 'randomized', ',', 'clinical', ',', 'single', '-', 'blinded', ',', 'controlledstudywasinitiallyplannedtoinclude', '35', 'patients', 'diagnosed', 'with', 'tarsal', 'tunnel', 'who', 'applied', 'to', 'Kütahya', 'Health', 'Sciences', 'University', ',', 'Evliya', 'Çelebi', 'Training', 'and', 'Research', 'Hospital', ',', 'Physical', 'Medicine', 'and', 'Rehabilitation', 'outpatient', 'clinic', '.', 'Patients', 'aged', '20', '-', '55', 'years', 'who', 'were', 'diagnosed', 'with', 'tarsal', 'tunnel', 'syndrome', 'by', 'electromyography', '(', 'EMG', ')', 'in', 'the', 'last', '6', 'months', 'were', 'included', 'in', 'the', 'study', '.', 'The', 'patients', 'were', 'randomized', 'into', 'two', 'groups', 'using', 'the', 'computer', '-', 'assisted', 'randomization', 'method', '.', 'Tibial', 'nerve', 'mobilization', 'and', 'foot', '-', 'ankle', 'range', 'of', 'motion', 'exercises', 'will', 'be', 'given', 'to', 'the', 'study', 'group', ',', 'and', 'only', 'foot', '-', 'ankle', 'joint', 'range', 'of', 'motion', 'exercises', 'will', 'be', 'given', 'to', 'the', 'control', 'group', '.', 'All', 'the', 'patients', 'were', 'evaluated', 'with', 'the', 'Visual', 'Analog', 'Scale', '(', 'VAS', ')', ',', 'Foot', 'Functional', 'Index', '(', 'FFI', ')', ',', 'Neuropathic', 'Pain', 'QuestionnaireN', '(', 'NPQ', ')', 'and', 'Tibial', 'Nerve', 'ultrasonography', 'before', 'the', 'intervention', 'and', 'at', 'the', 'fourth', 'week', 'of', 'intervention', '.']","['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05307354,NCT05307354,"The Effectiveness of Tibial Nerve Mobilization in Patients With Tarsal Tunnel Syndrome | This randomized, clinical, single-blinded, controlledstudywasinitiallyplannedtoinclude 35 patients diagnosed with tarsal tunnel who applied to Kütahya Health Sciences University, Evliya Çelebi Training and Research Hospital, Physical Medicine and Rehabilitation outpatient clinic.Patients aged 20-55 years who were diagnosed with tarsal tunnel syndrome by electromyography (EMG) in the last 6 months were included in the study. The patients were randomized into two groups using the computer-assisted randomization method. Tibial nerve mobilization and foot-ankle range of motion exercises will be given to the study group, and only foot-ankle joint range of motion exercises will be given to the control group. All the patients were evaluated with the Visual Analog Scale (VAS), Foot Functional Index (FFI), Neuropathic Pain QuestionnaireN (NPQ) and Tibial Nerve ultrasonography before the intervention and at the fourth week of intervention.","[(21, 46, 'PHYSICAL', 'Tibial Nerve Mobilization'), (64, 86, 'CONDITION', 'Tarsal Tunnel Syndrome'), (203, 216, 'CONDITION', 'tarsal tunnel'), (419, 441, 'CONDITION', 'tarsal tunnel syndrome'), (612, 637, 'PHYSICAL', 'Tibial nerve mobilization'), (642, 678, 'PHYSICAL', 'foot-ankle range of motion exercises'), (717, 764, 'CONTROL', 'only foot-ankle joint range of motion exercises')]"
"['Measurements', 'of', 'Displacement', 'Amplitude', 'and', 'Angular', 'Velocities', 'During', 'Passive', 'Extension', 'of', 'the', 'Wrist', 'and', 'Hand', 'Complex', 'in', 'Stroke', 'Patients', '|', 'The', 'main', 'objective', 'of', 'this', 'monocentric', 'prospective', 'study', 'is', 'to', 'evaluate', 'the', 'amplitudes', 'and', 'angular', 'velocities', 'of', 'extension', 'of', 'the', 'hand', 'and', 'wrist', 'joints', 'during', 'passive', 'mobilization', 'by', 'a', 'physiotherapist', 'in', 'healthy', 'subjects', 'and', 'stroke', 'patients', 'with', 'spastic', 'hands', '.', '\n\n', 'Secondary', 'objectives', ':', '\n\n', 'To', 'compare', 'amplitude', 'and', 'angular', 'velocity', 'values', 'between', 'the', 'group', 'of', 'stroke', 'patients', 'and', 'the', 'group', 'of', 'healthy', 'volunteers', ',', '\n', 'To', 'compare', 'amplitude', 'and', 'angular', 'velocity', 'values', 'according', 'to', 'the', 'two', 'types', 'of', 'mobilization', '(', 'i', ',', 'e', ',', 'thumb', 'or', 'fifth', 'finger', ')', ',', '\n', 'To', 'assess', 'pain', 'due', 'to', 'mobilization', 'in', 'stroke', 'patients', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT04502927,NCT04502927,"Measurements of Displacement Amplitude and Angular Velocities During Passive Extension of the Wrist and Hand Complex in Stroke Patients | The main objective of this monocentric prospective study is to evaluate the amplitudes and angular velocities of extension of the hand and wrist joints during passive mobilization by a physiotherapist in healthy subjects and stroke patients with spastic hands.

Secondary objectives:

To compare amplitude and angular velocity values between the group of stroke patients and the group of healthy volunteers,
To compare amplitude and angular velocity values according to the two types of mobilization (i,e, thumb or fifth finger),
To assess pain due to mobilization in stroke patients.","[(120, 126, 'CONDITION', 'Stroke'), (363, 369, 'CONDITION', 'stroke'), (384, 391, 'CONDITION', 'spastic'), (493, 499, 'CONDITION', 'stroke'), (678, 682, 'CONDITION', 'pain'), (706, 712, 'CONDITION', 'stroke')]"
"['Comparison', 'of', 'Two', 'Analgesic', 'Strategies', 'After', 'Scheduled', 'Caesarean', ':', 'Block', 'of', 'the', 'Lumbar', 'Region', 'With', 'Ropivacaine', 'Versus', 'Intrathecal', 'Morphine', '|', 'To', 'demonstrate', 'the', 'superiority', 'of', 'square', 'lumbar', 'block', 'to', 'ropivacaine', 'compared', 'to', 'intrathecal', 'morphine', 'in', 'the', 'efficacy', 'of', 'postoperative', 'analgesia', 'following', 'scheduled', 'caesarean', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04755712,NCT04755712,Comparison of Two Analgesic Strategies After Scheduled Caesarean : Block of the Lumbar Region With Ropivacaine Versus Intrathecal Morphine | To demonstrate the superiority of square lumbar block to ropivacaine compared to intrathecal morphine in the efficacy of postoperative analgesia following scheduled caesarean.,"[(55, 64, 'CONDITION', 'Caesarean'), (99, 110, 'DRUG', 'Ropivacaine'), (130, 138, 'DRUG', 'Morphine'), (198, 209, 'DRUG', 'ropivacaine'), (234, 242, 'DRUG', 'morphine'), (306, 315, 'CONDITION', 'caesarean')]"
"['LEukoaraiosis', 'and', 'blOod', 'Pressure', 'Reduction', 'in', 'OLD', 'People', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'test', 'the', 'hypothesis', 'of', 'slowing', 'the', 'progression', 'of', 'White', 'Matter', 'Lesions', '(', 'WML', ')', 'by', 'lowering', 'blood', 'pressure', '(', 'BP', ')', 'in', 'patients', 'with', 'cognitive', 'complaints', 'and', 'a', 'moderate', 'to', 'high', 'grade', 'of', 'WML', 'on', 'brain', 'MRI', '.']","['B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT02472028,NCT02472028,LEukoaraiosis and blOod Pressure Reduction in OLD People | The purpose of the study is to test the hypothesis of slowing the progression of White Matter Lesions (WML) by lowering blood pressure (BP) in patients with cognitive complaints and a moderate to high grade of WML on brain MRI.,"[(0, 13, 'CONDITION', 'LEukoaraiosis'), (18, 42, 'OTHER', 'blOod Pressure Reduction'), (140, 160, 'CONDITION', 'White Matter Lesions'), (162, 165, 'CONDITION', 'WML'), (170, 193, 'OTHER', 'lowering blood pressure'), (269, 272, 'CONDITION', 'WML')]"
"['A', 'Phase', '2', ',', 'Multicenter', 'Study', 'of', '[', '18F]APN-1607', 'Positron', 'Emission', 'Tomography', 'in', 'Subjects', 'With', 'Alzheimer', ""'s"", 'Disease', 'Compared', 'to', 'Healthy', 'Subjects', '|', 'The', 'overall', 'objective', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'overall', 'pattern', 'of', '[', '18F]APN-1607', 'uptake', 'in', 'subjects', 'with', 'MDAD', ',', 'subjects', 'with', 'AD', 'dementia', ',', 'and', 'healthy', 'subjects', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",NCT04141150,NCT04141150,"A Phase 2, Multicenter Study of [18F]APN-1607 Positron Emission Tomography in Subjects With Alzheimer's Disease Compared to Healthy Subjects | The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MDAD, subjects with AD dementia, and healthy subjects.","[(92, 111, 'CONDITION', ""Alzheimer's Disease""), (274, 285, 'CONDITION', 'AD dementia')]"
"['The', 'Optimal', 'Treatment', 'for', 'Treatment', '-', 'resistant', 'Schizophrenia', '|', 'The', 'Optimal', 'Treatment', 'for', 'Treatment', '-', 'resistant', 'Schizophrenia']","['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND']",NCT02926976,NCT02926976,The Optimal Treatment for Treatment-resistant Schizophrenia | The Optimal Treatment for Treatment-resistant Schizophrenia,"[(26, 59, 'CONDITION', 'Treatment-resistant Schizophrenia'), (88, 121, 'CONDITION', 'Treatment-resistant Schizophrenia')]"
"['Memantine', 'Versus', 'Donepezil', 'in', 'Mild', 'to', 'Moderate', 'Alzheimer', ""'s"", 'Disease', '.', 'A', 'Randomized', 'Trial', 'With', 'Magnetic', 'Resonance', 'Spectroscopy', '.', '|', 'It', 'is', 'well', 'known', 'that', 'in', 'the', 'brain', 'of', 'the', 'patients', 'with', 'Alzheimer', ""'s"", 'disease', 'there', 'is', 'a', 'glutamatergic', 'hyperstimulation', 'leading', 'to', 'neuronal', 'death', '.', 'Memantine', 'is', 'a', 'low', 'affinity', 'antagonist', 'of', 'NMDA', 'glutamate', 'receptors', '.', 'The', 'use', 'of', 'this', 'drug', 'in', 'the', 'early', 'phases', 'of', 'the', 'disease', 'could', 'provide', 'neuroprotective', 'effects', 'and', 'delay', 'of', 'progression', '.', 'The', 'effects', 'of', 'memantine', 'should', 'be', 'compared', 'to', 'those', 'of', 'donepezil', ',', 'which', 'is', 'the', 'most', 'prescribed', 'anticholinesterase', 'drug', '.']","['B-DRUG', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00505167,NCT00505167,"Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy. | It is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors. The use of this drug in the early phases of the disease could provide neuroprotective effects and delay of progression. The effects of memantine should be compared to those of donepezil, which is the most prescribed anticholinesterase drug.","[(0, 9, 'DRUG', 'Memantine'), (17, 26, 'DRUG', 'Donepezil'), (30, 67, 'CONDITION', ""Mild to Moderate Alzheimer's Disease.""), (183, 202, 'CONDITION', ""Alzheimer's disease""), (272, 281, 'DRUG', 'Memantine'), (475, 484, 'DRUG', 'memantine'), (516, 525, 'DRUG', 'donepezil')]"
"['A', 'Multidisciplinary', 'Delirium', 'Prevention', 'Strategy', 'Involving', 'Psychiatry', 'in', 'the', 'Intensive', 'Care', 'Unit', '(', 'ICU', '):', 'Effects', 'on', 'Delirium', 'Incidence', 'and', 'Outcomes', '|', 'Delirium', 'affects', 'up', 'to', '80', '%', 'of', 'intensive', 'care', 'unit', '(', 'ICU', ')', 'patients', 'and', 'is', 'associated', 'with', 'longer', 'hospital', 'stays', ',', 'increased', 'morbidity', 'and', 'mortality', ',', 'and', 'increased', 'costs', '.', 'There', 'is', 'no', 'FDA', '-', 'approved', 'treatment', 'for', 'delirium', ';', 'the', 'most', 'effective', 'strategy', 'is', 'prevention', 'by', 'nonpharmacological', 'methods', '.', 'The', 'investigators', 'propose', 'to', 'study', 'a', 'comprehensive', 'delirium', 'prevention', 'bundle', 'that', 'has', 'been', 'effective', 'against', 'delirium', 'in', 'preliminary', 'studies', 'in', 'elderly', 'in', '-', 'hospital', 'patients', 'and', 'elderly', 'ICU', 'patients', '.', 'This', 'delirium', 'prevention', 'bundle', 'includes', 'the', 'novel', 'addition', 'of', 'psychiatrists', 'to', 'daily', 'ICU', 'rounds', ',', 'as', 'these', 'professionals', 'are', 'specially', 'trained', 'to', 'screen', 'for', 'latent', 'mental', 'illness', 'and', 'provide', 'treatment', 'for', 'these', 'illnesses', '.', 'The', 'effects', 'of', 'daily', 'psychiatric', 'evaluation', 'of', 'ICU', 'patients', 'has', 'never', 'been', 'systematically', 'studied', ',', 'as', 'ICU', 'professionals', 'are', 'well', '-', 'equipped', 'to', 'manage', 'ICU', 'delirium', '.', 'Psychiatric', 'consultation', 'is', 'reserved', 'for', 'severe', 'and/or', 'refractory', 'cases', 'of', 'delirium', '.', 'The', 'investigators', 'hypothesize', 'that', 'a', 'multidisciplinary', 'rounding', 'approach', 'including', 'psychiatry', 'within', 'the', 'ICU', 'team', 'will', 'help', 'diagnose', 'psychiatric', 'components', 'that', 'may', 'contribute', 'to', 'delirium', 'at', 'an', 'earlier', 'time', 'point', ',', 'and', 'thus', 'can', 'reduce', 'the', 'incidence', 'and', 'duration', 'of', 'delirium', '.', 'The', 'investigators', 'also', 'hypothesize', 'that', 'the', 'proposed', 'multidisciplinary', 'approach', 'will', 'shorten', 'hospital', 'and', 'ICU', 'lengths', 'of', 'stay', ',', 'duration', 'of', 'mechanical', 'ventilation', ',', 'and', 'decrease', 'in', '-', 'hospital', 'mortality', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03550495,NCT03550495,"A Multidisciplinary Delirium Prevention Strategy Involving Psychiatry in the Intensive Care Unit (ICU): Effects on Delirium Incidence and Outcomes | Delirium affects up to 80% of intensive care unit (ICU) patients and is associated with longer hospital stays, increased morbidity and mortality, and increased costs. There is no FDA-approved treatment for delirium; the most effective strategy is prevention by nonpharmacological methods. The investigators propose to study a comprehensive delirium prevention bundle that has been effective against delirium in preliminary studies in elderly in-hospital patients and elderly ICU patients. This delirium prevention bundle includes the novel addition of psychiatrists to daily ICU rounds, as these professionals are specially trained to screen for latent mental illness and provide treatment for these illnesses. The effects of daily psychiatric evaluation of ICU patients has never been systematically studied, as ICU professionals are well-equipped to manage ICU delirium. Psychiatric consultation is reserved for severe and/or refractory cases of delirium. The investigators hypothesize that a multidisciplinary rounding approach including psychiatry within the ICU team will help diagnose psychiatric components that may contribute to delirium at an earlier time point, and thus can reduce the incidence and duration of delirium. The investigators also hypothesize that the proposed multidisciplinary approach will shorten hospital and ICU lengths of stay, duration of mechanical ventilation, and decrease in-hospital mortality.","[(2, 48, 'OTHER', 'Multidisciplinary Delirium Prevention Strategy'), (59, 69, 'OTHER', 'Psychiatry'), (77, 96, 'CONDITION', 'Intensive Care Unit'), (98, 101, 'CONDITION', 'ICU'), (115, 123, 'CONDITION', 'Delirium'), (149, 157, 'CONDITION', 'Delirium'), (179, 198, 'CONDITION', 'intensive care unit'), (200, 203, 'CONDITION', 'ICU'), (355, 363, 'CONDITION', 'delirium'), (489, 515, 'OTHER', 'delirium prevention bundle'), (548, 556, 'CONDITION', 'delirium'), (624, 627, 'CONDITION', 'ICU'), (643, 669, 'OTHER', 'delirium prevention bundle'), (689, 734, 'OTHER', 'addition of psychiatrists to daily ICU rounds'), (881, 903, 'OTHER', 'psychiatric evaluation'), (907, 910, 'CONDITION', 'ICU'), (962, 965, 'CONDITION', 'ICU'), (1008, 1011, 'CONDITION', 'ICU'), (1012, 1020, 'CONDITION', 'delirium'), (1022, 1046, 'OTHER', 'Psychiatric consultation'), (1097, 1105, 'CONDITION', 'delirium'), (1144, 1220, 'OTHER', 'multidisciplinary rounding approach including psychiatry within the ICU team'), (1286, 1294, 'CONDITION', 'delirium'), (1371, 1379, 'CONDITION', 'delirium'), (1434, 1460, 'OTHER', 'multidisciplinary approach'), (1487, 1490, 'CONDITION', 'ICU'), (1520, 1542, 'CONDITION', 'mechanical ventilation')]"
"['An', 'Open', '-', 'label', 'Extension', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Tolerability', 'of', 'Perampanel', '(', 'E2007', ')', 'Administered', 'as', 'an', 'Adjunctive', 'Therapy', 'in', 'Epilepsy', 'Subjects', '|', 'To', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'perampanel', 'given', 'as', 'an', 'adjunctive', 'therapy', 'in', 'participants', 'with', 'epilepsy', '.', 'This', 'study', 'will', 'be', 'continued', 'until', 'perampanel', 'is', 'commercially', 'available', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",NCT02427607,NCT02427607,An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects | To evaluate the safety and tolerability of perampanel given as an adjunctive therapy in participants with epilepsy. This study will be continued until perampanel is commercially available.,"[(73, 83, 'DRUG', 'Perampanel'), (85, 90, 'DRUG', 'E2007'), (133, 141, 'CONDITION', 'Epilepsy'), (196, 206, 'DRUG', 'perampanel'), (259, 267, 'CONDITION', 'epilepsy'), (304, 314, 'DRUG', 'perampanel')]"
"['Phase', '1', 'Study', 'to', 'Determine', 'the', 'Efficacy', 'of', 'Using', 'Far', 'Infrared', 'Radiation', 'for', 'the', 'Treatment', 'of', 'Alzheimer', ""'s"", 'Disease', '.', '|', 'Alzheimer', ""'s"", 'disease', 'is', 'a', 'progressive', 'and', 'fatal', 'brain', 'disease', '.', 'This', 'study', 'will', 'investigate', 'the', 'use', 'of', 'far', 'infrared', 'radiation', 'treatment', 'for', 'the', 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O']",NCT00599469,NCT00599469,Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Treatment of Alzheimer's Disease. | Alzheimer's disease is a progressive and fatal brain disease. This study will investigate the use of far infrared radiation treatment for the disease.,"[(49, 71, 'RADIOTHERAPY', 'Far Infrared Radiation'), (93, 112, 'CONDITION', ""Alzheimer's Disease""), (116, 135, 'CONDITION', ""Alzheimer's disease""), (217, 239, 'RADIOTHERAPY', 'far infrared radiation')]"
"['Sphenopalatine', 'Ganglion', 'Block', 'for', 'Treatment', 'of', 'Postdural', 'Puncture', 'Headache', 'in', 'the', 'Emergency', 'Department', ':', 'A', 'Prospective', ',', 'Randomized', ',', 'Double', '-', 'Blind', 'Placebo', 'Controlled', 'Study', '|', 'This', 'study', 'evaluates', 'sphenopalatine', 'ganglion', 'block', '(', 'SPGB', ')', 'for', 'the', 'treatment', 'of', 'postdural', 'puncture', 'headache', '(', 'PDPH', ')', 'in', 'the', 'emergency', 'department', '(', 'ED', ')', '.', 'Half', 'of', 'the', 'patients', 'will', 'receive', 'a', 'true', 'nerve', 'block', 'with', 'lidocaine', 'and', 'bupivacaine', '.', 'The', 'other', 'half', 'will', 'receive', 'a', 'placebo', 'nerve', 'block', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT02517931,NCT02517931,"Sphenopalatine Ganglion Block for Treatment of Postdural Puncture Headache in the Emergency Department: A Prospective, Randomized, Double-Blind Placebo Controlled Study | This study evaluates sphenopalatine ganglion block (SPGB) for the treatment of postdural puncture headache (PDPH) in the emergency department (ED). Half of the patients will receive a true nerve block with lidocaine and bupivacaine. The other half will receive a placebo nerve block.","[(0, 29, 'OTHER', 'Sphenopalatine Ganglion Block'), (47, 74, 'CONDITION', 'Postdural Puncture Headache'), (144, 151, 'CONTROL', 'Placebo'), (192, 221, 'OTHER', 'sphenopalatine ganglion block'), (223, 227, 'OTHER', 'SPGB'), (250, 277, 'CONDITION', 'postdural puncture headache'), (279, 283, 'CONDITION', 'PDPH'), (377, 386, 'DRUG', 'lidocaine'), (391, 402, 'DRUG', 'bupivacaine'), (434, 453, 'CONTROL', 'placebo nerve block')]"
"['Assessment', 'of', 'the', 'Emfit', 'Mattress', 'Sensor', '(', 'L-4060SLC', ')', 'and', 'Monitor', '(', 'DVM', '-', 'GPRS', '-', 'V2', ')', 'and', 'Their', 'Acoustic', 'and', 'Cloud', 'Interface', 'Notification', 'Capabilities', 'as', 'a', 'Nocturnal', 'Detection', 'System', 'for', 'Movements', 'Associated', 'With', 'Generalized', 'Tonic', '-', 'clonic', 'Seizures', '.', '|', 'Sudden', 'unexpected', 'death', 'in', 'epilepsy', '(', 'SUDEP', ')', 'is', 'the', 'most', 'important', 'epilepsy', '-', 'related', 'mode', 'of', 'death', '.', 'The', 'exact', 'mechanism', 'of', 'SUDEP', 'is', 'not', 'known', '.', 'It', 'is', 'thought', 'that', 'cardiac', 'and', 'respiratory', 'factors', 'are', 'involved', '.', 'Several', 'ways', 'of', 'preventing', 'SUDEP', 'have', 'been', 'identified', '.', 'These', 'include', 'seizure', 'control', ',', 'stress', 'reduction', ',', 'physical', 'activity', ',', 'family', ""'s"", 'ability', 'to', 'perform', 'CPR', ',', 'and', 'night', 'supervision', '.', '\n\n', 'A', 'mattress', 'alarm', 'system', 'that', 'monitors', 'nocturnal', 'seizures', 'can', 'alert', 'family', 'members', 'of', 'night', 'time', 'seizure', 'activity', '.', 'Thus', ',', 'a', 'family', 'member', 'could', 'provide', 'aid', 'and', 'therefore', 'potentially', 'avoid', 'SUDEP', '.', 'The', 'Emfit', 'monitor', 'is', 'intended', 'to', 'perform', 'these', 'tasks', '.', '\n\n', 'Investigators', 'tested', 'the', 'Emfit', 'mattress', 'monitor', 'DVM', '-', 'GPRS', '-', 'V2', 'in', 'combination', 'with', 'the', 'Emfit', 'bed', 'sensor', 'L-4060SL', 'in', 'the', 'epilepsy', 'monitoring', 'unit', 'and', 'were', 'able', 'to', 'demonstrate', 'that', 'the', 'device', 'has', 'a', 'high', 'predictive', 'value', 'for', 'detection', 'of', 'generalized', 'convulsions', 'and', 'that', 'it', 'can', 'notify', 'caregivers', 'in', 'the', 'early', 'stages', 'of', 'convulsive', 'activity', '.', '\n\n', 'This', 'study', 'will', 'further', 'investigate', 'the', 'upgraded', '(', 'connected', 'to', 'a', 'cloud', 'server', 'via', 'an', 'integrated', 'cellular', 'GPRS', 'module', ')', 'Emfit', 'mattress', 'monitor', 'DVM', '-', 'GPRS', '-', 'V2', 'and', 'the', 'upgraded', 'Emfit', 'mattress', 'sensor', 'L-4060SLC', 'in', 'combination', 'with', 'an', 'acoustic', 'and', 'new', 'cloud', '-', 'based', 'notification', 'system', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O']",NCT02661919,NCT02661919,"Assessment of the Emfit Mattress Sensor (L-4060SLC) and Monitor (DVM-GPRS-V2) and Their Acoustic and Cloud Interface Notification Capabilities as a Nocturnal Detection System for Movements Associated With Generalized Tonic-clonic Seizures. | Sudden unexpected death in epilepsy (SUDEP) is the most important epilepsy-related mode of death. The exact mechanism of SUDEP is not known. It is thought that cardiac and respiratory factors are involved. Several ways of preventing SUDEP have been identified. These include seizure control, stress reduction, physical activity, family's ability to perform CPR, and night supervision.

A mattress alarm system that monitors nocturnal seizures can alert family members of night time seizure activity. Thus, a family member could provide aid and therefore potentially avoid SUDEP. The Emfit monitor is intended to perform these tasks.

Investigators tested the Emfit mattress monitor DVM-GPRS-V2 in combination with the Emfit bed sensor L-4060SL in the epilepsy monitoring unit and were able to demonstrate that the device has a high predictive value for detection of generalized convulsions and that it can notify caregivers in the early stages of convulsive activity.

This study will further investigate the upgraded (connected to a cloud server via an integrated cellular GPRS module) Emfit mattress monitor DVM-GPRS-V2 and the upgraded Emfit mattress sensor L-4060SLC in combination with an acoustic and new cloud-based notification system.","[(18, 39, 'OTHER', 'Emfit Mattress Sensor'), (41, 50, 'OTHER', 'L-4060SLC'), (56, 63, 'OTHER', 'Monitor'), (65, 76, 'OTHER', 'DVM-GPRS-V2'), (205, 238, 'CONDITION', 'Generalized Tonic-clonic Seizures'), (242, 277, 'CONDITION', 'Sudden unexpected death in epilepsy'), (279, 284, 'CONDITION', 'SUDEP'), (308, 316, 'CONDITION', 'epilepsy'), (363, 368, 'CONDITION', 'SUDEP'), (475, 480, 'CONDITION', 'SUDEP'), (517, 524, 'CONDITION', 'seizure'), (630, 651, 'OTHER', 'mattress alarm system'), (676, 684, 'CONDITION', 'seizures'), (724, 731, 'CONDITION', 'seizure'), (814, 819, 'CONDITION', 'SUDEP'), (825, 838, 'OTHER', 'Emfit monitor'), (901, 935, 'OTHER', 'Emfit mattress monitor DVM-GPRS-V2'), (960, 985, 'OTHER', 'Emfit bed sensor L-4060SL'), (993, 1001, 'CONDITION', 'epilepsy'), (1108, 1131, 'CONDITION', 'generalized convulsions'), (1189, 1199, 'CONDITION', 'convulsive'), (1329, 1363, 'OTHER', 'Emfit mattress monitor DVM-GPRS-V2'), (1381, 1412, 'OTHER', 'Emfit mattress sensor L-4060SLC'), (1436, 1484, 'OTHER', 'acoustic and new cloud-based notification system')]"
"['Studying', 'of', 'Acupuncture', 'for', 'Bell', ""'s"", 'Palsy', 'According', 'to', 'Different', 'Stages', '|', 'The', 'purpose', 'of', 'this', 'trial', 'will', 'certify', 'the', 'efficacy', 'of', 'using', 'staging', 'acupuncture', 'and', 'moxibustion', 'to', 'treat', 'Bell', ""'s"", 'Palsy']","['O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT00608660,NCT00608660,Studying of Acupuncture for Bell's Palsy According to Different Stages | The purpose of this trial will certify the efficacy of using staging acupuncture and moxibustion to treat Bell's Palsy,"[(12, 23, 'OTHER', 'Acupuncture'), (28, 40, 'CONDITION', ""Bell's Palsy""), (142, 153, 'OTHER', 'acupuncture'), (158, 169, 'OTHER', 'moxibustion'), (179, 191, 'CONDITION', ""Bell's Palsy"")]"
"['Study', 'on', 'the', 'Inner', 'Ear', 'Immunisation', 'Post', '-', 'cohlear', 'Implantation', 'and', 'Perilymph', 'Molecular', 'Profiling', 'in', 'Sensorineural', 'Hearing', 'Loss', '|', 'Many', 'patients', 'receiving', 'cochlear', 'implant', '(', 'CI', ')', 'have', 'some', 'residual', 'hearing', 'prior', 'to', 'implantation', 'surgery', '.', 'However', ',', 'approximately', 'one', 'third', 'of', 'them', 'will', 'lose', 'it', 'in', 'next', '6', 'months', 'after', 'cochlear', 'implantation', '.', 'Although', 'the', 'mechanisms', 'involved', 'in', 'the', 'residual', 'audition', 'loss', 'remain', 'unknown', ',', 'animal', 'experiments', 'suggest', 'the', 'role', 'of', 'inflammatory', 'or', 'immune', 'reaction', 'in', 'the', 'cochlea', '.', 'The', 'goal', 'of', 'this', 'project', 'is', 'to', 'search', 'in', 'the', 'perilymph', '(', 'a', 'fluid', 'which', 'fills', 'the', 'scala', 'vestibuli', 'and', 'scala', 'tympani', 'of', 'the', 'cochlea', ')', 'some', 'predictive', 'biomarkers', 'of', 'the', 'residual', 'hearing', 'loss', 'using', 'modern', 'proteomics', 'and', 'immunological', 'techniques', '.', 'A', 'parallel', 'search', 'for', 'blood', 'biomarkers', 'of', 'post', '-', 'implantation', 'residual', 'hearing', 'loss', 'and', 'for', 'molecular', 'and', 'cellular', 'evidences', 'of', 'immune', 'response', 'to', 'cochlear', 'implantation', 'will', 'be', 'performed', '.', '\n\n', 'The', 'study', 'will', 'recruit', '50', 'subjects', '-', 'candidates', 'for', 'cochlear', 'implantation', 'surgery', ';', '30', 'normally', 'hearing', 'individuals', 'eligible', 'for', 'other', 'types', 'of', 'otological', 'interventions', 'will', 'form', 'a', 'control', 'group', '.', 'For', 'all', 'the', 'participants', 'blood', 'samples', 'will', 'be', 'collected', 'and', 'preserved', '.', 'In', 'addition', ',', 'the', 'perilymph', 'sampling', 'will', 'be', 'performed', 'during', 'cochlear', 'implantation', 'surgery', '.', '\n\n', 'This', 'project', 'relies', 'on', 'the', 'calculation', 'that', 'from', '50', 'patients', 'post', '-', 'cochlear', 'implantation', ',', '15', 'patients', 'will', 'form', 'a', 'group', 'with', 'maintained', 'residual', 'hearing', 'and', '15', 'will', 'display', 'delayed', 'hearing', 'loss', '.', 'For', 'these', '30', 'subjects', 'together', 'with', 'the', 'control', 'group', 'the', 'blood', 'biomarkers', 'search', 'will', 'be', 'performed', '.', '\n\n', 'For', 'the', 'group', 'of', 'implanted', 'patients', ',', 'the', 'follow', '-', 'up', 'will', 'last', 'for', '12', 'months', 'with', '6', 'visits', 'in', 'total', ':', '\n\n', 'the', 'inclusion', 'visit', 'V0', 'during', 'which', 'the', 'study', 'will', 'be', 'presented', 'and', 'the', 'consent', 'form', 'will', 'be', 'signed', '\n', 'the', 'surgery', 'visit', 'V1', 'with', 'blood', 'sample', 'and', 'perilymph', 'collection', '\n', 'the', 'activation', 'visit', 'V2', ',', '1', 'month', '±', '1', 'week', 'after', 'V1', ',', 'visit', 'V3', '3', 'months', '±', '7', 'days', 'after', 'V1', ',', 'V4', '6', 'months', '±', '7', 'days', 'after', 'V1', ',', 'V5', '12', 'months', '±', '1', 'month', 'after', 'V1', '.', 'During', 'each', 'of', 'this', 'visit', 'blood', 'sampling', 'will', 'be', 'performed', '.', '\n\n', 'For', 'the', 'control', 'group', ',', 'the', 'follow', 'up', 'will', 'be', '6', 'months', 'long', 'with', '4', 'visits', 'in', 'total', 'arranged', 'during', 'the', 'routine', 'follow', '-', 'up', 'appointments', ':', '\n\n', 'the', 'inclusion', 'visit', 'V0', 'during', 'which', 'the', 'study', 'will', 'be', 'presented', 'and', 'the', 'consent', 'form', 'will', 'be', 'signed', '\n', 'the', 'surgery', 'visit', 'V1', ',', 'the', '1', 'month', 'visit', 'V2', 'and', 'the', '6', 'months', 'visit', 'V3', 'during', 'which', 'the', 'blood', 'sampling', 'will', 'be', 'performed', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05670158,NCT05670158,"Study on the Inner Ear Immunisation Post-cohlear Implantation and Perilymph Molecular Profiling in Sensorineural Hearing Loss | Many patients receiving cochlear implant (CI) have some residual hearing prior to implantation surgery. However, approximately one third of them will lose it in next 6 months after cochlear implantation. Although the mechanisms involved in the residual audition loss remain unknown, animal experiments suggest the role of inflammatory or immune reaction in the cochlea. The goal of this project is to search in the perilymph (a fluid which fills the scala vestibuli and scala tympani of the cochlea) some predictive biomarkers of the residual hearing loss using modern proteomics and immunological techniques. A parallel search for blood biomarkers of post-implantation residual hearing loss and for molecular and cellular evidences of immune response to cochlear implantation will be performed.

The study will recruit 50 subjects-candidates for cochlear implantation surgery; 30 normally hearing individuals eligible for other types of otological interventions will form a control group. For all the participants blood samples will be collected and preserved. In addition, the perilymph sampling will be performed during cochlear implantation surgery.

This project relies on the calculation that from 50 patients post-cochlear implantation, 15 patients will form a group with maintained residual hearing and 15 will display delayed hearing loss. For these 30 subjects together with the control group the blood biomarkers search will be performed.

For the group of implanted patients, the follow-up will last for 12 months with 6 visits in total :

the inclusion visit V0 during which the study will be presented and the consent form will be signed
the surgery visit V1 with blood sample and perilymph collection
the activation visit V2, 1 month ± 1 week after V1, visit V3 3 months ± 7 days after V1, V4 6 months ± 7 days after V1, V5 12 months ± 1 month after V1. During each of this visit blood sampling will be performed.

For the control group, the follow up will be 6 months long with 4 visits in total arranged during the routine follow-up appointments:

the inclusion visit V0 during which the study will be presented and the consent form will be signed
the surgery visit V1, the 1 month visit V2 and the 6 months visit V3 during which the blood sampling will be performed.","[(41, 61, 'SURGICAL', 'cohlear Implantation'), (99, 125, 'CONDITION', 'Sensorineural Hearing Loss'), (152, 168, 'SURGICAL', 'cochlear implant'), (170, 172, 'SURGICAL', 'CI'), (309, 330, 'SURGICAL', 'cochlear implantation'), (372, 394, 'CONDITION', 'residual audition loss'), (662, 683, 'CONDITION', 'residual hearing loss'), (798, 819, 'CONDITION', 'residual hearing loss'), (975, 1004, 'SURGICAL', 'cochlear implantation surgery'), (1051, 1090, 'CONTROL', 'other types of otological interventions'), (1251, 1272, 'SURGICAL', 'cochlear implantation'), (1349, 1370, 'SURGICAL', 'cochlear implantation'), (1455, 1475, 'CONDITION', 'delayed hearing loss')]"
"['Non', '-', 'invasive', 'Brain', '-', 'computer', 'Interfaces', 'for', 'Control', 'of', 'Assistive', 'Devices', '|', 'A', 'brain', '-', 'computer', 'interface', '(', 'BCI', ')', 'decodes', 'users', ""'"", 'behavioral', 'intentions', 'or', 'mental', 'states', 'directly', 'from', 'their', 'brain', 'activity', ',', 'thus', 'allowing', 'operation', 'of', 'devices', 'without', 'requiring', 'any', 'overt', 'motor', 'action', '.', 'One', 'major', 'modality', 'for', 'BCI', 'control', 'is', 'based', 'on', 'motor', 'imagery', '(', 'MI', ')', ',', 'which', 'is', 'the', 'mental', 'rehearsal', 'of', 'the', 'kinesthetics', 'of', 'a', 'movement', 'without', 'actually', 'performing', 'it', '.', 'MI', '-', 'based', 'BCIs', 'translate', 'motor', 'intents', 'into', 'control', 'commands', 'for', 'external', 'devices', '.', 'A', 'major', 'challenge', 'in', 'such', 'BCIs', 'is', 'differentiating', 'MI', 'patterns', 'corresponding', 'to', 'fine', 'hand', 'movements', 'of', 'the', 'same', 'limb', 'from', 'non', '-', 'invasive', 'EEG', 'recordings', 'with', 'low', 'spatial', 'resolution', 'since', 'the', 'cortical', 'sources', 'responsible', 'for', 'these', 'movements', 'are', 'overlapping', '.', 'In', 'this', 'study', ',', 'the', 'investigators', 'hypothesize', 'that', 'neuromuscular', 'electrical', 'stimulation', '(', 'NMES', ')', 'applied', 'contingent', 'to', 'the', 'voluntary', 'activation', 'of', 'the', 'primary', 'motor', 'cortex', 'through', 'MI', 'can', 'help', 'differentiate', 'patterns', 'of', 'activity', 'associated', 'with', 'different', 'hand', 'movements', 'of', 'the', 'same', 'limb', 'by', 'consistently', 'recruiting', 'the', 'separate', 'neural', 'pathways', 'associated', 'with', 'each', 'of', 'the', 'movements', 'within', 'a', 'closed', '-', 'loop', 'BCI', 'setup', '.', 'This', 'is', 'expected', 'to', 'be', 'associated', 'with', 'neuroplastic', 'changes', 'at', 'the', 'cortical', 'or', 'corticospinal', 'levels', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05183152,NCT05183152,"Non-invasive Brain-computer Interfaces for Control of Assistive Devices | A brain-computer interface (BCI) decodes users' behavioral intentions or mental states directly from their brain activity, thus allowing operation of devices without requiring any overt motor action. One major modality for BCI control is based on motor imagery (MI), which is the mental rehearsal of the kinesthetics of a movement without actually performing it. MI-based BCIs translate motor intents into control commands for external devices. A major challenge in such BCIs is differentiating MI patterns corresponding to fine hand movements of the same limb from non-invasive EEG recordings with low spatial resolution since the cortical sources responsible for these movements are overlapping. In this study, the investigators hypothesize that neuromuscular electrical stimulation (NMES) applied contingent to the voluntary activation of the primary motor cortex through MI can help differentiate patterns of activity associated with different hand movements of the same limb by consistently recruiting the separate neural pathways associated with each of the movements within a closed-loop BCI setup. This is expected to be associated with neuroplastic changes at the cortical or corticospinal levels.","[(13, 38, 'OTHER', 'Brain-computer Interfaces'), (54, 71, 'OTHER', 'Assistive Devices'), (76, 100, 'OTHER', 'brain-computer interface'), (102, 105, 'OTHER', 'BCI'), (297, 300, 'OTHER', 'BCI'), (321, 334, 'OTHER', 'motor imagery'), (336, 338, 'OTHER', 'MI'), (437, 450, 'OTHER', 'MI-based BCIs'), (545, 549, 'OTHER', 'BCIs'), (569, 571, 'OTHER', 'MI'), (822, 858, 'OTHER', 'neuromuscular electrical stimulation'), (860, 864, 'OTHER', 'NMES'), (949, 951, 'OTHER', 'MI'), (1157, 1172, 'OTHER', 'closed-loop BCI')]"
"['Vestibular', 'Schwannoma', '-', 'Radiosurgery', 'or', 'Expectation', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'outcome', 'of', 'patients', 'with', 'vestibular', 'schwannomas', 'in', 'two', 'groups', 'of', 'randomised', 'to', 'either', 'radiosurgery', 'or', 'expectation', '.', '\n\n', 'The', 'optimal', 'treatment', 'for', 'a', 'small', 'vestibular', 'schwannoma', 'is', 'a', 'matter', 'of', 'controversy', 'and', 'there', 'are', 'no', 'class', '1', 'studies', 'investigating', 'this', '.', 'Even', 'the', 'natural', 'tumor', 'growth', 'rate', 'remains', 'controversial', 'and', 'is', 'reported', 'to', 'be', 'from', 'near', '100', '%', 'of', 'cases', 'showing', 'growth', 'to', '40', '-', '60', '%', 'in', 'various', 'reports', '.', 'The', 'clinical', 'results', 'of', 'various', 'treatment', 'strategies', 'are', 'documented', ',', 'but', 'comparative', 'studies', 'are', 'very', 'few', '.', 'Immediate', 'radiosurgery', 'or', 'wait', '-', 'and', 'scan', 'with', 'subsequent', 'treatment', 'upon', 'growth', 'are', 'two', 'strategies', 'that', 'have', 'both', 'been', 'used', 'in', 'many', 'different', 'centers', '.', 'There', 'are', 'only', 'two', 'studies', 'comparing', 'these', 'treatment', 'modalities', '.These', 'studies', 'indicate', 'significant', 'effect', 'of', 'GKRS', 'in', 'reducing', 'tumor', 'growth', ',', 'with', 'less', 'differences', 'in', 'hearing', 'and', 'complaint', 'outcomes', '.', 'None', 'of', 'the', 'studies', 'are', 'blinded', 'or', 'randomised', ',', 'allowing', 'for', 'bias', '.', '\n\n', 'The', 'present', 'study', 'aims', 'at', 'comparing', 'the', 'two', 'modalities', 'above', '.', 'To', 'achieve', 'this', ',', 'we', 'intend', 'to', 'randomise', 'patients', 'with', 'newly', 'diagnosed', 'VS', 'to', 'either', 'of', 'Wait', '-', 'and', 'Scan', 'or', 'immediate', 'radiosurgery', '.', '\n\n', 'The', 'primary', 'study', 'endpoint', 'is', 'the', 'relative', 'tumor', 'size', 'measured', 'as', 'the', 'ratio', 'between', 'tumor', 'volume', 'at', 'four', 'years', 'compared', 'with', 'volume', 'at', 'inclusion', '.', 'Secondary', 'endpoints', 'include', 'symptom', 'and', 'sign', 'development', 'measured', 'by', 'clinical', 'examination', 'and', 'by', 'patient', ""'s"", 'responses', 'to', 'standardised', 'validated', 'questionnaires', '.', 'In', 'addition', ',', 'the', 'health', 'economics', 'involved', 'with', 'both', 'strategies', 'will', 'be', 'evaluated', 'and', 'compared', ',', 'as', 'well', 'as', 'the', 'patient', ""'s"", 'working', 'status', '.', '\n\n', 'Patients', 'will', 'be', 'asked', 'to', 'participate', 'if', 'their', 'VS', 'is', 'diagnosed', 'within', 'the', 'last', 'six', 'months', ',', 'their', 'age', 'is', 'between', '18', 'and', '70', ',', 'and', 'pending', 'there', 'are', 'no', 'exclusion', 'criteria', '(', 'see', 'below', ')', '.', 'A', 'power', 'analysis', 'indicates', 'that', 'about', '50', 'patients', 'per', 'group', 'is', 'sufficient', '.', '\n\n', 'In', 'case', 'of', 'failure', 'to', 'recruit', 'patients', ',', 'we', 'will', 'change', 'the', 'design', 'to', 'a', 'study', 'based', 'on', 'patient', ""'s"", 'own', 'choice', 'of', 'treatment', '.', '\n\n', 'The', 'study', 'will', 'be', 'announced', 'according', 'to', 'international', 'guidelines', '.', 'A', 'steering', 'committee', 'will', 'monitor', 'the', 'study', 'and', 'an', 'intermediate', 'analysis', 'will', 'be', 'performed', 'when', 'the', 'study', 'group', 'has', 'been', 'followed', 'for', 'two', 'years', '.', 'If', 'the', 'effect', 'aim', 'is', 'already', 'observed', ',', 'the', 'study', 'should', 'nonetheless', 'continue', ',', 'as', 'it', 'is', 'too', 'early', 'to', 'evaluate', 'the', 'results', 'after', 'such', 'a', 'short', 'time', 'course', '.', '\n\n', 'It', 'will', 'also', 'be', 'discussed', 'to', 'do', 'a', 'follow', '-', 'up', 'of', 'all', 'patients', 'ten', 'years', 'after', 'inclusion', '.']","['B-COND', 'I-COND', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02249572,NCT02249572,"Vestibular Schwannoma - Radiosurgery or Expectation | The purpose of this study is to compare the outcome of patients with vestibular schwannomas in two groups of randomised to either radiosurgery or expectation.

The optimal treatment for a small vestibular schwannoma is a matter of controversy and there are no class 1 studies investigating this. Even the natural tumor growth rate remains controversial and is reported to be from near 100% of cases showing growth to 40-60% in various reports. The clinical results of various treatment strategies are documented, but comparative studies are very few. Immediate radiosurgery or wait-and scan with subsequent treatment upon growth are two strategies that have both been used in many different centers. There are only two studies comparing these treatment modalities .These studies indicate significant effect of GKRS in reducing tumor growth, with less differences in hearing and complaint outcomes. None of the studies are blinded or randomised, allowing for bias.

The present study aims at comparing the two modalities above. To achieve this, we intend to randomise patients with newly diagnosed VS to either of Wait-and Scan or immediate radiosurgery.

The primary study endpoint is the relative tumor size measured as the ratio between tumor volume at four years compared with volume at inclusion. Secondary endpoints include symptom and sign development measured by clinical examination and by patient's responses to standardised validated questionnaires. In addition, the health economics involved with both strategies will be evaluated and compared, as well as the patient's working status.

Patients will be asked to participate if their VS is diagnosed within the last six months, their age is between 18 and 70, and pending there are no exclusion criteria (see below). A power analysis indicates that about 50 patients per group is sufficient.

In case of failure to recruit patients, we will change the design to a study based on patient's own choice of treatment.

The study will be announced according to international guidelines. A steering committee will monitor the study and an intermediate analysis will be performed when the study group has been followed for two years. If the effect aim is already observed, the study should nonetheless continue, as it is too early to evaluate the results after such a short time course.

It will also be discussed to do a follow-up of all patients ten years after inclusion.","[(0, 21, 'CONDITION', 'Vestibular Schwannoma'), (24, 36, 'RADIOTHERAPY', 'Radiosurgery'), (123, 145, 'CONDITION', 'vestibular schwannomas'), (184, 196, 'RADIOTHERAPY', 'radiosurgery'), (248, 269, 'CONDITION', 'vestibular schwannoma'), (367, 372, 'CONDITION', 'tumor'), (615, 627, 'RADIOTHERAPY', 'radiosurgery'), (864, 868, 'RADIOTHERAPY', 'GKRS'), (881, 886, 'CONDITION', 'tumor'), (1135, 1153, 'CONDITION', 'newly diagnosed VS'), (1194, 1206, 'RADIOTHERAPY', 'radiosurgery'), (1252, 1257, 'CONDITION', 'tumor'), (1293, 1298, 'CONDITION', 'tumor'), (1699, 1701, 'CONDITION', 'VS')]"
"['Effect', 'of', 'Segmental', 'Muscle', 'Vibration', 'on', 'Upper', 'Extremity', 'Functional', 'Ability', 'Post', 'Stroke', '|', 'Background', 'and', 'objective', ':', 'Upper', 'extremity', 'functional', 'impairments', 'are', 'common', 'consequences', 'post', 'stroke', '.', 'The', 'aim', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'influence', 'of', 'Segmental', 'muscle', 'vibration', '(', 'SMV', ')', 'application', 'along', 'with', 'supervised', 'physical', 'therapy', '(', 'SPT', ')', 'on', 'improving', 'activities', 'of', 'daily', 'living', '(', 'ADL', ')', 'and', 'motor', 'recovery', 'on', 'the', 'hemiparetic', 'upper', 'extremity', 'in', 'patients', 'with', 'stroke', '.', '\n\n', 'Methods', ':', 'A', 'sample', 'of', '37', 'patients', 'post', 'stroke', '(', '29', 'males', ')', 'was', 'randomly', 'assigned', 'to', 'either', 'supervised', 'physical', 'therapy', '(', 'SPT', ')', 'control', 'group', '(', 'n=18', ')', 'or', 'supervised', 'physical', 'therapy', 'and', 'segmental', 'muscle', 'vibration', '(', 'SPT', '-', 'SMV', ')', 'experimental', 'group', '(', 'n=19', ')', '.', 'All', 'patients', 'received', '3', 'sessions', 'per', 'week', 'of', 'SPT', 'for', '8', 'weeks', '.', 'The', 'SPT', '-', 'SMV', 'experimental', 'group', 'received', 'SMV', 'at', 'the', 'end', 'of', 'each', 'SPT', 'session', '.', 'Outcome', 'measures', 'used', 'were', 'Barthel', 'Index', '(', 'BI', ')', ',', 'Modified', 'Ashworth', 'Scale', '(', 'MAS', ')', ',', 'Manual', 'Muscle', 'Testing', '(', 'MMT', ')', ',', 'and', 'goniometry', 'for', 'Range', 'of', 'Motion', '(', 'ROM', ')', 'assessment', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03419793,NCT03419793,"Effect of Segmental Muscle Vibration on Upper Extremity Functional Ability Post Stroke | Background and objective: Upper extremity functional impairments are common consequences post stroke. The aim of this study was to investigate the influence of Segmental muscle vibration (SMV) application along with supervised physical therapy (SPT) on improving activities of daily living (ADL) and motor recovery on the hemiparetic upper extremity in patients with stroke.

Methods: A sample of 37 patients post stroke (29 males) was randomly assigned to either supervised physical therapy (SPT) control group (n=18) or supervised physical therapy and segmental muscle vibration (SPT-SMV) experimental group (n=19). All patients received 3 sessions per week of SPT for 8 weeks. The SPT-SMV experimental group received SMV at the end of each SPT session. Outcome measures used were Barthel Index (BI), Modified Ashworth Scale (MAS), Manual Muscle Testing (MMT), and goniometry for Range of Motion (ROM) assessment.","[(10, 36, 'OTHER', 'Segmental Muscle Vibration'), (75, 86, 'CONDITION', 'Post Stroke'), (115, 153, 'CONDITION', 'Upper extremity functional impairments'), (178, 189, 'CONDITION', 'post stroke'), (249, 275, 'OTHER', 'Segmental muscle vibration'), (277, 280, 'OTHER', 'SMV'), (305, 332, 'PHYSICAL', 'supervised physical therapy'), (334, 337, 'PHYSICAL', 'SPT'), (456, 462, 'CONDITION', 'stroke'), (498, 509, 'CONDITION', 'post stroke'), (553, 580, 'PHYSICAL', 'supervised physical therapy'), (582, 585, 'PHYSICAL', 'SPT'), (611, 638, 'PHYSICAL', 'supervised physical therapy'), (643, 669, 'OTHER', 'segmental muscle vibration'), (671, 678, 'OTHER', 'SPT-SMV'), (752, 755, 'PHYSICAL', 'SPT'), (773, 780, 'OTHER', 'SPT-SMV'), (809, 812, 'OTHER', 'SMV'), (832, 835, 'PHYSICAL', 'SPT')]"
"['Evaluation', 'of', 'Cerebrovascular', 'Events', 'in', 'Patients', 'With', 'Occlusive', 'Carotid', 'Artery', 'Disorders', 'Based', 'on', 'Morphological', 'and', 'Hemodynamical', 'Features', '|', 'As', 'of', 'today', ',', 'no', 'suitable', 'multiparametric', 'predictive', 'method', 'is', 'available', 'to', 'properly', 'estimate', 'stroke', 'risk', 'in', 'patients', 'with', 'carotid', 'artery', 'stenosis', '.', 'Carotid', 'artery', 'stenosis', 'is', 'one', 'of', 'the', 'proven', 'risk', 'factors', 'of', 'stroke', 'incidence', ',', 'but', 'the', 'indication', 'of', 'its', 'intervention', 'is', 'merely', 'the', 'grade', 'of', 'stenosis', 'itself', '.', 'The', 'current', 'international', 'guidelines', 'suggest', 'intervention', 'for', 'asymptomatic', 'patients', 'only', 'with', 'potentially', 'high', 'risk', 'plaques', 'but', 'pharmacological', 'treatment', 'is', 'advised', 'to', 'low', 'risk', 'patients', '.', 'Unfortunately', 'there', 'is', 'no', 'proven', 'and', 'widely', 'accepted', 'system', 'to', 'distinguish', 'these', 'two', 'categories', 'of', 'patients', 'with', 'carotid', 'artery', 'stenosis', '.', '\n\n', 'In', 'this', 'project', 'the', 'following', 'parameters', 'will', 'be', 'assessed', 'both', 'in', 'asymptomatic', 'and', 'symptomatic', 'patients', ':', '1', ',', 'preoperative', 'stroke', 'risk', 'prediction', 'based', 'on', 'comparative', 'analysis', 'of', 'CT', 'angiography', '(', 'CTA', ')', 'results', 'of', 'plaque', 'morphology', 'and', 'ultrasound', '(', 'US', ')', 'based', 'plaque', 'elastography', 'analysis', ',', '2', ')', 'intracranial', 'bloodflow', 'will', 'be', 'measured', 'by', 'transcranial', 'Doppler', 'sonography(TCD', ')', ',', '3', ')', 'presence', 'recent', 'of', 'silent', 'brain', 'ischemia', 'on', 'diffusion', 'weighted', 'imaging', '(', 'DWI', ')', 'MR', '(', 'magnetic', 'resonance', ')', ',', '4', ')', 'retinal', 'perfusion', 'measurement', 'by', 'optical', 'coherence', 'tomography', 'angiography', '(', 'OCT', ')', '.', 'The', 'investigators', 'aim', 'to', 'establish', 'a', 'clinically', 'meaningful', 'and', 'more', 'accurate', '(', 'than', 'stenosis', 'grade', ')', 'stroke', 'risk', 'prediction', 'algorithm', 'for', 'asymptomatic', 'carotid', 'stenosis', 'patients', 'based', 'on', 'these', 'parameters', '.']","['O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03840265,NCT03840265,"Evaluation of Cerebrovascular Events in Patients With Occlusive Carotid Artery Disorders Based on Morphological and Hemodynamical Features | As of today, no suitable multiparametric predictive method is available to properly estimate stroke risk in patients with carotid artery stenosis. Carotid artery stenosis is one of the proven risk factors of stroke incidence, but the indication of its intervention is merely the grade of stenosis itself. The current international guidelines suggest intervention for asymptomatic patients only with potentially high risk plaques but pharmacological treatment is advised to low risk patients. Unfortunately there is no proven and widely accepted system to distinguish these two categories of patients with carotid artery stenosis.

In this project the following parameters will be assessed both in asymptomatic and symptomatic patients: 1, preoperative stroke risk prediction based on comparative analysis of CT angiography (CTA) results of plaque morphology and ultrasound (US) based plaque elastography analysis, 2) intracranial bloodflow will be measured by transcranial Doppler sonography(TCD), 3) presence recent of silent brain ischemia on diffusion weighted imaging (DWI) MR (magnetic resonance), 4) retinal perfusion measurement by optical coherence tomography angiography (OCT). The investigators aim to establish a clinically meaningful and more accurate (than stenosis grade) stroke risk prediction algorithm for asymptomatic carotid stenosis patients based on these parameters.","[(14, 36, 'CONDITION', 'Cerebrovascular Events'), (54, 88, 'CONDITION', 'Occlusive Carotid Artery Disorders'), (234, 240, 'CONDITION', 'stroke'), (263, 286, 'CONDITION', 'carotid artery stenosis'), (288, 311, 'CONDITION', 'Carotid artery stenosis'), (349, 355, 'CONDITION', 'stroke'), (746, 769, 'CONDITION', 'carotid artery stenosis'), (893, 899, 'CONDITION', 'stroke'), (1161, 1182, 'CONDITION', 'silent brain ischemia'), (1427, 1433, 'CONDITION', 'stroke'), (1464, 1493, 'CONDITION', 'asymptomatic carotid stenosis')]"
"['Study', 'of', 'Efficacy', 'and', 'Tolerance', 'of', 'Early', 'Launching', 'of', 'Nocturnal', 'Non', 'Invasive', 'Ventilation', 'in', 'Adults', 'With', 'Myotonic', 'Dystrophy', 'Type', '1(DM1', ')', '|', 'This', 'is', 'a', 'multicenter', 'randomized', 'controlled', 'open', 'labeled', 'study', 'testing', 'efficacy', 'and', 'tolerance', 'of', 'early', 'launching', 'of', 'night', 'non', 'invasive', 'ventilation', 'in', 'patients', 'with', 'myotonic', 'dystrophy', 'type', '1(DM1', ')', '.', 'The', 'object', 'of', 'this', 'project', 'is', 'to', 'estimate', 'the', 'effects', 'of', 'the', 'early', 'introduction', 'of', 'non', 'invasive', 'ventilation', 'on', 'the', 'arisen', 'of', 'complication', '(', 'non', 'expected', 'hospitalization', ',', 'tracheostomy', 'even', 'death', ')', 'with', 'regard', 'to', 'a', 'simple', 'respiratory', 'follow', '-', 'up', 'in', 'patients', 'affected', 'by', 'myotonic', 'dystrophy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT01225614,NCT01225614,"Study of Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Ventilation in Adults With Myotonic Dystrophy Type 1(DM1) | This is a multicenter randomized controlled open labeled study testing efficacy and tolerance of early launching of night non invasive ventilation in patients with myotonic dystrophy type 1(DM1). The object of this project is to estimate the effects of the early introduction of non invasive ventilation on the arisen of complication (non expected hospitalization, tracheostomy even death) with regard to a simple respiratory follow-up in patients affected by myotonic dystrophy.","[(35, 88, 'OTHER', 'Early Launching of Nocturnal Non Invasive Ventilation'), (104, 134, 'CONDITION', 'Myotonic Dystrophy Type 1(DM1)'), (234, 283, 'OTHER', 'early launching of night non invasive ventilation'), (301, 331, 'CONDITION', 'myotonic dystrophy type 1(DM1)'), (394, 440, 'OTHER', 'early introduction of non invasive ventilation'), (597, 615, 'CONDITION', 'myotonic dystrophy')]"
"['""', 'Brain', 'Changes', 'After', 'Repetitive', 'Head', 'Impacts', 'in', 'Soccer', 'and', 'the', 'Effects', 'of', 'a', 'Protective', 'Device', ':', 'Biomechanical', ',', 'Cognitive', ',', 'Electrophysiological', 'and', 'Multimodal', 'Neuroimaging', 'Study', '""', '|', 'Soccer', ',', 'the', 'most', 'popular', 'sport', 'in', 'the', 'world', ',', 'exposes', 'players', 'to', 'repeated', 'head', 'impacts', 'and', 'concussions', ',', 'due', 'to', 'contact', 'with', 'another', 'player', 'or', 'with', 'the', 'ground', '.', 'Moreover', ',', 'routine', 'game', '-', 'play', 'in', 'soccer', 'involves', 'intentional', 'and', 'repeated', 'head', 'impacts', 'through', 'ball', '""', 'heading', '""', ',', 'with', 'frequent', 'high', 'velocities', ',', 'which', 'might', 'cause', 'a', 'transient', 'brain', 'dysfunction', '.', 'In', 'this', 'pre', '-', 'post', 'prospective', 'interventional', 'study', ',', '22', 'soccer', 'players', 'will', 'perform', '10', 'headers', 'from', 'machine', '-', 'projected', 'soccer', 'balls', 'at', 'standardized', 'speeds', ',', 'modelling', 'routine', 'soccer', 'practice', '.', 'They', 'will', 'perform', 'heading', 'series', 'in', '2', 'different', 'oral', 'conditions', ',', 'on', 'different', 'days', 'at', 'least', '1', 'week', 'apart', ':', '1', ')', 'Without', 'mouthguard', 'and', 'tight', 'jaws', ';', '2', ')', 'With', 'mouthguard', 'and', 'tight', 'jaws', '.', 'The', 'strength', 'of', 'the', 'neck', 'muscles', 'will', 'be', 'measured', 'before', 'the', 'heading', 'series', '.', 'The', 'kinematic', 'of', 'the', 'movement', 'will', 'be', 'recorded', 'during', 'each', 'impact', 'during', 'the', '2', 'heading', 'series', ',', 'as', 'well', 'as', 'the', 'activity', 'of', 'the', 'jaw', 'muscles', 'which', 'will', 'be', 'recorded', 'by', 'electromyogram', '.', 'Before', 'and', 'after', 'each', 'heading', 'series', ',', 'electrophysiological', 'data', ',', 'multimodal', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', ',', 'and', 'cognitive', 'computerized', 'assessment', 'will', 'be', 'acquired']","['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04426188,NCT04426188,""" Brain Changes After Repetitive Head Impacts in Soccer and the Effects of a Protective Device: Biomechanical, Cognitive, Electrophysiological and Multimodal Neuroimaging Study "" | Soccer, the most popular sport in the world, exposes players to repeated head impacts and concussions, due to contact with another player or with the ground. Moreover, routine game-play in soccer involves intentional and repeated head impacts through ball ""heading"", with frequent high velocities, which might cause a transient brain dysfunction. In this pre-post prospective interventional study, 22 soccer players will perform 10 headers from machine-projected soccer balls at standardized speeds, modelling routine soccer practice. They will perform heading series in 2 different oral conditions, on different days at least 1 week apart: 1) Without mouthguard and tight jaws ; 2) With mouthguard and tight jaws. The strength of the neck muscles will be measured before the heading series. The kinematic of the movement will be recorded during each impact during the 2 heading series, as well as the activity of the jaw muscles which will be recorded by electromyogram. Before and after each heading series, electrophysiological data, multimodal magnetic resonance imaging (MRI), and cognitive computerized assessment will be acquired","[(22, 45, 'CONDITION', 'Repetitive Head Impacts'), (77, 94, 'OTHER', 'Protective Device'), (245, 266, 'CONDITION', 'repeated head impacts'), (271, 282, 'CONDITION', 'concussions'), (402, 423, 'CONDITION', 'repeated head impacts'), (825, 858, 'CONTROL', 'Without mouthguard and tight jaws'), (869, 879, 'OTHER', 'mouthguard'), (884, 894, 'OTHER', 'tight jaws')]"
"['Mind', '-', 'Body', 'Interventions', 'to', 'Mitigate', 'Effects', 'of', 'Media', 'Use', 'on', 'Sleep', '(', 'Sleepazoid', 'Study', ')', '|', 'Eliminating', 'media', 'use', 'is', 'neither', 'feasible', 'at', 'a', 'public', 'health', 'level', 'nor', 'perhaps', 'even', 'desirable', 'given', 'the', 'role', 'it', 'plays', 'in', 'the', 'lives', 'of', 'youth', 'and', 'adults', ',', 'but', 'mind', '-', 'body', 'interventions', 'have', 'the', 'potential', 'to', 'mitigate', 'state', 'arousal', 'effects', 'and', 'thus', 'reduce', 'negative', 'impacts', 'on', 'sleep', '.', 'Given', 'emerging', 'literature', 'on', 'links', 'between', 'intensive', 'media', 'use', ',', 'sensory', 'and', 'interoceptive', 'awareness', ',', 'and', 'self', '-', 'regulation', ',', 'this', 'study', 'will', 'examine', 'two', 'related', 'mind', '-', 'body', 'approaches', '--', 'a', 'mindfulness', 'sensory', 'awareness', 'exercises', 'and', 'mindful', 'body', 'awareness', 'check', '-', 'ins', '--', 'in', 'a', 'randomized', 'clinical', 'trial', 'of', 'early', 'adolescents', 'with', 'evening', 'media', 'use', 'and', 'sleep', 'problems', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04550507,NCT04550507,"Mind-Body Interventions to Mitigate Effects of Media Use on Sleep (Sleepazoid Study) | Eliminating media use is neither feasible at a public health level nor perhaps even desirable given the role it plays in the lives of youth and adults, but mind-body interventions have the potential to mitigate state arousal effects and thus reduce negative impacts on sleep. Given emerging literature on links between intensive media use, sensory and interoceptive awareness, and self-regulation, this study will examine two related mind-body approaches -- a mindfulness sensory awareness exercises and mindful body awareness check-ins -- in a randomized clinical trial of early adolescents with evening media use and sleep problems.","[(0, 23, 'OTHER', 'Mind-Body Interventions'), (243, 266, 'OTHER', 'mind-body interventions'), (521, 541, 'OTHER', 'mind-body approaches'), (547, 586, 'OTHER', 'mindfulness sensory awareness exercises'), (591, 623, 'OTHER', 'mindful body awareness check-ins'), (706, 720, 'CONDITION', 'sleep problems')]"
"['Applied', 'Research', 'in', 'Children', 'With', 'Spastic', 'Cerebral', 'Palsy', 'in', 'the', 'Extracorporeal', 'Shock', 'Wave', 'Therapy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'radial', 'extracorporeal', 'shock', 'wave', 'therapy', 'in', 'combination', 'with', 'traditional', 'physical', 'therapy', 'is', 'safe', 'and', 'effective', 'for', 'the', 'management', 'of', 'spastic', 'plantar', 'flexor', 'muscles', 'in', 'patients', 'with', 'cerebral', 'palsy', 'younger', 'than', 'averaged', 'three', 'years', 'of', 'age', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02719483,NCT02719483,Applied Research in Children With Spastic Cerebral Palsy in the Extracorporeal Shock Wave Therapy | The purpose of this study is to determine whether radial extracorporeal shock wave therapy in combination with traditional physical therapy is safe and effective for the management of spastic plantar flexor muscles in patients with cerebral palsy younger than averaged three years of age.,"[(34, 56, 'CONDITION', 'Spastic Cerebral Palsy'), (64, 97, 'OTHER', 'Extracorporeal Shock Wave Therapy'), (150, 190, 'OTHER', 'radial extracorporeal shock wave therapy'), (223, 239, 'PHYSICAL', 'physical therapy'), (284, 291, 'CONDITION', 'spastic'), (332, 346, 'CONDITION', 'cerebral palsy')]"
"['A', 'Single', '-', 'Center', ',', 'Randomized', ',', 'Investigator', '/', 'Subject', '-', 'Blind', ',', 'Adaptive', 'Single', '-', 'Ascending', '-', 'Dose(SAD', ')', ',', 'Placebo', '-', 'Controlled', ',', 'Parallel', 'Study', 'to', 'Investigate', 'the', 'Safety', ',', 'Tolerability', ',', 'Pharmacokinetics', '(', 'Including', 'the', 'Effect', 'of', 'Food', 'and', 'the', 'Effect', 'of', 'Itraconazole', 'on', 'the', 'Pharmacokinetics', 'of', 'a', 'Single', 'Oral', 'Dose', 'of', 'RO7034067', ')', ',', 'and', 'Pharmacodynamics', 'of', 'RO7034067', 'Following', 'Oral', 'Administration', 'in', 'Healthy', 'Subjects', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'safety', 'and', 'tolerability', 'of', 'Risdiplam', '(', 'RO7034067', ')', 'in', 'healthy', 'people', '.', 'The', 'study', 'will', 'assess', 'what', 'the', 'body', 'does', 'to', 'Risdiplam', '(', 'RO7034067', ')', 'and', 'what', 'Risdiplam', '(', 'RO7034067', ')', 'does', 'to', 'the', 'body', '.', 'Risdiplam', '(', 'RO7034067', ')', 'will', 'be', 'given', 'by', 'mouth', 'in', 'gradually', 'increasing', 'doses', '.', 'The', 'data', 'from', 'this', 'study', 'will', 'help', 'to', 'define', 'the', 'dose', 'to', 'further', 'explore', 'Risdiplam', '(', 'RO7034067', ')', 'in', 'patients', 'with', 'Spinal', 'Muscular', 'Atrophy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02633709,NCT02633709,"A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Single-Ascending-Dose(SAD), Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food and the Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of RO7034067), and Pharmacodynamics of RO7034067 Following Oral Administration in Healthy Subjects | The objective of this study is to assess the safety and tolerability of Risdiplam (RO7034067) in healthy people. The study will assess what the body does to Risdiplam (RO7034067) and what Risdiplam (RO7034067) does to the body. Risdiplam (RO7034067) will be given by mouth in gradually increasing doses. The data from this study will help to define the dose to further explore Risdiplam (RO7034067) in patients with Spinal Muscular Atrophy.","[(94, 101, 'CONTROL', 'Placebo'), (235, 247, 'DRUG', 'Itraconazole'), (297, 306, 'DRUG', 'RO7034067'), (333, 342, 'DRUG', 'RO7034067'), (467, 476, 'DRUG', 'Risdiplam'), (478, 487, 'DRUG', 'RO7034067'), (552, 561, 'DRUG', 'Risdiplam'), (563, 572, 'DRUG', 'RO7034067'), (583, 592, 'DRUG', 'Risdiplam'), (594, 603, 'DRUG', 'RO7034067'), (623, 632, 'DRUG', 'Risdiplam'), (634, 643, 'DRUG', 'RO7034067'), (772, 781, 'DRUG', 'Risdiplam'), (783, 792, 'DRUG', 'RO7034067')]"
"['Perceptual', '-', 'Cognitive', 'Training', 'After', 'a', 'Mild', 'Traumatic', 'Brain', 'Injury', ':', 'Towards', 'a', 'Sensitive', 'Marker', 'for', 'Recovery', '|', 'This', 'study', 'is', 'part', 'of', 'a', 'larger', ',', 'multi', '-', 'centered', 'project', 'done', 'with', 'the', 'collaboration', 'of', 'University', 'Of', 'Victoria', '.', 'This', 'study', 'holds', 'three', 'separate', 'studies', 'on', 'the', 'mild', 'traumatic', 'brain', 'injured', 'population', 'and', 'the', 'use', 'of', 'perceptual', '-', 'cognitive', 'training', '(', '3D', '-', 'MOT', ')', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O']",NCT03213730,NCT03213730,"Perceptual-Cognitive Training After a Mild Traumatic Brain Injury: Towards a Sensitive Marker for Recovery | This study is part of a larger, multi-centered project done with the collaboration of University Of Victoria. This study holds three separate studies on the mild traumatic brain injured population and the use of perceptual-cognitive training (3D-MOT).","[(0, 29, 'BEHAVIOURAL', 'Perceptual-Cognitive Training'), (38, 65, 'CONDITION', 'Mild Traumatic Brain Injury'), (266, 294, 'CONDITION', 'mild traumatic brain injured'), (321, 350, 'BEHAVIOURAL', 'perceptual-cognitive training'), (352, 358, 'BEHAVIOURAL', '3D-MOT')]"
"['PET', 'Imaging', 'Study', 'of', 'α7', 'and', 'α4β2', '-', 'nAChR', 'in', 'Schizophrenia', ':', 'Cognitive', 'Relationships', '|', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'use', 'specialized', 'brain', 'imaging', 'techniques', ',', 'Positron', 'Emission', 'Tomography', '(', 'PET', ')', 'scan', 'and', 'Magnetic', 'Resonance', 'Imaging', '(', 'MRI', ')', ',', 'to', 'learn', 'more', 'about', 'the', 'brain', 'chemistry', ',', 'e.g.', ',', 'how', 'neurotransmitters', 'and', 'receptors', 'in', 'the', 'brain', 'function', 'in', 'people', 'with', 'schizophrenia', 'compared', 'to', 'healthy', 'controls', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",NCT05462340,NCT05462340,"PET Imaging Study of α7 and α4β2-nAChR in Schizophrenia: Cognitive Relationships | The purpose of this research is to use specialized brain imaging techniques, Positron Emission Tomography (PET) scan and Magnetic Resonance Imaging (MRI), to learn more about the brain chemistry, e.g., how neurotransmitters and receptors in the brain function in people with schizophrenia compared to healthy controls.","[(42, 55, 'CONDITION', 'Schizophrenia'), (358, 371, 'CONDITION', 'schizophrenia')]"
"['The', 'Impact', 'of', 'Dementia', 'on', 'Care', 'and', 'Outcomes', 'Associated', 'With', 'a', 'Function', 'Focused', 'Care', 'Intervention', 'Among', 'Residents', 'in', 'Assisted', 'Living', 'Settings', '.', '|', 'This', 'study', 'will', 'evaluate', 'pain', ',', 'management', 'of', 'pain', ',', 'behavioral', 'symptoms', ',', 'and', 'the', 'quality', 'of', 'staff', '-', 'resident', 'interactions', 'between', 'residents', 'with', 'and', 'without', 'dementia', ',', 'test', 'the', 'relationship', 'of', 'these', 'variables', 'to', 'participation', 'in', 'function', 'focused', 'care', 'at', 'baseline', ',', 'and', 'consider', 'if', 'there', 'is', 'a', 'differential', 'impact', 'of', 'FFC', '-', 'AL', '-', 'EIT', 'between', 'those', 'with', 'and', 'without', 'dementia', 'with', 'regard', 'to', 'participation', 'in', 'function', 'focused', 'care', ',', 'functional', 'outcomes', 'and', 'physical', 'activity', 'over', 'the', '12', 'month', 'study', 'period', '.', 'Findings', 'from', 'this', 'study', 'will', 'provide', 'new', 'information', 'on', 'how', 'to', 'optimize', 'function', 'and', 'physical', 'activity', 'among', 'older', 'adults', 'with', 'dementia', 'in', 'assisted', 'living', '.']","['O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT03459118,NCT03459118,"The Impact of Dementia on Care and Outcomes Associated With a Function Focused Care Intervention Among Residents in Assisted Living Settings. | This study will evaluate pain, management of pain, behavioral symptoms, and the quality of staff-resident interactions between residents with and without dementia, test the relationship of these variables to participation in function focused care at baseline, and consider if there is a differential impact of FFC-AL-EIT between those with and without dementia with regard to participation in function focused care, functional outcomes and physical activity over the 12 month study period. Findings from this study will provide new information on how to optimize function and physical activity among older adults with dementia in assisted living.","[(14, 22, 'CONDITION', 'Dementia'), (62, 83, 'OTHER', 'Function Focused Care'), (169, 173, 'CONDITION', 'pain'), (189, 193, 'CONDITION', 'pain'), (298, 306, 'CONDITION', 'dementia'), (454, 464, 'OTHER', 'FFC-AL-EIT'), (496, 504, 'CONDITION', 'dementia'), (762, 770, 'CONDITION', 'dementia')]"
"['Outcomes', 'of', 'Cognitive', 'Behavioral', 'Therapy', '(', 'CBT', ')', 'Interventions', 'Provided', 'by', 'Unlicensed', 'Professionals', 'in', 'a', 'General', 'Hospital', 'Setting', '|', 'To', 'examine', 'the', 'effectiveness', 'and', 'clinical', 'care', 'outcomes', 'of', 'cognitive', '-', 'behavioral', 'therapy', 'interventions', 'at', 'Massachusetts', 'General', 'Hospital', '(', 'MGH', ')', '.']","['O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01075672,NCT01075672,Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals in a General Hospital Setting | To examine the effectiveness and clinical care outcomes of cognitive-behavioral therapy interventions at Massachusetts General Hospital (MGH).,"[(12, 40, 'BEHAVIOURAL', 'Cognitive Behavioral Therapy'), (42, 45, 'BEHAVIOURAL', 'CBT'), (189, 217, 'BEHAVIOURAL', 'cognitive-behavioral therapy')]"
"['Comparing', 'Cognitive', 'Remediation', 'Approaches', 'for', 'Schizophrenia', '|', 'This', 'research', 'compares', 'the', 'relative', 'efficacy', 'of', 'two', 'empirically', '-', 'supported', ',', 'standardized', 'programs', 'of', 'cognitive', 'remediation', 'for', 'treatment', 'of', 'cognitive', 'deficits', 'and', 'community', 'function', 'in', 'schizophrenia', 'to', 'help', 'inform', 'best', 'practices', '.', 'The', 'proposed', 'study', 'advances', 'public', 'health', 'by', 'developing', 'and', 'evaluating', 'new', 'behavioral', 'techniques', 'for', 'improving', 'psychosocial', 'outcome', 'in', 'individuals', 'diagnosed', 'with', 'schizophrenia', '.']","['O', 'B-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04123223,NCT04123223,"Comparing Cognitive Remediation Approaches for Schizophrenia | This research compares the relative efficacy of two empirically-supported, standardized programs of cognitive remediation for treatment of cognitive deficits and community function in schizophrenia to help inform best practices. The proposed study advances public health by developing and evaluating new behavioral techniques for improving psychosocial outcome in individuals diagnosed with schizophrenia.","[(10, 31, 'BEHAVIOURAL', 'Cognitive Remediation'), (47, 60, 'CONDITION', 'Schizophrenia'), (163, 184, 'BEHAVIOURAL', 'cognitive remediation'), (202, 220, 'CONDITION', 'cognitive deficits'), (247, 260, 'CONDITION', 'schizophrenia'), (367, 388, 'BEHAVIOURAL', 'behavioral techniques'), (454, 467, 'CONDITION', 'schizophrenia')]"
"['Effectiveness', 'and', 'Cost', '-', 'effectiveness', 'of', 'Ozone', 'Therapy', 'in', 'Patients', 'With', 'Pain', 'Secondary', 'to', 'Chemotherapy', '-', 'induced', 'Peripheral', 'Neuropathy', '.', 'Randomized', ',', 'Triple', '-', 'blind', 'Clinical', 'Trial', '(', 'O3NPIQ', ')', '|', 'The', 'main', 'objective', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'and', 'cost', '-', 'effectiveness', 'of', 'adding', 'ozone', 'therapy', 'to', 'the', 'clinical', 'management', 'of', 'patients', 'with', 'pain', 'secondary', 'to', 'chemotherapy', '-', 'induced', 'peripheral', 'neuropathy']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND']",NCT04299893,NCT04299893,"Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ) | The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy","[(40, 45, 'DRUG', 'Ozone'), (71, 75, 'CONDITION', 'Pain'), (89, 131, 'CONDITION', 'Chemotherapy-induced Peripheral Neuropathy'), (292, 297, 'DRUG', 'ozone'), (350, 354, 'CONDITION', 'pain'), (368, 410, 'CONDITION', 'chemotherapy-induced peripheral neuropathy')]"
"['Mild', 'Cognitive', 'Impairment', 'and', 'Endurance', 'Exercise', 'in', 'Parkinson', ""'s"", 'Disease', '|', 'The', 'overall', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'how', 'high', 'intensity', 'endurance', 'exercise', 'affects', 'both', 'cognition', 'and', 'the', 'signs', 'and', 'symptoms', 'of', 'Parkinson', ""'s"", 'disease', 'as', 'well', 'as', 'if', 'certain', 'brain', 'structures', 'and', 'functions', 'also', 'change', 'with', 'this', 'exercise', '.']","['B-COND', 'I-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O']",NCT03542474,NCT03542474,Mild Cognitive Impairment and Endurance Exercise in Parkinson's Disease | The overall objective of this study is to determine how high intensity endurance exercise affects both cognition and the signs and symptoms of Parkinson's disease as well as if certain brain structures and functions also change with this exercise.,"[(0, 25, 'CONDITION', 'Mild Cognitive Impairment'), (30, 48, 'PHYSICAL', 'Endurance Exercise'), (52, 71, 'CONDITION', ""Parkinson's Disease""), (130, 163, 'PHYSICAL', 'high intensity endurance exercise'), (217, 236, 'CONDITION', ""Parkinson's disease""), (312, 320, 'PHYSICAL', 'exercise')]"
"['Randomised', ',', 'Controlled', 'Trial', 'of', 'Physician', 'Prehospital', 'Management', 'of', 'Severe', 'Blunt', 'Head', 'Injury', '|', 'The', 'study', 'hypothesis', 'is', 'that', 'advanced', 'interventions', 'as', 'provided', 'by', 'a', 'physician', 'at', 'an', 'accident', 'scene', 'will', 'decrease', 'the', 'death', 'rate', 'and', 'the', 'rate', 'of', 'severe', 'disability', 'in', 'survivors', 'of', 'severe', 'head', 'injury', '.', 'Extended', 'interventions', 'by', 'advanced', 'level', 'prehospital', 'providers', 'may', 'include', 'rapid', 'sequence', 'intubation', '(', 'RSI', ')', 'airway', 'management', ',', 'blood', 'transfusions', ',', 'surgical', 'procedures', ',', 'etc', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O']",NCT00112398,NCT00112398,"Randomised, Controlled Trial of Physician Prehospital Management of Severe Blunt Head Injury | The study hypothesis is that advanced interventions as provided by a physician at an accident scene will decrease the death rate and the rate of severe disability in survivors of severe head injury. Extended interventions by advanced level prehospital providers may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.","[(32, 64, 'OTHER', 'Physician Prehospital Management'), (68, 92, 'CONDITION', 'Severe Blunt Head Injury'), (124, 194, 'OTHER', 'advanced interventions as provided by a physician at an accident scene'), (274, 292, 'CONDITION', 'severe head injury'), (369, 418, 'OTHER', 'rapid sequence intubation (RSI) airway management'), (420, 438, 'OTHER', 'blood transfusions'), (440, 459, 'SURGICAL', 'surgical procedures')]"
"['Assessment', 'of', 'Cerebellar', 'Stimulation', 'Effect', 'on', 'Motor', 'Learning', 'in', 'Ageing', 'Population', 'and', 'Stroke', 'Patients', '|', 'This', 'study', 'will', 'assess', 'the', 'putative', 'advantages', 'of', 'cerebellar', 'stimulation', 'on', 'motor', 'learning', 'abilities', 'of', 'stroke', 'patients', '.', 'In', 'order', 'to', 'have', 'a', 'control', 'group', 'to', 'refer', 'to', ',', 'the', 'effect', 'of', 'cerebellar', 'stimulation', 'on', 'healthy', 'young', 'and', 'old', 'participants', 'will', 'also', 'be', 'assessed', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03092570,NCT03092570,"Assessment of Cerebellar Stimulation Effect on Motor Learning in Ageing Population and Stroke Patients | This study will assess the putative advantages of cerebellar stimulation on motor learning abilities of stroke patients. In order to have a control group to refer to, the effect of cerebellar stimulation on healthy young and old participants will also be assessed.","[(14, 36, 'OTHER', 'Cerebellar Stimulation'), (87, 93, 'CONDITION', 'Stroke'), (155, 177, 'OTHER', 'cerebellar stimulation'), (209, 215, 'CONDITION', 'stroke'), (286, 308, 'OTHER', 'cerebellar stimulation')]"
"['Effect', 'of', 'Acupuncture', 'on', 'Inflammation', 'and', 'Immune', 'Function', 'After', 'Craniotomy', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'acupuncture', 'on', 'inflammation', 'and', 'immune', 'function', 'after', 'craniotomy', '.', 'This', 'study', 'will', 'be', 'a', 'single', '-', 'center', ',', 'parallel', 'group', 'clinical', 'trial', 'that', 'will', 'be', 'conducted', 'at', 'Kyung', 'Hee', 'University', 'Hospital', 'at', 'Gangdong', ',', 'Seoul', ',', 'Korea', '.']","['O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02761096,NCT02761096,"Effect of Acupuncture on Inflammation and Immune Function After Craniotomy | The aim of this study is to evaluate the effect of acupuncture on inflammation and immune function after craniotomy. This study will be a single-center, parallel group clinical trial that will be conducted at Kyung Hee University Hospital at Gangdong, Seoul, Korea.","[(10, 21, 'OTHER', 'Acupuncture'), (25, 37, 'CONDITION', 'Inflammation'), (64, 74, 'CONDITION', 'Craniotomy'), (128, 139, 'OTHER', 'acupuncture'), (143, 155, 'CONDITION', 'inflammation'), (182, 192, 'CONDITION', 'craniotomy')]"
"['Phase', '2/3', ',', 'Multistage', ',', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Parallel', 'Group', 'Withdrawal', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Nipocalimab', 'Administered', 'to', 'Adults', 'With', 'Chronic', 'Inflammatory', 'Demyelinating', 'Polyneuropathy', '(', 'CIDP', ')', '|', 'The', 'main', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'nipocalimab', 'compared', 'to', 'placebo', 'in', 'delaying', 'relapse', 'in', 'adults', 'with', 'chronic', 'inflammatory', 'demyelinating', 'polyneuropathy', '(', 'CIDP', ')', 'who', 'initially', 'respond', 'to', 'nipocalimab', 'in', 'Stage', 'A.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O']",NCT05327114,NCT05327114,"Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.","[(62, 69, 'CONTROL', 'Placebo'), (152, 163, 'DRUG', 'Nipocalimab'), (192, 241, 'CONDITION', 'Chronic Inflammatory Demyelinating Polyneuropathy'), (243, 247, 'CONDITION', 'CIDP'), (324, 335, 'DRUG', 'nipocalimab'), (348, 355, 'CONTROL', 'placebo'), (391, 440, 'CONDITION', 'chronic inflammatory demyelinating polyneuropathy'), (442, 446, 'CONDITION', 'CIDP'), (473, 484, 'DRUG', 'nipocalimab')]"
"['An', 'Evaluation', 'of', 'the', 'Effect', 'of', 'a', 'Surface', 'Acoustic', 'Wave', 'Patch', 'Device', 'on', 'the', 'Symptons', 'of', 'Trigeminal', 'Neuralgia', '|', 'This', 'is', 'a', 'double', 'blinded', 'randomized', 'control', 'trial', 'of', 'a', 'Surface', 'Acoustic', 'Wave', 'Patch', 'device', 'for', 'the', 'treatment', 'of', 'Trigeminal', 'Neuralgia', '.', 'This', 'will', 'be', 'a', 'crossover', 'study', 'for', 'the', 'group', 'that', 'receives', 'the', 'sham', 'device', '.', 'Subjects', 'will', 'be', 'monitored', 'for', 'subjective', 'criteria', 'of', 'pain', 'and', 'quality', 'of', 'life', ',', 'as', 'well', 'as', 'objective', 'measurement', 'of', 'analgesic', 'usage', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02801630,NCT02801630,"An Evaluation of the Effect of a Surface Acoustic Wave Patch Device on the Symptons of Trigeminal Neuralgia | This is a double blinded randomized control trial of a Surface Acoustic Wave Patch device for the treatment of Trigeminal Neuralgia. This will be a crossover study for the group that receives the sham device. Subjects will be monitored for subjective criteria of pain and quality of life, as well as objective measurement of analgesic usage.","[(33, 67, 'OTHER', 'Surface Acoustic Wave Patch Device'), (87, 107, 'CONDITION', 'Trigeminal Neuralgia'), (165, 199, 'OTHER', 'Surface Acoustic Wave Patch device'), (221, 241, 'CONDITION', 'Trigeminal Neuralgia'), (306, 317, 'CONTROL', 'sham device'), (373, 377, 'CONDITION', 'pain')]"
"['Preventing', 'Loss', 'of', 'Independence', 'Through', 'Exercise', '(', 'PLIE', ')', 'in', 'Persons', 'With', 'Dementia', '|', 'Nearly', '1', 'in', '10', 'older', 'Veterans', 'have', 'dementia', ',', 'which', 'is', 'a', 'devastating', 'condition', 'that', 'leads', 'to', 'a', 'progressive', 'loss', 'of', 'independence', 'and', 'functional', 'status', '.', 'Currently', 'available', 'dementia', 'medications', 'do', 'not', 'alter', 'the', 'disease', 'course', '.', 'Therefore', ',', 'it', 'is', 'critically', 'important', 'to', 'identify', 'effective', 'strategies', 'for', 'helping', 'older', 'Veterans', 'living', 'with', 'dementia', 'to', 'enhance', 'their', 'functional', 'status', 'and', 'quality', 'of', 'life', '.', 'The', 'investigators', 'have', 'developed', 'a', 'novel', ',', 'integrative', 'group', 'movement', 'program', 'called', 'Preventing', 'Loss', 'of', 'Independence', 'through', 'Exercise', '(', 'PLIE', ')', 'that', 'incorporates', 'elements', 'from', 'Eastern', 'and', 'Western', 'exercise', 'modalities', 'and', 'is', 'designed', 'to', 'build', 'and', 'maintain', 'the', 'capacity', 'to', 'perform', 'basic', 'functional', 'movements', 'while', 'increasing', 'mindful', 'body', 'awareness', 'and', 'enhancing', 'social', 'connection', '.', 'Pilot', 'study', 'results', 'suggested', 'that', 'PLIE', 'is', 'associated', 'with', 'meaningful', 'improvements', 'in', 'physical', 'function', ',', 'cognitive', 'function', 'and', 'quality', 'of', 'life', 'as', 'well', 'as', 'reduced', 'caregiver', 'burden', '.', 'The', 'goal', 'of', 'the', 'current', 'study', 'is', 'to', 'perform', 'a', 'full', '-', 'scale', 'randomized', ',', 'controlled', 'trial', 'to', 'test', 'the', 'efficacy', 'of', 'PLIE', 'in', 'older', 'Veterans', 'with', 'dementia', '.']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT02350127,NCT02350127,"Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia | Nearly 1 in 10 older Veterans have dementia, which is a devastating condition that leads to a progressive loss of independence and functional status. Currently available dementia medications do not alter the disease course. Therefore, it is critically important to identify effective strategies for helping older Veterans living with dementia to enhance their functional status and quality of life. The investigators have developed a novel, integrative group movement program called Preventing Loss of Independence through Exercise (PLIE) that incorporates elements from Eastern and Western exercise modalities and is designed to build and maintain the capacity to perform basic functional movements while increasing mindful body awareness and enhancing social connection. Pilot study results suggested that PLIE is associated with meaningful improvements in physical function, cognitive function and quality of life as well as reduced caregiver burden. The goal of the current study is to perform a full-scale randomized, controlled trial to test the efficacy of PLIE in older Veterans with dementia.","[(0, 48, 'PHYSICAL', 'Preventing Loss of Independence Through Exercise'), (50, 54, 'PHYSICAL', 'PLIE'), (72, 80, 'CONDITION', 'Dementia'), (118, 126, 'CONDITION', 'dementia'), (253, 261, 'CONDITION', 'dementia'), (417, 425, 'CONDITION', 'dementia'), (524, 558, 'PHYSICAL', 'integrative group movement program'), (566, 614, 'PHYSICAL', 'Preventing Loss of Independence through Exercise'), (616, 620, 'PHYSICAL', 'PLIE'), (891, 895, 'PHYSICAL', 'PLIE'), (1147, 1151, 'PHYSICAL', 'PLIE'), (1175, 1183, 'CONDITION', 'dementia')]"
"['OCT', 'Eccentric', 'Fixation', ',', 'Fixation', 'Stability', ',', 'and', 'Amblyopia', 'in', 'Children', '|', 'The', 'objectives', 'of', 'this', 'proposal', 'are', 'to', 'characterize', 'the', 'relationship', 'between', 'OCT', 'eccentric', 'fixation', '(', 'OCT', '-', 'EF', ')', ',', 'fixation', 'eye', 'movement', '(', 'FEM', ')', ',', 'macular', 'sensitivity', 'in', 'children', 'with', 'amblyopia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT05714449,NCT05714449,"OCT Eccentric Fixation, Fixation Stability, and Amblyopia in Children | The objectives of this proposal are to characterize the relationship between OCT eccentric fixation (OCT-EF), fixation eye movement (FEM), macular sensitivity in children with amblyopia.","[(48, 57, 'CONDITION', 'Amblyopia'), (248, 257, 'CONDITION', 'amblyopia')]"
"['A', 'Randomized', 'Controlled', 'Trial', 'of', 'Adjunctive', 'D', '-', 'Cycloserine', 'to', 'Intermittent', 'Theta', '-', 'burst', 'Stimulation', 'Transcranial', 'Magnetic', 'Stimulation', 'in', 'Fibromyalgia', '|', 'Background', '&', 'Rationale', ':', 'Fibromyalgia', 'is', 'characterized', 'by', 'widespread', 'pain', ',', 'fatigue', ',', 'mood', 'and', 'anxiety', 'as', 'well', 'as', 'cognitive', 'complaints', '.', 'For', 'an', 'unacceptable', 'proportion', 'of', 'patients', ',', 'depressive', 'symptoms', 'remain', 'impairing', 'despite', 'multiple', 'treatments', '.', '\n\n', 'For', 'such', 'patients', ',', 'novel', 'treatments', 'include', 'non', '-', 'invasive', 'brain', 'stimulation', '.', 'Transcranial', 'Magnetic', 'Stimulation', '(', 'TMS', ')', 'targeting', 'the', 'dorsolateral', 'prefrontal', 'cortex', '(', 'DLPFC', ')', 'or', 'the', 'primary', 'motor', 'cortex', '(', 'M1', ')', 'is', 'the', 'non', '-', 'invasive', 'neurostimulation', 'method', 'with', 'the', 'largest', 'evidence', 'base', 'in', 'fibromyalgia', '.', 'It', 'involves', 'generating', 'magnetic', 'fields', 'outside', 'of', 'the', 'body', 'to', 'change', 'the', 'firing', 'of', 'neurons', 'in', 'the', 'brain', ',', 'and', 'has', 'a', 'very', 'favorable', 'tolerability', 'profile', '.', 'Recent', 'meta', '-', 'analyses', 'indicate', 'that', 'both', 'the', 'DLPFC', 'and', 'M1', 'targets', 'are', 'associated', 'with', 'improvements', 'in', 'pain', ',', 'mood', 'and', 'anxiety', ',', 'however', 'the', 'benefits', 'are', 'more', 'persistent', 'when', 'the', 'DLPFC', 'is', 'targeted', '(', 'Su', 'et', 'al', ',', '2021', '-', 'J', 'Clin', 'Med', ')', '.', 'The', 'DLPFC', 'is', 'important', 'in', 'fibromyalgia', 'through', 'its', 'implication', 'in', 'several', 'symptoms', 'domains', 'in', 'fibromyalgia', ',', 'as', 'well', 'as', 'pain', 'catastrophization', '.', '\n\n', 'The', 'researchers', 'neurophysiological', 'data', 'and', 'clinical', 'data', 'in', 'depression', 'suggests', 'that', 'the', 'researchers', 'can', 'enhance', 'the', 'effects', 'of', 'TMS', 'by', 'using', 'an', 'adjunctive', 'medication', 'called', 'D', '-', 'Cycloserine', '(', 'DCS', ',', '100', 'mg', ')', 'in', 'conjunction', 'with', 'a', 'protocol', 'called', 'intermittent', 'theta', '-', 'burst', 'stimulation', '(', 'iTBS', ')', '.', 'Specifically', ',', 'this', 'data', 'indicated', 'that', 'several', 'converging', 'features', 'of', 'fibromyalgia', 'improve', 'with', 'augmented', 'iTBS', ',', 'specifically', 'depressive', 'symptoms', ',', 'anxiety', 'symptoms', ',', 'fatigue', ',', 'and', 'cognitive', 'function', '.', 'The', 'researchers', 'therefore', 'hypothesize', 'that', 'the', 'combination', 'of', 'D', '-', 'cycloserine', 'and', 'TMS', 'will', 'lead', 'to', 'greater', 'improvements', 'in', 'fibromyalgia', 'symptoms', 'than', 'TMS', 'alone', '.', '\n\n', 'Although', 'iTBS', 'has', 'not', 'yet', 'been', 'studied', 'in', 'fibromyalgia', ',', 'it', 'has', 'a', 'well', 'characterized', 'neurophysiological', 'effect', 'and', 'been', 'shown', 'to', 'be', 'non', '-', 'inferior', 'to', 'conventional', 'TMS', 'protocols', 'in', 'conditions', 'such', 'as', 'depression', '.', 'More', 'importantly', ',', 'its', 'physiological', 'basis', 'can', 'be', 'manipulated', 'with', 'D', '-', 'Cycloserine', 'whereas', 'this', 'has', 'not', 'been', 'convincingly', 'demonstrated', 'with', 'rTMS', '(', 'see', 'Brown', 'et', 'al', ',', '2019', ',', '2021', 'Brain', 'Stim', ')', '.', '\n\n', 'Research', 'Question', 'and', 'Objectives', ':', 'To', 'conduct', 'a', 'randomized', 'placebo', '-', 'controlled', 'trial', 'of', 'DCS', 'in', 'adjunct', 'with', 'rTMS', 'in', 'Fibromyalgia', '.', 'Participants', 'will', 'be', 'randomized', 'to', 'receive', '100', 'mg', 'of', 'DCS', 'or', 'placebo', 'together', 'with', 'TMS', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT05395494,NCT05395494,"A Randomized Controlled Trial of Adjunctive D-Cycloserine to Intermittent Theta-burst Stimulation Transcranial Magnetic Stimulation in Fibromyalgia | Background & Rationale: Fibromyalgia is characterized by widespread pain, fatigue, mood and anxiety as well as cognitive complaints. For an unacceptable proportion of patients, depressive symptoms remain impairing despite multiple treatments.

For such patients, novel treatments include non-invasive brain stimulation. Transcranial Magnetic Stimulation (TMS) targeting the dorsolateral prefrontal cortex (DLPFC) or the primary motor cortex (M1) is the non-invasive neurostimulation method with the largest evidence base in fibromyalgia. It involves generating magnetic fields outside of the body to change the firing of neurons in the brain, and has a very favorable tolerability profile. Recent meta-analyses indicate that both the DLPFC and M1 targets are associated with improvements in pain, mood and anxiety, however the benefits are more persistent when the DLPFC is targeted (Su et al, 2021 - J Clin Med). The DLPFC is important in fibromyalgia through its implication in several symptoms domains in fibromyalgia, as well as pain catastrophization.

The researchers neurophysiological data and clinical data in depression suggests that the researchers can enhance the effects of TMS by using an adjunctive medication called D-Cycloserine (DCS, 100mg) in conjunction with a protocol called intermittent theta-burst stimulation (iTBS). Specifically, this data indicated that several converging features of fibromyalgia improve with augmented iTBS, specifically depressive symptoms, anxiety symptoms, fatigue, and cognitive function. The researchers therefore hypothesize that the combination of D-cycloserine and TMS will lead to greater improvements in fibromyalgia symptoms than TMS alone.

Although iTBS has not yet been studied in fibromyalgia, it has a well characterized neurophysiological effect and been shown to be non-inferior to conventional TMS protocols in conditions such as depression. More importantly, its physiological basis can be manipulated with D-Cycloserine whereas this has not been convincingly demonstrated with rTMS (see Brown et al, 2019, 2021 Brain Stim).

Research Question and Objectives: To conduct a randomized placebo-controlled trial of DCS in adjunct with rTMS in Fibromyalgia. Participants will be randomized to receive 100mg of DCS or placebo together with TMS.","[(44, 57, 'DRUG', 'D-Cycloserine'), (61, 131, 'OTHER', 'Intermittent Theta-burst Stimulation Transcranial Magnetic Stimulation'), (135, 147, 'CONDITION', 'Fibromyalgia'), (174, 186, 'CONDITION', 'Fibromyalgia'), (218, 222, 'CONDITION', 'pain'), (224, 231, 'CONDITION', 'fatigue'), (242, 249, 'CONDITION', 'anxiety'), (327, 337, 'CONDITION', 'depressive'), (438, 468, 'OTHER', 'non-invasive brain stimulation'), (470, 595, 'OTHER', 'Transcranial Magnetic Stimulation (TMS) targeting the dorsolateral prefrontal cortex (DLPFC) or the primary motor cortex (M1)'), (674, 686, 'CONDITION', 'fibromyalgia'), (884, 889, 'OTHER', 'DLPFC'), (894, 896, 'OTHER', 'M1'), (941, 945, 'CONDITION', 'pain'), (956, 963, 'CONDITION', 'anxiety'), (1015, 1020, 'OTHER', 'DLPFC'), (1068, 1073, 'OTHER', 'DLPFC'), (1090, 1102, 'CONDITION', 'fibromyalgia'), (1158, 1170, 'CONDITION', 'fibromyalgia'), (1183, 1205, 'CONDITION', 'pain catastrophization'), (1269, 1279, 'CONDITION', 'depression'), (1337, 1340, 'OTHER', 'TMS'), (1382, 1395, 'DRUG', 'D-Cycloserine'), (1397, 1400, 'DRUG', 'DCS'), (1447, 1483, 'OTHER', 'intermittent theta-burst stimulation'), (1485, 1489, 'OTHER', 'iTBS'), (1562, 1574, 'CONDITION', 'fibromyalgia'), (1598, 1602, 'OTHER', 'iTBS'), (1617, 1627, 'CONDITION', 'depressive'), (1638, 1645, 'CONDITION', 'anxiety'), (1656, 1663, 'CONDITION', 'fatigue'), (1751, 1764, 'DRUG', 'D-cycloserine'), (1769, 1772, 'OTHER', 'TMS'), (1810, 1822, 'CONDITION', 'fibromyalgia'), (1837, 1840, 'OTHER', 'TMS'), (1858, 1862, 'OTHER', 'iTBS'), (1891, 1903, 'CONDITION', 'fibromyalgia'), (2009, 2012, 'OTHER', 'TMS'), (2045, 2055, 'CONDITION', 'depression'), (2123, 2136, 'DRUG', 'D-Cycloserine'), (2194, 2198, 'OTHER', 'rTMS'), (2300, 2307, 'CONTROL', 'placebo'), (2328, 2331, 'DRUG', 'DCS'), (2348, 2352, 'OTHER', 'rTMS'), (2356, 2368, 'CONDITION', 'Fibromyalgia'), (2422, 2425, 'DRUG', 'DCS'), (2429, 2454, 'CONTROL', 'placebo together with TMS')]"
"['Influence', 'of', 'Radial', 'Extracorpeal', 'Shock', 'Wave', 'Therapy', 'on', 'Sonographic', 'Findings', 'in', 'Patients', 'With', 'Hemiplegic', 'Shoulder', 'Pain', '|', 'The', 'purposes', 'of', 'this', 'study', 'are', 'to', 'examine', 'sonographic', 'structural', 'changes', 'pre', 'and', 'post', 'the', 'radial', 'extracorporeal', 'shock', 'wave', 'intervention', 'in', 'hemiplegic', 'shoulder', 'pain', ',', 'and', 'to', 'assess', 'the', 'relationships', 'between', 'sonographic', 'structural', 'changes', 'and', 'hemiplegic', 'shoulder', 'pain', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'I-COND', 'O']",NCT04859673,NCT04859673,"Influence of Radial Extracorpeal Shock Wave Therapy on Sonographic Findings in Patients With Hemiplegic Shoulder Pain | The purposes of this study are to examine sonographic structural changes pre and post the radial extracorporeal shock wave intervention in hemiplegic shoulder pain, and to assess the relationships between sonographic structural changes and hemiplegic shoulder pain.","[(13, 51, 'OTHER', 'Radial Extracorpeal Shock Wave Therapy'), (93, 103, 'CONDITION', 'Hemiplegic'), (104, 117, 'CONDITION', 'Shoulder Pain'), (210, 255, 'OTHER', 'radial extracorporeal shock wave intervention'), (259, 269, 'CONDITION', 'hemiplegic'), (270, 283, 'CONDITION', 'shoulder pain'), (360, 370, 'CONDITION', 'hemiplegic'), (371, 384, 'CONDITION', 'shoulder pain')]"
"['A', 'Double', 'Blind', 'Placebo', 'Controlled', 'Study', 'of', 'Guanfacine', 'Adjunctive', 'Treatment', 'to', 'Atypical', 'Antipsychotics', 'for', 'Cognitive', 'Dysfunction', 'in', 'Schizophrenia', '|', 'Our', 'overall', 'aim', 'is', 'to', 'determine', 'if', 'the', 'administration', 'of', 'guanfacine', 'in', 'combination', 'with', 'aripiprazole', ',', 'olanzapine', ',', 'quetiapine', ',', 'and/or', 'risperidone', 'is', 'significantly', 'more', 'effective', 'than', 'any', 'of', 'those', 'medications', 'alone', 'in', 'treating', 'some', 'of', 'the', 'cognitive', 'impairment', 'in', 'schizophrenia', '.']","['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O']",NCT00469664,NCT00469664,"A Double Blind Placebo Controlled Study of Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia | Our overall aim is to determine if the administration of guanfacine in combination with aripiprazole, olanzapine, quetiapine, and/or risperidone is significantly more effective than any of those medications alone in treating some of the cognitive impairment in schizophrenia.","[(15, 22, 'CONTROL', 'Placebo'), (43, 53, 'DRUG', 'Guanfacine'), (131, 144, 'CONDITION', 'Schizophrenia'), (204, 214, 'DRUG', 'guanfacine'), (235, 247, 'DRUG', 'aripiprazole'), (249, 259, 'DRUG', 'olanzapine'), (261, 271, 'DRUG', 'quetiapine'), (280, 291, 'DRUG', 'risperidone'), (384, 404, 'CONDITION', 'cognitive impairment'), (408, 421, 'CONDITION', 'schizophrenia')]"
"['Efficacy', 'of', 'Moxibustion', 'in', 'Diabetes', 'Peripheral', 'Neuropathy', '|', 'This', 'pragmatic', 'randomized', 'controlled', 'study', 'aimed', 'to', 'evaluate', 'the', 'effectiveness', 'and', 'safety', 'of', 'moxibustion', 'therapy', 'on', 'diabetes', 'peripheral', 'neuropathy', '.']","['O', 'O', 'B-OTHER', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'B-COND', 'I-COND', 'O']",NCT04894461,NCT04894461,Efficacy of Moxibustion in Diabetes Peripheral Neuropathy | This pragmatic randomized controlled study aimed to evaluate the effectiveness and safety of moxibustion therapy on diabetes peripheral neuropathy.,"[(12, 23, 'OTHER', 'Moxibustion'), (27, 35, 'CONDITION', 'Diabetes'), (36, 57, 'CONDITION', 'Peripheral Neuropathy'), (153, 172, 'OTHER', 'moxibustion therapy'), (176, 184, 'CONDITION', 'diabetes'), (185, 206, 'CONDITION', 'peripheral neuropathy')]"
"['Combinatorial', 'Treatment', 'of', 'Acute', 'Intermittent', 'Hypoxia', 'and', 'Transcutaneous', 'Electrical', 'Spinal', 'Cord', 'Stimulation', 'to', 'Improve', 'Hand', 'Function', 'in', 'People', 'With', 'Cervical', 'Spinal', 'Cord', 'Injury', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'test', 'the', 'efficacy', 'of', 'mild', 'breathing', 'bouts', 'of', 'low', 'oxygen', '(', 'intermittent', 'hypoxia', ')', 'combined', 'with', 'transcutaneous', 'electrical', 'spinal', 'cord', 'stimulation', 'on', 'restoring', 'hand', 'function', 'in', 'persons', 'with', 'chronic', 'incomplete', 'spinal', 'cord', 'injury', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04854057,NCT04854057,Combinatorial Treatment of Acute Intermittent Hypoxia and Transcutaneous Electrical Spinal Cord Stimulation to Improve Hand Function in People With Cervical Spinal Cord Injury | The purpose of this study is to test the efficacy of mild breathing bouts of low oxygen (intermittent hypoxia) combined with transcutaneous electrical spinal cord stimulation on restoring hand function in persons with chronic incomplete spinal cord injury.,"[(27, 53, 'OTHER', 'Acute Intermittent Hypoxia'), (58, 107, 'OTHER', 'Transcutaneous Electrical Spinal Cord Stimulation'), (148, 175, 'CONDITION', 'Cervical Spinal Cord Injury'), (231, 265, 'OTHER', 'mild breathing bouts of low oxygen'), (267, 287, 'OTHER', 'intermittent hypoxia'), (303, 352, 'OTHER', 'transcutaneous electrical spinal cord stimulation'), (396, 433, 'CONDITION', 'chronic incomplete spinal cord injury')]"
"['The', 'Role', 'of', 'Dietary', 'Calcium', 'for', 'the', 'Treatment', 'of', 'Osteopenia', 'in', 'Girls', 'With', 'Rett', 'Syndrome', '|', 'Randomized', ',', 'placebo', '-', 'controlled', 'trial', 'of', 'oral', 'calcium', 'supplementation', 'for', 'osteopenia', 'in', 'girls', 'and', 'women', 'with', 'Rett', 'syndrome']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND']",NCT05352373,NCT05352373,"The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome | Randomized, placebo-controlled trial of oral calcium supplementation for osteopenia in girls and women with Rett syndrome","[(20, 27, 'DRUG', 'Calcium'), (49, 59, 'CONDITION', 'Osteopenia'), (74, 87, 'CONDITION', 'Rett Syndrome'), (102, 109, 'CONTROL', 'placebo'), (135, 142, 'DRUG', 'calcium'), (163, 173, 'CONDITION', 'osteopenia'), (198, 211, 'CONDITION', 'Rett syndrome')]"
"['Rehabilitative', 'Trial', 'With', 'Cerebello', '-', 'Spinal', 'tDCS', 'for', 'the', 'Treatment', 'of', 'Neurodegenerative', 'Ataxia', '|', 'Neurodegenerative', 'cerebellar', 'ataxias', 'represent', 'a', 'group', 'of', 'disabling', 'disorders', 'for', 'which', 'we', 'currently', 'lack', 'effective', 'therapies', '.', 'Cerebellar', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'is', 'a', 'non', '-', 'invasive', 'technique', ',', 'which', 'has', 'been', 'demonstrated', 'to', 'modulate', 'cerebellar', 'excitability', 'and', 'improve', 'symptoms', 'in', 'patients', 'with', 'cerebellar', 'ataxias', '.', 'In', 'this', 'randomized', ',', 'double', '-', 'blind', ',', 'sham', '-', 'controlled', 'study', ',', 'the', 'investigators', 'will', 'evaluate', 'whether', 'a', 'two', '-', 'weeks', ""'"", 'treatment', 'with', 'cerebellar', 'anodal', 'tDCS', 'and', 'spinal', 'cathodal', 'tDCS', 'can', 'improve', 'symptoms', 'in', 'patients', 'with', 'neurodegenerative', 'cerebellar', 'ataxia', 'and', 'can', 'modulate', 'cerebello', '-', 'motor', 'connectivity', ',', 'at', 'short', 'and', 'long', 'term', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03120013,NCT03120013,"Rehabilitative Trial With Cerebello-Spinal tDCS for the Treatment of Neurodegenerative Ataxia | Neurodegenerative cerebellar ataxias represent a group of disabling disorders for which we currently lack effective therapies. Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been demonstrated to modulate cerebellar excitability and improve symptoms in patients with cerebellar ataxias. In this randomized, double-blind, sham-controlled study, the investigators will evaluate whether a two-weeks' treatment with cerebellar anodal tDCS and spinal cathodal tDCS can improve symptoms in patients with neurodegenerative cerebellar ataxia and can modulate cerebello-motor connectivity, at short and long term.","[(26, 47, 'OTHER', 'Cerebello-Spinal tDCS'), (69, 93, 'CONDITION', 'Neurodegenerative Ataxia'), (96, 132, 'CONDITION', 'Neurodegenerative cerebellar ataxias'), (223, 273, 'OTHER', 'Cerebellar transcranial direct current stimulation'), (275, 279, 'OTHER', 'tDCS'), (412, 430, 'CONDITION', 'cerebellar ataxias'), (466, 470, 'CONTROL', 'sham'), (557, 579, 'OTHER', 'cerebellar anodal tDCS'), (584, 604, 'OTHER', 'spinal cathodal tDCS'), (643, 678, 'CONDITION', 'neurodegenerative cerebellar ataxia')]"
"['A', 'Comparison', ':', 'High', 'Intense', 'Periodic', 'vs.', 'Every', 'Week', 'Therapy', 'in', 'Children', 'With', 'Cerebral', 'Palsy', '(', 'ACHIEVE', ')', '|', 'The', 'ACHIEVE', 'study', 'is', 'a', 'comparison', 'of', 'the', 'effectiveness', 'of', '2', 'intensities', 'of', 'physical', 'therapy', 'treatment', 'for', 'children', 'with', 'Cerebral', 'Palsy', 'in', 'an', 'outpatient', 'physical', 'therapy', 'setting', '.', 'High', 'intensity', 'periodic', 'is', '2', 'hours', 'of', 'focused', 'and', 'high', 'intense', 'treatment', 'per', 'weekday', 'for', '4', 'weeks', '.', 'In', 'comparison', ',', 'usual', 'weekly', 'is', 'considered', 'standard', 'of', 'care', ';', 'although', 'both', 'dosing', 'models', 'are', 'used', 'clinically', 'for', 'children', 'with', 'CP', '.', 'Participants', 'are', 'assign', 'to', 'the', 'treatment', 'group', 'at', 'random', '.', 'Participant', 'who', 'are', 'unable', 'to', 'consent', 'to', 'randomization', 'are', 'allowed', 'to', 'chose', 'a', 'treatment', 'group', '.']","['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02897024,NCT02897024,"A Comparison: High Intense Periodic vs. Every Week Therapy in Children With Cerebral Palsy (ACHIEVE) | The ACHIEVE study is a comparison of the effectiveness of 2 intensities of physical therapy treatment for children with Cerebral Palsy in an outpatient physical therapy setting. High intensity periodic is 2 hours of focused and high intense treatment per weekday for 4 weeks. In comparison, usual weekly is considered standard of care; although both dosing models are used clinically for children with CP. Participants are assign to the treatment group at random. Participant who are unable to consent to randomization are allowed to chose a treatment group.","[(14, 58, 'PHYSICAL', 'High Intense Periodic vs. Every Week Therapy'), (76, 90, 'CONDITION', 'Cerebral Palsy'), (178, 194, 'PHYSICAL', 'physical therapy'), (223, 237, 'CONDITION', 'Cerebral Palsy'), (319, 365, 'PHYSICAL', 'focused and high intense treatment per weekday'), (394, 406, 'CONTROL', 'usual weekly'), (505, 507, 'CONDITION', 'CP')]"
"['Comparison', 'of', 'Inspiratory', 'Muscle', 'Training', 'and', 'Usual', 'Care', 'in', 'Individuals', 'Post', '-', 'Liver', 'Transplant', '|', 'Individuals', 'with', 'chronic', 'liver', 'disease', 'develop', 'significant', 'muscle', 'wasting', 'that', 'remains', 'post', '-', 'liver', 'transplant', '.', 'The', 'transplant', 'surgery', 'additionally', 'challenges', 'respiratory', 'mechanics', '.', 'Respiratory', 'muscle', 'strength', 'has', 'been', 'measured', 'to', 'be', 'impaired', 'in', 'individuals', 'post', 'liver', 'transplant', '.', 'This', 'study', 'proposes', 'an', '8', 'week', 'intervention', 'designed', 'to', 'increase', 'respiratory', 'muscle', 'strength', 'and', 'pulmonary', 'function', 'that', 'we', 'hypothesize', 'will', 'correlate', 'to', 'improved', 'functional', 'performance', 'and', 'quality', 'of', 'life', 'post', '-', 'liver', 'transplant', '.', '\n\n', 'Pre', '-', 'test', 'post', '-', 'test', 'design', ',', 'that', 'will', 'randomize', 'subjects', 'into', 'an', 'experimental', 'group', 'that', 'will', 'receive', 'the', 'inspiratory', 'muscle', 'strengthening', 'exercise', 'in', 'addition', 'to', 'usual', 'post', '-', 'liver', 'transplant', 'care', 'and', 'a', 'control', 'group', 'that', 'will', 'only', 'receive', 'the', 'usual', 'post', '-', 'transplant', 'care', '.', '\n\n', 'Up', 'to', '50', 'subjects', 'will', 'be', 'recruited', 'from', 'the', 'Post', '-', 'Liver', 'Transplant', 'Outpatient', 'Clinic', 'at', 'the', 'Miami', 'Transplant', 'Institute', '.', '\n\n', 'The', 'subjects', 'will', 'have', 'repeated', 'measurements', 'of', 'respiratory', 'muscle', 'strength', ',', 'pulmonary', 'function', ',', 'functional', 'mobility', 'performance', ',', 'and', 'quality', 'of', 'life', 'at', 'baseline', ',', '4', 'weeks', ',', 'and', '8', 'weeks', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03130608,NCT03130608,"Comparison of Inspiratory Muscle Training and Usual Care in Individuals Post-Liver Transplant | Individuals with chronic liver disease develop significant muscle wasting that remains post-liver transplant. The transplant surgery additionally challenges respiratory mechanics. Respiratory muscle strength has been measured to be impaired in individuals post liver transplant. This study proposes an 8 week intervention designed to increase respiratory muscle strength and pulmonary function that we hypothesize will correlate to improved functional performance and quality of life post-liver transplant.

Pre-test post-test design, that will randomize subjects into an experimental group that will receive the inspiratory muscle strengthening exercise in addition to usual post-liver transplant care and a control group that will only receive the usual post-transplant care.

Up to 50 subjects will be recruited from the Post-Liver Transplant Outpatient Clinic at the Miami Transplant Institute.

The subjects will have repeated measurements of respiratory muscle strength, pulmonary function, functional mobility performance, and quality of life at baseline, 4 weeks, and 8 weeks.","[(14, 41, 'PHYSICAL', 'Inspiratory Muscle Training'), (46, 56, 'CONTROL', 'Usual Care'), (72, 93, 'CONDITION', 'Post-Liver Transplant'), (113, 134, 'CONDITION', 'chronic liver disease'), (183, 204, 'CONDITION', 'post-liver transplant'), (352, 373, 'CONDITION', 'post liver transplant'), (580, 601, 'CONDITION', 'post-liver transplant'), (709, 750, 'PHYSICAL', 'inspiratory muscle strengthening exercise'), (766, 798, 'OTHER', 'usual post-liver transplant care'), (842, 872, 'CONTROL', 'the usual post-transplant care'), (920, 941, 'CONDITION', 'Post-Liver Transplant')]"
"['Digital', 'Rehabilitation', 'Environment', 'Augmenting', 'Medical', 'System', '|', 'D.R.E.A.M.S.', 'will', 'assess', 'an', 'immersive', 'digital', 'reality', '-', 'augmenting', 'system', 'in', 'reducing', 'the', 'occurrence', 'of', 'cognitive', ',', 'behavioral', ',', 'and', 'emotional', 'consequences', 'of', 'critical', 'illness', 'and', 'environmental', 'exposures', 'that', 'are', 'risk', 'factors', 'for', 'the', 'development', 'of', 'delirium', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT03385993,NCT03385993,"Digital Rehabilitation Environment Augmenting Medical System | D.R.E.A.M.S. will assess an immersive digital reality-augmenting system in reducing the occurrence of cognitive, behavioral, and emotional consequences of critical illness and environmental exposures that are risk factors for the development of delirium.","[(91, 134, 'OTHER', 'immersive digital reality-augmenting system'), (218, 234, 'CONDITION', 'critical illness'), (308, 316, 'CONDITION', 'delirium')]"
"['Evaluating', 'the', 'Use', 'of', 'Acute', 'Intermittent', 'Hypoxia', 'to', 'Improve', 'Symptoms', 'in', 'Persons', 'With', 'Multiple', 'Sclerosis', '|', 'The', 'overall', 'objective', 'of', 'this', 'project', 'is', 'to', 'investigate', 'the', 'effectiveness', 'of', 'Acute', 'Intermittent', 'Hypoxia', '(', 'AIH', ')', ',', 'to', 'improve', 'muscle', 'strength', 'and', 'activity', 'level', 'in', 'individuals', 'with', 'relapsing', '-', 'remitting', 'MS', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04280484,NCT04280484,"Evaluating the Use of Acute Intermittent Hypoxia to Improve Symptoms in Persons With Multiple Sclerosis | The overall objective of this project is to investigate the effectiveness of Acute Intermittent Hypoxia (AIH), to improve muscle strength and activity level in individuals with relapsing-remitting MS.","[(22, 48, 'OTHER', 'Acute Intermittent Hypoxia'), (85, 103, 'CONDITION', 'Multiple Sclerosis'), (183, 209, 'OTHER', 'Acute Intermittent Hypoxia'), (211, 214, 'OTHER', 'AIH'), (283, 305, 'CONDITION', 'relapsing-remitting MS')]"
"['Effects', 'of', 'Exenatide', 'on', 'Obesity', 'and', 'Appetite', 'in', 'Overweight', 'Patients', 'With', 'Prader', '-', 'Willi', 'Syndrome', '|', 'Prader', '-', 'Willi', 'Syndrome', '(', 'PWS', ')', 'is', 'one', 'of', 'the', 'most', 'common', 'genetic', 'causes', 'of', 'obesity', '.', 'Obesity', 'is', 'a', 'major', 'source', 'of', 'morbidity', 'and', 'mortality', 'in', 'this', 'population', '.', 'It', 'can', 'lead', 'to', 'sleep', 'apnea', ',', 'cor', 'pulmonale', ',', 'diabetes', 'mellitus', ',', 'and', 'atherosclerosis', '.', 'PWS', 'has', 'distinct', 'characteristics', 'that', 'set', 'it', 'apart', 'from', 'other', 'forms', 'of', 'obesity', 'including', 'insatiable', 'appetite', 'and', 'food', '-', 'seeking', 'behavior', 'which', 'can', 'be', 'disruptive', 'to', 'home', 'and', 'school', 'activities', ',', 'and', 'can', 'cause', 'severe', 'social', 'and', 'psychological', 'turmoil', 'within', 'families', '.', 'PWS', 'is', 'also', 'associated', 'with', 'unique', 'hormonal', 'abnormalities', ',', 'most', 'notably', 'hyperghrelinemia', '.', 'Ghrelin', 'is', 'a', 'gut', 'hormone', 'produced', 'in', 'the', 'stomach', 'that', 'stimulates', 'food', 'intake', 'during', 'a', 'fast', '.', 'It', 'is', 'hypothesized', 'that', 'the', 'extremely', 'high', 'ghrelin', 'levels', 'in', 'patients', 'with', 'PWS', 'may', 'cause', 'or', 'contribute', 'to', 'their', 'insatiable', 'appetite', '.', 'Exenatide', ',', 'a', 'medication', 'used', 'in', 'the', 'treatment', 'of', 'type', '2', 'diabetes', 'mellitus', 'in', 'adults', ',', 'appears', 'to', 'suppress', 'ghrelin', 'levels', 'and', 'cause', 'weight', 'loss', '.', 'It', 'was', 'designed', 'to', 'mimic', 'glucagon', '-', 'like', 'peptide', '1', '(', 'GLP-1', ')', ',', 'an', 'incretin', 'hormone', 'that', 'stimulates', 'insulin', 'secretion', 'and', 'delays', 'gastric', 'emptying', ',', 'among', 'other', 'effects', '.', 'In', 'the', 'present', 'study', ',', 'the', 'investigators', 'will', 'investigate', 'the', 'effects', 'of', 'a', '6', 'month', 'trial', 'of', 'exenatide', 'in', 'overweight', 'adolescents', 'with', 'PWS', '.', 'The', 'investigators', 'will', 'quantify', 'the', 'changes', 'in', 'weight', 'and', 'body', 'composition', ',', 'as', 'well', 'as', 'subjective', 'measures', 'of', 'appetite', ',', 'and', 'concentrations', 'of', 'appetite', '-', 'associated', 'hormones', '.', 'The', 'investigators', 'hypothesize', 'that', 'exenatide', 'will', 'improve', 'weight', ',', 'body', 'composition', ',', 'appetite', ',', 'and', 'plasma', 'ghrelin', 'levels', 'during', 'the', 'treatment', 'period', '.']","['O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01444898,NCT01444898,"Effects of Exenatide on Obesity and Appetite in Overweight Patients With Prader-Willi Syndrome | Prader-Willi Syndrome (PWS) is one of the most common genetic causes of obesity. Obesity is a major source of morbidity and mortality in this population. It can lead to sleep apnea, cor pulmonale, diabetes mellitus, and atherosclerosis. PWS has distinct characteristics that set it apart from other forms of obesity including insatiable appetite and food-seeking behavior which can be disruptive to home and school activities, and can cause severe social and psychological turmoil within families. PWS is also associated with unique hormonal abnormalities, most notably hyperghrelinemia. Ghrelin is a gut hormone produced in the stomach that stimulates food intake during a fast. It is hypothesized that the extremely high ghrelin levels in patients with PWS may cause or contribute to their insatiable appetite. Exenatide, a medication used in the treatment of type 2 diabetes mellitus in adults, appears to suppress ghrelin levels and cause weight loss. It was designed to mimic glucagon-like peptide 1 (GLP-1), an incretin hormone that stimulates insulin secretion and delays gastric emptying, among other effects. In the present study, the investigators will investigate the effects of a 6 month trial of exenatide in overweight adolescents with PWS. The investigators will quantify the changes in weight and body composition, as well as subjective measures of appetite, and concentrations of appetite-associated hormones. The investigators hypothesize that exenatide will improve weight, body composition, appetite, and plasma ghrelin levels during the treatment period.","[(11, 20, 'DRUG', 'Exenatide'), (24, 31, 'CONDITION', 'Obesity'), (48, 58, 'CONDITION', 'Overweight'), (73, 94, 'CONDITION', 'Prader-Willi Syndrome'), (97, 118, 'CONDITION', 'Prader-Willi Syndrome'), (120, 123, 'CONDITION', 'PWS'), (169, 176, 'CONDITION', 'obesity'), (178, 185, 'CONDITION', 'Obesity'), (334, 337, 'CONDITION', 'PWS'), (405, 412, 'CONDITION', 'obesity'), (595, 598, 'CONDITION', 'PWS'), (852, 855, 'CONDITION', 'PWS'), (910, 919, 'DRUG', 'Exenatide'), (1306, 1315, 'DRUG', 'exenatide'), (1319, 1329, 'CONDITION', 'overweight'), (1347, 1350, 'CONDITION', 'PWS'), (1559, 1568, 'DRUG', 'exenatide')]"
"['Comparison', 'of', 'Corticosteroid', 'and', 'Repeated', 'Dextrose', 'Hydro', '-', 'dissection', 'for', 'Carpal', 'Tunnel', 'Syndrome', 'Patients', '|', 'Carpal', 'tunnel', 'syndrome', '(', 'CTS', ')', 'is', 'the', 'most', 'prevalent', 'peripheral', 'nerve', 'entrapment', 'of', 'upper', 'limb', '.', 'Typical', 'symptoms', 'comprise', 'pain', ',', 'numbness', 'or', 'tingling', 'of', 'the', 'thumb', 'and', 'index', ',', 'middle', 'or', 'ring', 'fingers', '.', 'Thumb', 'weakness', 'and', 'decreased', 'grip', 'strength', 'can', 'occur', 'in', 'the', 'later', 'stage', '.', 'Currently', 'treatments', 'included', 'physical', 'modalities', '(', 'low', 'power', 'laser', ',', 'transcutaneous', 'electrical', 'nerve', 'stimulation', ',', 'ultrasound', ')', ',', 'medication', ',', 'splinting', ',', 'injection', 'and', 'surgery', '.', 'Ultrasound', 'guided', 'intracarpal', 'hydro', '-', 'dissection', 'of', 'median', 'nerve', 'had', 'been', 'proposed', 'based', 'on', 'its', 'accurate', 'localization', ',', 'while', 'the', 'injectates', 'were', 'diverse', '.', 'Corticosteroid', 'has', 'been', 'widely', 'used', 'for', 'CTS', 'for', 'decades', '.', 'However', ',', 'growing', 'evidences', 'suggested', 'that', '5', '%', 'dextrose', ',', 'normal', 'saline', ',', 'platelet', 'rich', 'plasma', 'injection', 'also', 'have', 'therapeutic', 'effects', 'on', 'alleviating', 'CTS', 'symptoms', '.', 'Among', 'the', 'injectates', ',', 'a', 'single', '5', '%', 'dextrose', 'injection', 'could', 'be', 'considered', 'as', 'a', 'substitute', 'of', 'corticosteroid', 'based', 'on', 'its', 'long', 'term', 'effect', 'up', 'to', 'six', 'months', '.', 'However', ',', 'the', 'clinical', 'efficacy', 'of', '5', '%', 'dextrose', 'injection', 'has', 'not', 'validated', 'by', 'the', 'further', 'study', '.', 'The', 'investigators', 'aim', 'to', 'compare', 'the', 'therapeutic', 'effect', 'of', '5', '%', 'dextrose', 'injection', 'with', 'corticosteroid', 'injection', 'in', 'patients', 'with', 'CTS', ',', 'up', 'to', '12', 'weeks', 'follow', 'up', '.']","['O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04579783,NCT04579783,"Comparison of Corticosteroid and Repeated Dextrose Hydro-dissection for Carpal Tunnel Syndrome Patients | Carpal tunnel syndrome (CTS) is the most prevalent peripheral nerve entrapment of upper limb. Typical symptoms comprise pain, numbness or tingling of the thumb and index, middle or ring fingers. Thumb weakness and decreased grip strength can occur in the later stage. Currently treatments included physical modalities (low power laser, transcutaneous electrical nerve stimulation, ultrasound), medication, splinting, injection and surgery. Ultrasound guided intracarpal hydro-dissection of median nerve had been proposed based on its accurate localization, while the injectates were diverse. Corticosteroid has been widely used for CTS for decades. However, growing evidences suggested that 5% dextrose, normal saline, platelet rich plasma injection also have therapeutic effects on alleviating CTS symptoms. Among the injectates, a single 5% dextrose injection could be considered as a substitute of corticosteroid based on its long term effect up to six months. However, the clinical efficacy of 5% dextrose injection has not validated by the further study. The investigators aim to compare the therapeutic effect of 5% dextrose injection with corticosteroid injection in patients with CTS, up to 12 weeks follow up.","[(14, 28, 'DRUG', 'Corticosteroid'), (42, 50, 'DRUG', 'Dextrose'), (72, 94, 'CONDITION', 'Carpal Tunnel Syndrome'), (106, 128, 'CONDITION', 'Carpal tunnel syndrome'), (130, 133, 'CONDITION', 'CTS'), (226, 230, 'CONDITION', 'pain'), (546, 592, 'OTHER', 'Ultrasound guided intracarpal hydro-dissection'), (698, 712, 'DRUG', 'Corticosteroid'), (738, 741, 'CONDITION', 'CTS'), (800, 808, 'DRUG', 'dextrose'), (817, 823, 'DRUG', 'saline'), (825, 845, 'DRUG', 'platelet rich plasma'), (901, 904, 'CONDITION', 'CTS'), (949, 957, 'DRUG', 'dextrose'), (1007, 1021, 'DRUG', 'corticosteroid'), (1107, 1115, 'DRUG', 'dextrose'), (1228, 1236, 'DRUG', 'dextrose'), (1252, 1266, 'DRUG', 'corticosteroid'), (1294, 1297, 'CONDITION', 'CTS')]"
"['An', 'International', 'Open', '-', 'label', 'Extension', 'Trial', 'to', 'Determine', 'Safety', 'and', 'Efficacy', 'of', 'Long', '-', 'term', 'Oral', 'Lacosamide', '(', 'SPM', '927', ')', 'in', 'Patients', 'With', 'Partial', 'Seizures', '|', 'The', 'main', 'purpose', 'of', 'this', 'trial', 'is', 'to', 'determine', 'safety', 'and', 'efficacy', 'of', 'Lacosamide', 'under', 'long', 'term', 'therapy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O']",NCT00515619,NCT00515619,An International Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral Lacosamide (SPM 927) in Patients With Partial Seizures | The main purpose of this trial is to determine safety and efficacy of Lacosamide under long term therapy.,"[(95, 105, 'DRUG', 'Lacosamide'), (107, 114, 'DRUG', 'SPM 927'), (133, 149, 'CONDITION', 'Partial Seizures'), (222, 232, 'DRUG', 'Lacosamide')]"
"['An', 'Open', '-', 'Label', ',', 'Multicenter', 'Study', 'in', 'Subjects', 'With', 'Relapsing', '-', 'Remitting', 'Multiple', 'Sclerosis', 'to', 'Evaluate', 'the', 'Safety', 'of', '240', 'mg', 'BG00012', 'TID', 'Administered', 'as', 'Add', '-', 'On', 'Therapy', 'to', 'Beta', 'Interferons', '(', 'IFNβ', ')', 'or', 'Glatiramer', 'Acetate', '(', 'GA', ')', '|', 'The', 'primary', 'objective', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'BG00012', '(', 'dimethyl', 'fumarate', ')', 'administered', 'in', 'combination', 'with', 'interferon', 'b', '(', 'IFNß', ')', 'or', 'glatiramer', 'acetate', '(', 'GA', ')', 'in', 'participants', 'with', 'relapsing', '-', 'remitting', 'multiple', 'sclerosis', '(', 'RRMS', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT01156311,NCT01156311,"An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA) | The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFNß) or glatiramer acetate (GA) in participants with relapsing-remitting multiple sclerosis (RRMS).","[(50, 88, 'CONDITION', 'Relapsing-Remitting Multiple Sclerosis'), (122, 129, 'DRUG', 'BG00012'), (168, 184, 'DRUG', 'Beta Interferons'), (186, 190, 'DRUG', 'IFNβ'), (195, 213, 'DRUG', 'Glatiramer Acetate'), (215, 217, 'DRUG', 'GA'), (302, 309, 'DRUG', 'BG00012'), (311, 328, 'DRUG', 'dimethyl fumarate'), (363, 375, 'DRUG', 'interferon b'), (377, 381, 'DRUG', 'IFNß'), (386, 404, 'DRUG', 'glatiramer acetate'), (406, 408, 'DRUG', 'GA'), (431, 469, 'CONDITION', 'relapsing-remitting multiple sclerosis'), (471, 475, 'CONDITION', 'RRMS')]"
"['The', 'Mediating', 'Role', 'of', 'Dissociative', 'Symptoms', 'and', 'Early', 'Maladaptive', 'Schemas', 'in', 'the', 'Relationship', 'Between', 'Childhood', 'Trauma', 'and', 'Auditory', 'Hallucinations', 'in', 'Schizophrenia', '|', 'BACKGROUND', 'It', 'is', 'demonstrated', 'that', 'strong', 'associations', 'between', 'trauma', 'suffered', 'in', 'childhood', 'and', 'having', 'schizophrenia', ',', 'and', 'more', 'specifically', 'to', 'experience', 'acoustic', '-', 'verbal', 'hallucinations', '(', 'AVH', ')', '.', 'A', 'second', 'generation', 'of', 'research', 'is', 'currently', 'examining', 'the', 'cognitive', 'and', 'affective', 'processes', 'likely', 'to', 'play', 'a', 'mediating', 'role', 'in', 'this', 'association', '.', 'These', 'mediators', 'appear', 'to', 'include', 'early', 'maladaptive', 'personality', 'patterns', 'and', 'dissociative', 'experiences', '.', 'Although', 'these', 'factors', 'have', 'most', 'often', 'been', 'explored', 'separately', ',', 'recent', 'research', 'indicates', 'that', 'they', 'could', 'be', 'associated', ',', 'and', 'thus', 'contribute', 'to', 'AVH', '.', 'More', 'specifically', ',', 'another', 'study', 'has', 'shown', 'that', 'the', 'association', 'between', 'childhood', 'trauma', 'and', 'predisposition', 'to', 'AVH', 'is', 'not', 'direct', 'but', 'depends', 'on', 'cognitive', 'factors', 'including', 'the', 'impact', 'of', 'violence', 'suffered', 'during', 'childhood', 'on', 'early', 'maladaptive', 'schemas', 'and', 'dissociation', '.', 'However', ',', 'this', 'study', 'was', 'carried', 'out', 'on', 'a', 'non', '-', 'clinical', 'sample', 'of', 'subjects', 'with', 'a', 'predisposition', 'to', 'AVH', '.', '\n\n', 'OBJECTIVES', ':', 'testing', 'a', 'structural', 'model', 'of', 'AVH', ',', 'childhood', 'trauma', ',', 'early', 'maladaptive', 'schemas', 'and', 'dissociative', 'symptoms', 'in', 'large', 'multicentric', 'sample', 'of', 'inpatients', 'diagnosed', 'with', 'schizophrenia', 'and', 'AVH', '(', 'n=350', ')', '.', 'Secondary', 'objectives', 'are', '(', 'i', ')', 'test', 'in', 'the', 'model', 'the', 'role', 'of', 'all', 'the', 'early', 'patterns', 'described', 'by', 'Jeffrey', 'Young', 'instead', 'of', 'targeting', 'only', 'the', 'schemes', 'that', 'are', 'part', 'of', 'the', 'model', 'tested', 'in', 'previous', 'study', 'as', 'the', 'one', 'by', 'Bortolon', 'and', 'colleagues', ',', '(', 'ii', ')', 'compare', 'the', 'quality', 'of', 'the', 'adjustment', 'of', 'the', 'confirmatory', 'model', 'to', 'the', 'quality', 'of', 'the', 'adjustment', 'of', 'the', 'exploratory', 'model', '.', '\n\n', 'METHODS', ':', 'one', 'single', 'visit', 'in', 'which', 'subjects', 'will', 'receive', 'self', '-', 'reported', 'questionnaires', '(', 'Childhood', 'trauma', 'questionnaire', ',', 'The', 'Young', 'schema', 'questionnaire', 'short', 'form', ',', 'Dissociative', 'experiences', 'scale', ',', 'Launay', '-', 'Slade', 'hallucination', 'scale', 'and', 'Cardiff', 'Anomalous', 'Perceptions', 'Scale', '.', '\n\n', 'ANALYSES', ':', 'Structural', 'equation', 'model', 'performed', 'additional', 'analysis', 'using', 'Partial', 'Least', 'Squares', 'Structural', 'Equation', 'Modelling', '.', 'The', 'primary', 'endpoint', 'corresponds', 'to', 'significant', 'associations', 'between', 'the', 'variables', '.', 'The', 'quality', 'of', 'the', 'model', 'will', 'be', 'assessed', 'using', 'a', 'fit', 'quality', 'measure', '.', 'The', 'secondary', 'endpoints', 'are', 'significant', 'associations', 'between', 'the', 'different', 'variables', '(', 'p', '<', '0.05', ')', 'and', 'the', 'model', 'quality', 'assessed', 'with', 'a', 'quality', 'measure', 'of', 'the', 'fit', '.', '\n\n', 'MAIN', 'HYPOTHESIS', ':', 'the', 'association', 'between', 'childhood', 'trauma', 'and', 'predisposition', 'to', 'AVH', 'is', 'not', 'direct', ',', 'but', 'depends', 'on', 'the', 'impact', 'of', 'violence', 'suffered', 'during', 'childhood', 'on', 'early', 'maladaptive', 'schemas', 'and', 'dissociative', 'symptoms', 'in', 'patients', 'with', 'schizophrenia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04481217,NCT04481217,"The Mediating Role of Dissociative Symptoms and Early Maladaptive Schemas in the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia | BACKGROUND It is demonstrated that strong associations between trauma suffered in childhood and having schizophrenia, and more specifically to experience acoustic-verbal hallucinations (AVH). A second generation of research is currently examining the cognitive and affective processes likely to play a mediating role in this association. These mediators appear to include early maladaptive personality patterns and dissociative experiences. Although these factors have most often been explored separately, recent research indicates that they could be associated, and thus contribute to AVH. More specifically, another study has shown that the association between childhood trauma and predisposition to AVH is not direct but depends on cognitive factors including the impact of violence suffered during childhood on early maladaptive schemas and dissociation. However, this study was carried out on a non-clinical sample of subjects with a predisposition to AVH.

OBJECTIVES: testing a structural model of AVH, childhood trauma, early maladaptive schemas and dissociative symptoms in large multicentric sample of inpatients diagnosed with schizophrenia and AVH (n=350). Secondary objectives are (i) test in the model the role of all the early patterns described by Jeffrey Young instead of targeting only the schemes that are part of the model tested in previous study as the one by Bortolon and colleagues, (ii) compare the quality of the adjustment of the confirmatory model to the quality of the adjustment of the exploratory model.

METHODS: one single visit in which subjects will receive self-reported questionnaires (Childhood trauma questionnaire, The Young schema questionnaire short form, Dissociative experiences scale, Launay-Slade hallucination scale and Cardiff Anomalous Perceptions Scale.

ANALYSES: Structural equation model performed additional analysis using Partial Least Squares Structural Equation Modelling. The primary endpoint corresponds to significant associations between the variables. The quality of the model will be assessed using a fit quality measure. The secondary endpoints are significant associations between the different variables (p <0.05) and the model quality assessed with a quality measure of the fit.

MAIN HYPOTHESIS: the association between childhood trauma and predisposition to AVH is not direct, but depends on the impact of violence suffered during childhood on early maladaptive schemas and dissociative symptoms in patients with schizophrenia.","[(123, 146, 'CONDITION', 'Auditory Hallucinations'), (150, 163, 'CONDITION', 'Schizophrenia'), (269, 282, 'CONDITION', 'schizophrenia'), (320, 350, 'CONDITION', 'acoustic-verbal hallucinations'), (352, 355, 'CONDITION', 'AVH'), (752, 755, 'CONDITION', 'AVH'), (868, 871, 'CONDITION', 'AVH'), (1123, 1126, 'CONDITION', 'AVH'), (1171, 1174, 'CONDITION', 'AVH'), (1224, 1245, 'CONDITION', 'dissociative symptoms'), (1304, 1317, 'CONDITION', 'schizophrenia'), (1322, 1325, 'CONDITION', 'AVH'), (2493, 2496, 'CONDITION', 'AVH'), (2648, 2661, 'CONDITION', 'schizophrenia')]"
"['Topiramate', '(', 'RWJ-17021', '-', '000', ')', 'Monotherapy', 'Clinical', 'Trial', 'in', 'Patients', 'With', 'Recently', 'Diagnosed', 'Partial', '-', 'Onset', 'Seizures', '|', 'The', 'purposes', 'of', 'this', 'study', 'are', '(', '1', ')', 'to', 'compare', 'the', 'effectiveness', 'of', 'two', 'doses', 'of', 'topiramate', 'and', '(', '2', ')', 'to', 'assess', 'the', 'safety', 'of', 'topiramate', 'alone', 'in', 'the', 'treatment', 'of', 'pediatric', 'and', 'adult', 'patients', 'with', 'recently', 'diagnosed', 'epilepsy', 'characterized', 'by', 'partial', '-', 'onset', 'seizures', '.']","['B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT00230698,NCT00230698,Topiramate (RWJ-17021-000) Monotherapy Clinical Trial in Patients With Recently Diagnosed Partial-Onset Seizures | The purposes of this study are (1) to compare the effectiveness of two doses of topiramate and (2) to assess the safety of topiramate alone in the treatment of pediatric and adult patients with recently diagnosed epilepsy characterized by partial-onset seizures.,"[(0, 10, 'DRUG', 'Topiramate'), (12, 25, 'DRUG', 'RWJ-17021-000'), (90, 112, 'CONDITION', 'Partial-Onset Seizures'), (195, 205, 'DRUG', 'topiramate'), (238, 248, 'DRUG', 'topiramate'), (328, 336, 'CONDITION', 'epilepsy'), (354, 376, 'CONDITION', 'partial-onset seizures')]"
"['Prospective', 'Study', 'on', 'the', 'Use', 'of', 'Middle', 'Meningeal', 'Artery', 'Embolization', 'for', 'Chronic', 'Subdural', 'Haematoma', '|', 'Subdural', 'haematoma', 'is', 'a', 'common', 'neurosurgical', 'condition', 'that', 'results', 'in', 'different', 'levels', 'of', 'neurological', 'deficits', 'in', 'patients', '.', 'It', 'can', 'be', 'further', 'classified', 'into', 'acute', 'and', 'chronic', ',', 'which', 'have', 'different', 'pathophysiology', '.', 'Acute', 'haematoma', 'is', 'a', 'common', 'result', 'of', 'traumatic', 'injuries', 'involving', 'the', 'tearing', 'of', 'the', 'bridging', 'veins', ',', 'while', 'chronic', 'subdural', 'haematoma', 'can', 'be', 'both', 'a', 'result', 'of', 'traumatic', 'injuries', 'or', 'recurrence', 'following', 'surgical', 'management', 'of', 'the', 'acute', 'counterpart', '.', 'For', 'symptomatic', 'patients', ',', 'they', 'are', 'often', 'surgically', 'managed', 'by', 'haematoma', 'drainage', 'via', 'burr', '-', 'hole', 'drainage', 'and', 'craniotomy', '.', 'Recurrent', 'bleeding', 'following', 'close', 'monitor', 'or', 'surgical', 'evacuation', 'of', 'haematoma', 'is', 'however', 'very', 'high', '.', 'Recent', 'studies', 'approximate', 'the', 'recurrence', 'rate', 'of', '2%-33.3', '%', '.', 'Recent', 'evidence', 'suggests', 'the', 'angiogenesis', 'of', 'middle', 'meningeal', 'arteries', '(', 'MMA', ')', 'in', 'response', 'to', 'inflammation', 'and', 'healing', 'process', 'contributes', 'to', 'the', 'development', 'of', 'chronic', 'subdural', 'haematoma', ',', 'and', 'its', 'high', 'recurrence', 'chance', '.', 'Several', 'studies', 'have', 'looked', 'into', 'the', 'use', 'of', 'middle', 'meningeal', 'artery', 'embolization', 'to', 'halt', 'the', 'bleeding', 'of', 'a', 'chronic', 'subdural', 'haematoma', ',', 'and', 'have', 'found', 'promising', 'results', 'in', 'terms', 'of', 'haematoma', 'reduction', 'and', 'prevention', 'of', 'surgical', 'rescues', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04500795,NCT04500795,"Prospective Study on the Use of Middle Meningeal Artery Embolization for Chronic Subdural Haematoma | Subdural haematoma is a common neurosurgical condition that results in different levels of neurological deficits in patients. It can be further classified into acute and chronic, which have different pathophysiology. Acute haematoma is a common result of traumatic injuries involving the tearing of the bridging veins, while chronic subdural haematoma can be both a result of traumatic injuries or recurrence following surgical management of the acute counterpart. For symptomatic patients, they are often surgically managed by haematoma drainage via burr-hole drainage and craniotomy. Recurrent bleeding following close monitor or surgical evacuation of haematoma is however very high. Recent studies approximate the recurrence rate of 2%-33.3%. Recent evidence suggests the angiogenesis of middle meningeal arteries (MMA) in response to inflammation and healing process contributes to the development of chronic subdural haematoma, and its high recurrence chance. Several studies have looked into the use of middle meningeal artery embolization to halt the bleeding of a chronic subdural haematoma, and have found promising results in terms of haematoma reduction and prevention of surgical rescues.","[(32, 68, 'SURGICAL', 'Middle Meningeal Artery Embolization'), (73, 99, 'CONDITION', 'Chronic Subdural Haematoma'), (102, 120, 'CONDITION', 'Subdural haematoma'), (319, 334, 'CONDITION', 'Acute haematoma'), (427, 453, 'CONDITION', 'chronic subdural haematoma'), (630, 639, 'CONDITION', 'haematoma'), (757, 766, 'CONDITION', 'haematoma'), (1008, 1034, 'CONDITION', 'chronic subdural haematoma'), (1112, 1148, 'SURGICAL', 'middle meningeal artery embolization'), (1175, 1201, 'CONDITION', 'chronic subdural haematoma'), (1248, 1257, 'CONDITION', 'haematoma')]"
"['Visual', 'Spatial', 'Exploration', 'and', 'Art', 'Therapy', 'Intervention', 'in', 'Patients', 'Diagnosed', 'With', 'Parkinson', ""'s"", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'dual', 'phase', 'cross', '-', 'sectional', ',', 'controlled', 'and', 'prospective', ',', 'open', 'label', ',', 'exploratory', 'study', 'is', 'to', 'determine', 'the', 'general', 'characteristics', 'of', 'visuospatial', 'exploration', 'and', 'its', 'neural', 'substrate', 'in', 'subjects', 'with', 'Parkinson', ""'s"", 'Disease', '(', 'PD', ')', 'and', 'to', 'explore', 'the', 'impact', 'of', 'professional', 'art', 'therapy', 'intervention', 'in', 'a', 'cohort', 'of', 'subjects', 'with', 'Parkinson', ""'s"", 'Disease', 'on', 'visuospatial', 'exploration', ',', 'visuomotor', 'integration', ',', 'neuropsychological', 'and', 'emotional', 'sphere', ',', 'quality', 'of', 'daily', 'living', 'and', 'motor', 'symptoms', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03178786,NCT03178786,"Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease | The purpose of this dual phase cross-sectional, controlled and prospective, open label, exploratory study is to determine the general characteristics of visuospatial exploration and its neural substrate in subjects with Parkinson's Disease (PD) and to explore the impact of professional art therapy intervention in a cohort of subjects with Parkinson's Disease on visuospatial exploration, visuomotor integration, neuropsychological and emotional sphere, quality of daily living and motor symptoms.","[(31, 42, 'OTHER', 'Art Therapy'), (83, 102, 'CONDITION', ""Parkinson's Disease""), (325, 344, 'CONDITION', ""Parkinson's Disease""), (346, 348, 'CONDITION', 'PD'), (392, 403, 'OTHER', 'art therapy'), (446, 465, 'CONDITION', ""Parkinson's Disease"")]"
"['IRB', '-', 'HSR', '#', '14299', ':', 'The', 'Use', 'of', 'the', 'Intrathoracic', 'Pressure', 'Regulator', '(', 'ITPR', ')', 'to', 'Improve', 'Cerebral', 'Perfusion', 'Pressure', 'in', 'Patients', 'With', 'Altered', 'Intracranial', 'Elastance', '|', 'Patients', 'who', 'have', 'a', 'functioning', 'intracranial', 'pressure', '-', 'monitoring', 'device', '(', 'either', 'a', 'subarachnoid', 'bolt', ',', 'or', 'an', 'intraventricular', 'catheter', ')', 'in', 'place', ',', 'and', 'are', 'either', 'sedated', ',', 'intubated', ',', 'and', 'mechanically', 'ventilated', '(', 'i.e.', 'in', 'the', 'NNICU', ')', ',', 'or', 'are', 'scheduled', 'to', 'undergo', 'an', 'operation', 'or', 'interventional', 'neuroradiological', 'procedure', 'at', 'the', 'University', 'of', 'Virginia', '.', 'Patients', 'with', 'a', 'contraindication', 'to', 'TTE', 'will', 'be', 'excluded', '.', '\n\n', 'For', 'patients', 'in', 'the', 'NNICU', ',', 'basic', 'hemodynamic', 'variables', '(', 'systemic', 'blood', 'pressure', ',', 'central', 'venous', 'pressure', ',', 'etc', '.', ')', 'will', 'be', 'collected', '.', 'In', 'addition', ',', 'left', 'ventricular', 'performance', '(', 'including', 'estimates', 'of', 'LVEDV', ',', 'LVESV', ',', 'EF', ',', 'FAC', ',', 'and', 'SV', ')', 'will', 'be', 'assessed', 'using', 'TTE', '.', 'Once', 'these', 'baseline', 'data', 'are', 'recorded', ',', 'the', 'ITPR', 'will', 'be', 'inserted', 'in', 'the', 'ventilator', 'circuit', 'and', 'activated', 'to', 'provide', 'either', '-5', 'mm', 'Hg', 'or', '-9', 'mm', 'Hg', 'endotracheal', 'rube', 'pressure', '(', 'ETP', ')', '(', 'based', 'on', 'a', 'randomization', 'scheme', ')', '.', 'After', 'the', 'ITPR', 'has', 'been', 'active', 'for', 'at', 'least', 'five', 'minutes', ',', 'the', 'same', 'intracranial', ',', 'hemodynamic', ',', 'and', 'TTE', 'data', 'obtained', 'above', 'will', 'be', 'gathered', '.', 'The', 'ITPR', 'will', 'then', 'be', 'turned', 'off', 'for', 'five', 'minutes', ',', 'and', 'intracranial', ',', 'hemodynamic', ',', 'and', 'TTE', 'data', 'will', 'again', 'be', 'recorded', '.', 'The', 'ITPR', 'will', 'be', 'activated', 'a', 'second', 'time', '(', '-9', 'mm', 'Hg', 'or', '-5', 'mm', 'Hg', 'ETP', ',', 'i.e.', 'whichever', 'value', 'was', 'not', 'used', 'previously', ')', ',', 'and', 'after', 'five', 'minutes', 'of', 'use', 'data', 'will', 'be', 'recorded', 'again', '.', 'The', 'ITPR', 'will', 'then', 'be', 'disconnected', ',', 'data', 'will', 'be', 'collected', 'after', 'waiting', 'two', 'minutes', ',', 'and', 'no', 'further', 'interventions', 'will', 'be', 'made', '.', '\n\n', 'ABG', ""'s"", 'will', 'be', 'obtained', 'before', 'and', 'during', 'the', 'use', 'of', 'the', 'device', 'at', 'each', 'setting', '.', '\n\n', 'This', 'is', 'a', 'proof', 'of', 'concept', '/', 'feasibility', 'study', 'designed', 'to', 'test', 'the', 'primary', 'hypothesis', 'that', 'use', 'of', 'the', 'ITPR', 'will', 'result', 'in', 'decreased', 'intracranial', 'pressure', 'and', 'increased', 'cerebral', 'perfusion', 'pressure', '.', 'The', 'effect', 'of', 'the', 'ITPR', 'on', 'secondary', 'indicators', 'of', 'cardiac', 'performance', 'will', 'also', 'be', 'examined', '.', 'These', 'include', 'but', 'are', 'not', 'limited', 'estimates', 'of', 'ventricular', 'end', 'diastolic', 'volume', 'and', 'pressure', '(', 'LVEDV', '/', 'P', ')', ',', 'ejection', 'fraction', '(', 'EF', ')', ',', 'left', 'ventricular', 'end', 'systolic', 'volume', 'and', 'pressure', '(', 'LVESV', '/', 'P', ')', ',', 'fractional', 'area', 'change', '(', 'FAC', ')', ',', 'all', 'of', 'which', 'will', 'be', 'assessed', 'by', 'transthoracic', 'echocardiography', '(', 'TTE', ')', 'or', 'transesophageal', 'echocardiography', '(', 'TEE', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01205607,NCT01205607,"IRB-HSR# 14299: The Use of the Intrathoracic Pressure Regulator (ITPR) to Improve Cerebral Perfusion Pressure in Patients With Altered Intracranial Elastance | Patients who have a functioning intracranial pressure-monitoring device (either a subarachnoid bolt, or an intraventricular catheter) in place, and are either sedated, intubated, and mechanically ventilated (i.e. in the NNICU), or are scheduled to undergo an operation or interventional neuroradiological procedure at the University of Virginia. Patients with a contraindication to TTE will be excluded.

For patients in the NNICU, basic hemodynamic variables (systemic blood pressure, central venous pressure, etc.) will be collected. In addition, left ventricular performance (including estimates of LVEDV, LVESV, EF, FAC, and SV) will be assessed using TTE. Once these baseline data are recorded, the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal rube pressure (ETP) (based on a randomization scheme). After the ITPR has been active for at least five minutes, the same intracranial, hemodynamic, and TTE data obtained above will be gathered. The ITPR will then be turned off for five minutes, and intracranial, hemodynamic, and TTE data will again be recorded. The ITPR will be activated a second time (-9 mm Hg or -5 mm Hg ETP, i.e. whichever value was not used previously), and after five minutes of use data will be recorded again. The ITPR will then be disconnected, data will be collected after waiting two minutes, and no further interventions will be made.

ABG's will be obtained before and during the use of the device at each setting.

This is a proof of concept/feasibility study designed to test the primary hypothesis that use of the ITPR will result in decreased intracranial pressure and increased cerebral perfusion pressure. The effect of the ITPR on secondary indicators of cardiac performance will also be examined. These include but are not limited estimates of ventricular end diastolic volume and pressure (LVEDV/P), ejection fraction (EF), left ventricular end systolic volume and pressure (LVESV/P), fractional area change (FAC), all of which will be assessed by transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE).","[(31, 63, 'OTHER', 'Intrathoracic Pressure Regulator'), (65, 69, 'OTHER', 'ITPR'), (127, 157, 'CONDITION', 'Altered Intracranial Elastance'), (864, 868, 'OTHER', 'ITPR'), (1043, 1047, 'OTHER', 'ITPR'), (1177, 1181, 'OTHER', 'ITPR'), (1296, 1300, 'OTHER', 'ITPR'), (1470, 1474, 'OTHER', 'ITPR'), (1778, 1782, 'OTHER', 'ITPR'), (1891, 1895, 'OTHER', 'ITPR')]"
"['Erector', 'Spinae', 'Plane', 'Block', 'Versus', 'Subcostal', 'Transversus', 'Abdominis', 'Plane', 'Block', 'in', 'Patients', 'Undergoing', 'Open', 'Liver', 'Resection', 'Surgery', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'Liver', 'resection', 'surgery', 'is', 'a', 'common', 'surgical', 'procedure', 'which', 'is', 'performed', 'on', 'patients', 'with', 'benign', ',', 'malignant', 'or', 'metastatic', 'hepatic', 'tumor', 'as', 'well', 'as', 'for', 'living', 'liver', 'donor', '.', 'Liver', 'resection', 'surgery', 'is', 'usually', 'performed', 'through', 'either', 'right', 'subcostal', 'or', 'inversed', 'L', '-', 'shaped', 'incision', ';', 'both', 'approaches', 'are', 'associated', 'with', 'a', 'significant', 'postoperative', 'pain', 'which', 'requires', 'intensive', 'analgesic', 'plan', 'to', 'facilitate', 'early', 'mobilization', 'and', 'minimize', 'complications', '.', '\n\n', 'There', 'are', 'various', 'lines', 'for', 'pain', 'management', 'in', 'liver', 'resection', 'surgery', 'such', 'as', 'systemic', 'analgesic', 'drugs', ',', 'neuraxial', 'blocks', '(', 'e.g.', ',', 'thoracic', 'epidural', 'analgesia', ')', 'and', 'transversus', 'abdominis', 'plane', '[', 'TAP', ']', 'block', ')', '.', '\n\n', 'Systemic', 'analgesic', 'drugs', 'are', 'nearly', 'constantly', 'used', 'in', 'liver', 'resection', '.', 'However', ',', 'being', 'systemically', 'administered', ',', 'these', 'drugs', 'have', 'many', 'side', 'effects', 'on', 'many', 'organs', 'and', 'can', 'not', 'totally', 'eliminate', 'postoperative', 'pain', '.', 'Thoracic', 'epidural', 'block', 'is', 'commonly', 'associated', 'with', 'hypotension', ';', 'furthermore', ',', 'its', 'use', 'has', 'other', 'limitations', 'such', 'as', 'delaying', 'postoperative', 'mobilization', 'and', 'possible', 'hematoma', 'and', 'cord', 'compression', 'in', 'patients', 'with', 'coagulopathy', 'which', 'is', 'expected', 'following', 'liver', 'resection', '.', 'Therefore', ',', 'there', 'had', 'been', 'an', 'increased', 'interest', 'in', 'the', 'use', 'of', 'abdominal', 'field', 'blocks', 'to', 'avoid', 'disadvantages', 'of', 'neuraxial', 'blocks', 'and', 'minimize', 'the', 'use', 'of', 'parenteral', 'analgesic', 'drugs', '.', '\n\n', 'TAP', 'block', 'is', 'one', 'of', 'the', 'classic', 'field', 'blocks', 'which', 'is', 'extensively', 'used', 'in', 'laparotomies', 'including', 'liver', 'resection', '.', 'However', ',', 'the', 'lack', 'of', 'visceral', 'pain', 'control', 'TAP', 'block', 'influences', 'the', 'quality', 'of', 'its', 'analgesic', 'effect', 'in', 'this', 'type', 'of', 'patients', '.', 'Nevertheless', ',', 'TAP', 'block', ',', 'namely', 'the', 'subcostal', 'approach', ',', 'is', 'still', 'the', 'recommended', 'field', 'block', 'in', 'the', 'latest', 'procedure', '-', 'specific', 'recommendations', 'for', 'pain', 'management', 'in', 'liver', 'resection', 'as', 'it', 'is', 'the', 'only', 'block', 'which', 'showed', 'good', 'evidence', '.', '\n\n', 'In', 'recent', 'years', ',', 'there', 'has', 'been', 'increased', 'interest', 'in', 'a', 'newer', 'field', 'block', ',', 'the', 'erector', 'spinae', 'plane', 'block', '(', 'ESPB', ')', ',', 'due', 'its', 'easy', 'performance', 'and', 'the', 'possible', 'coverage', 'of', 'visceral', 'pain', 'in', 'addition', 'to', 'the', 'somatic', 'pain', '.', 'ESPB', 'showed', 'promising', 'results', 'in', 'liver', 'resection', 'surgery', '.', 'ESBP', 'was', 'superior', 'to', 'TAP', 'block', 'in', 'various', 'abdominal', 'surgeries', '.', 'However', ',', 'its', 'analgesic', 'efficacy', 'had', 'not', 'been', 'previously', 'compared', 'in', 'relation', 'to', 'TAP', 'in', 'patients', 'undergoing', 'open', 'liver', 'resection', 'surgery', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT05253079,NCT05253079,"Erector Spinae Plane Block Versus Subcostal Transversus Abdominis Plane Block in Patients Undergoing Open Liver Resection Surgery: A Randomized Controlled Trial | Liver resection surgery is a common surgical procedure which is performed on patients with benign, malignant or metastatic hepatic tumor as well as for living liver donor. Liver resection surgery is usually performed through either right subcostal or inversed L-shaped incision; both approaches are associated with a significant postoperative pain which requires intensive analgesic plan to facilitate early mobilization and minimize complications.

There are various lines for pain management in liver resection surgery such as systemic analgesic drugs, neuraxial blocks (e.g., thoracic epidural analgesia) and transversus abdominis plane [TAP] block).

Systemic analgesic drugs are nearly constantly used in liver resection. However, being systemically administered, these drugs have many side effects on many organs and cannot totally eliminate postoperative pain. Thoracic epidural block is commonly associated with hypotension; furthermore, its use has other limitations such as delaying postoperative mobilization and possible hematoma and cord compression in patients with coagulopathy which is expected following liver resection. Therefore, there had been an increased interest in the use of abdominal field blocks to avoid disadvantages of neuraxial blocks and minimize the use of parenteral analgesic drugs.

TAP block is one of the classic field blocks which is extensively used in laparotomies including liver resection. However, the lack of visceral pain control TAP block influences the quality of its analgesic effect in this type of patients. Nevertheless, TAP block, namely the subcostal approach, is still the recommended field block in the latest procedure-specific recommendations for pain management in liver resection as it is the only block which showed good evidence.

In recent years, there has been increased interest in a newer field block, the erector spinae plane block (ESPB), due its easy performance and the possible coverage of visceral pain in addition to the somatic pain. ESPB showed promising results in liver resection surgery. ESBP was superior to TAP block in various abdominal surgeries. However, its analgesic efficacy had not been previously compared in relation to TAP in patients undergoing open liver resection surgery.","[(0, 26, 'OTHER', 'Erector Spinae Plane Block'), (34, 77, 'OTHER', 'Subcostal Transversus Abdominis Plane Block'), (101, 121, 'CONDITION', 'Open Liver Resection'), (163, 186, 'CONDITION', 'Liver resection surgery'), (254, 299, 'CONDITION', 'benign, malignant or metastatic hepatic tumor'), (335, 358, 'CONDITION', 'Liver resection surgery'), (492, 510, 'CONDITION', 'postoperative pain'), (641, 645, 'CONDITION', 'pain'), (660, 683, 'CONDITION', 'liver resection surgery'), (775, 814, 'OTHER', 'transversus abdominis plane [TAP] block'), (873, 888, 'CONDITION', 'liver resection'), (1284, 1299, 'CONDITION', 'liver resection'), (1482, 1491, 'OTHER', 'TAP block'), (1579, 1594, 'CONDITION', 'liver resection'), (1617, 1630, 'CONDITION', 'visceral pain'), (1639, 1648, 'OTHER', 'TAP block'), (1736, 1745, 'OTHER', 'TAP block'), (1887, 1902, 'CONDITION', 'liver resection'), (2035, 2061, 'OTHER', 'erector spinae plane block'), (2063, 2067, 'OTHER', 'ESPB'), (2124, 2137, 'CONDITION', 'visceral pain'), (2157, 2169, 'CONDITION', 'somatic pain'), (2171, 2175, 'OTHER', 'ESPB'), (2204, 2219, 'CONDITION', 'liver resection'), (2229, 2233, 'OTHER', 'ESBP'), (2250, 2259, 'OTHER', 'TAP block'), (2372, 2375, 'OTHER', 'TAP'), (2399, 2427, 'CONDITION', 'open liver resection surgery')]"
"['A', 'Phase', 'II', 'Open', 'and', 'Parallel', 'Safety', ',', 'Immunogenicity', 'and', 'Reactogenicity', 'Trial', 'of', 'Mencevax', 'ACW135', 'Polysaccharide', 'Vaccine', 'Comparing', 'Three', 'Groups', ':', '2', '-', '4', 'Year', ',', '5', '-', '14', 'Year', 'and', '15', '-', '29', 'Year', 'Old', 'Ethiopians', '|', 'Primary', 'objective', ':', '\n\n', 'To', 'assess', 'the', 'immunogenicity', 'of', 'the', 'Mencevax', 'ACW135', 'polysaccharide', 'vaccine', 'at', '28', 'days', '(', '+6days', ')', 'post', 'vaccination', 'in', '2', '-', '4', ',', '5', '-', '14', ',', '15', '-', '29', 'year', 'age', 'groups', 'and', 'compare', 'the', 'immunogenicity', 'between', 'these', 'age', 'groups', '.', '\n\n', 'Secondary', 'Objectives', ':', '\n\n', 'To', 'estimate', 'the', 'incidence', 'of', 'common', 'adverse', 'events', 'following', 'immunization', '(', 'AEFI', ')', 'of', 'GSK', 'Nm', 'ACW135', 'polysaccharide', 'vaccine', 'at', '1h', ',', '1d', ',', '2d', ',', '3d', ',', '7d', 'and', '28', 'days', 'post', '-', 'vaccination', '\n', 'To', 'assess', 'the', 'persistence', 'of', 'antibody', 'against', 'meningitis', 'A', ',', 'C', 'and', 'W135', 'at', '11', 'and', '23', 'months', 'post', 'vaccination', 'in', '2', '-', '4', ',', '5', '-', '14', ',', '15', '-', '29', 'year', 'age', 'groups', '\n\n', 'Study', 'site', ':', 'Two', 'rural', 'communities', '(', 'Kebele', ')', 'in', 'Butajira', 'district', ',', 'Ethiopia', '.', '\n\n', 'Methods', ':', '\n\n', 'Phase', 'II', ',', 'open', 'and', 'parallel', 'safety', 'and', 'immunogenicity', 'trial', '.', '\n', '234', 'younger', 'children', '(', '2', '-', '4', 'years', ')', ',', '145', 'older', 'children', '(', '5', '-', '14', 'years', ')', 'and', '33', 'adults', '(', '15', '-', '29', 'years', 'of', 'age', ')', 'were', 'randomly', 'selected', 'from', 'the', 'demographic', 'surveillance', 'database', 'and', 'enrolled', 'after', 'screening', 'and', 'consenting', '.', '\n', 'Study', 'participant', 'received', 'Mencevax', 'ACW', 'polysaccharide', 'vaccine', '50', 'mg', 'in', '0.5ml', 'subcutaneously', '.', '\n', 'Blood', 'samples', 'for', 'measuring', 'SBA', 'titres', 'were', 'collected', 'at', 'pre', 'vaccination', 'and', 'on', 'day', '28', '(', '+6', 'days', ')', 'post', 'vaccination', '.', '\n', 'Active', 'follow', 'up', 'for', 'AEFI', 'on', 'post', 'vaccination', 'day', '0', ',', '1', ',', '2', ',', '3', ',', '7', ',', '&', '28', '.', '\n', 'Primary', 'end', 'point', 'was', 'vaccine', 'response', 'defined', 'as', 'sero', '-', 'conversion', '(', 'in', 'subjects', 'initially', 'seronegative', ')', 'or', 'a', '4', 'fold', 'increase', '(', 'in', 'subjects', 'initially', 'seropositive', ')', 'in', 'serum', 'bactericidal', 'antibodies', '(', 'SBA', ')', 'against', 'serogroups', 'Men', 'A', ',', 'C', 'and', 'W135', ')', 'on', 'post', 'vaccination', 'day', '28', '.', 'In', 'addition', 'seroconversion', 'was', 'assessed', 'by', 'ELISA', 'Men', 'A', 'IgG', 'on', 'day', '0', 'and', 'day', '28', 'post', 'vaccination', '.', '\n', 'Secondary', 'endpoints', 'were', 'incidence', 'of', 'general', 'and', 'local', 'symptoms', 'and', 'other', 'adverse', 'events', 'following', 'immunisation', 'during', 'the', 'post', 'vaccination', 'period', 'day', '0', 'to', '28', 'and', 'immune', 'persistence', 'on', 'post', 'vaccination', 'month-11', 'and', 'month-23', '.', '\n\n', 'Results', ':', '\n\n', 'No', 'significant', 'difference', 'in', 'the', 'incidence', 'of', 'general', 'or', 'local', 'AEFI', 'was', 'observed', 'between', 'the', 'age', 'groups', '\n', 'The', 'statistical', 'analysis', 'for', 'the', 'Immunogenicity', 'data', 'is', 'in', 'progress']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00994695,NCT00994695,"A Phase II Open and Parallel Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Polysaccharide Vaccine Comparing Three Groups: 2 - 4 Year, 5 - 14 Year and 15 - 29 Year Old Ethiopians | Primary objective:

To assess the immunogenicity of the Mencevax ACW135 polysaccharide vaccine at 28 days (+6days) post vaccination in 2-4, 5-14, 15-29 year age groups and compare the immunogenicity between these age groups.

Secondary Objectives:

To estimate the incidence of common adverse events following immunization (AEFI) of GSK Nm ACW135 polysaccharide vaccine at 1h, 1d, 2d, 3d, 7d and 28 days post-vaccination
To assess the persistence of antibody against meningitis A, C and W135 at 11 and 23 months post vaccination in 2-4, 5-14, 15-29 year age groups

Study site:Two rural communities (Kebele) in Butajira district, Ethiopia.

Methods:

Phase II, open and parallel safety and immunogenicity trial.
234 younger children (2-4 years), 145 older children (5-14 years) and 33 adults (15-29 years of age) were randomly selected from the demographic surveillance database and enrolled after screening and consenting.
Study participant received Mencevax ACW polysaccharide vaccine 50 mg in 0.5ml subcutaneously.
Blood samples for measuring SBA titres were collected at pre vaccination and on day 28 (+6 days) post vaccination.
Active follow up for AEFI on post vaccination day 0, 1, 2, 3, 7, & 28.
Primary end point was vaccine response defined as sero-conversion (in subjects initially seronegative) or a 4 fold increase (in subjects initially seropositive) in serum bactericidal antibodies (SBA) against serogroups Men A, C and W135) on post vaccination day 28. In addition seroconversion was assessed by ELISA Men A IgG on day 0 and day 28 post vaccination.
Secondary endpoints were incidence of general and local symptoms and other adverse events following immunisation during the post vaccination period day 0 to 28 and immune persistence on post vaccination month-11 and month-23.

Results:

No significant difference in the incidence of general or local AEFI was observed between the age groups
The statistical analysis for the Immunogenicity data is in progress","[(80, 118, 'DRUG', 'Mencevax ACW135 Polysaccharide Vaccine'), (257, 295, 'DRUG', 'Mencevax ACW135 polysaccharide vaccine'), (541, 570, 'DRUG', 'ACW135 polysaccharide vaccine'), (668, 692, 'CONDITION', 'meningitis A, C and W135'), (1152, 1187, 'DRUG', 'Mencevax ACW polysaccharide vaccine'), (1624, 1641, 'CONDITION', 'Men A, C and W135'), (1720, 1725, 'CONDITION', 'Men A')]"
"['A', 'Phase', 'IIa', 'Study', 'of', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Oral', 'LAT8881', 'in', 'Neuropathic', 'Pain', '|', 'This', 'is', 'a', 'randomised', ',', 'placebo', '-', 'controlled', ',', 'double', '-', 'blind', ',', 'crossover', ',', 'phase', 'IIa', 'study', 'to', 'investigate', 'the', 'efficacy', 'and', 'safety', 'of', 'oral', 'LAT8881', 'in', 'neuropathic', 'pain', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O']",NCT03865953,NCT03865953,"A Phase IIa Study of the Efficacy and Safety of Oral LAT8881 in Neuropathic Pain | This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.","[(53, 60, 'DRUG', 'LAT8881'), (64, 80, 'CONDITION', 'Neuropathic Pain'), (105, 112, 'CONTROL', 'placebo'), (213, 220, 'DRUG', 'LAT8881'), (224, 240, 'CONDITION', 'neuropathic pain')]"
"['The', 'Effects', 'of', 'Triggering', 'Points', 'Dry', 'Needling', 'on', 'Sternocleidomastoid', 'Muscle', 'for', 'Pain', 'and', 'Disability', 'in', 'Migraine', '|', 'To', 'determine', 'the', 'effects', ',', 'sequel', 'of', 'dry', 'needling', 'in', 'migraine', 'by', 'resolving', 'MTrPs', 'in', 'sternocleidomastoid', 'muscle', '.', '\n\n', 'To', 'determine', 'the', 'possession', 'of', 'dry', 'needling', 'technique', 'to', 'mitigate', 'the', 'frequency', ',', 'intensity', 'and', 'duration', 'of', 'headache', '.', '\n\n', 'To', 'determine', 'the', 'effectiveness', 'of', 'dry', 'needling', 'in', 'the', 'disability', 'hindrance', 'in', 'migraine', 'patients', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT05285852,NCT05285852,"The Effects of Triggering Points Dry Needling on Sternocleidomastoid Muscle for Pain and Disability in Migraine | To determine the effects, sequel of dry needling in migraine by resolving MTrPs in sternocleidomastoid muscle.

To determine the possession of dry needling technique to mitigate the frequency, intensity and duration of headache.

To determine the effectiveness of dry needling in the disability hindrance in migraine patients.","[(15, 75, 'OTHER', 'Triggering Points Dry Needling on Sternocleidomastoid Muscle'), (80, 84, 'CONDITION', 'Pain'), (103, 111, 'CONDITION', 'Migraine'), (150, 162, 'OTHER', 'dry needling'), (166, 174, 'CONDITION', 'migraine'), (257, 269, 'OTHER', 'dry needling'), (333, 341, 'CONDITION', 'headache'), (378, 390, 'OTHER', 'dry needling'), (422, 430, 'CONDITION', 'migraine')]"
"['A', 'Multi', '-', 'centre', ',', 'Double', '-', 'blind', ',', 'Placebo', 'Controlled', ',', 'Proof', 'of', 'Concept', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Tolerability', 'of', 'BAF312', 'in', 'Patients', 'With', 'Polymyositis', 'and', 'Dermatomyositis', '|', 'This', 'study', 'determined', 'the', 'efficacy', ',', 'safety', ',', 'tolerability', 'and', 'the', 'PK', 'profile', 'of', 'BAF312', ',', 'a', 'novel', 'immunomodulator', ',', 'in', 'polymyositis', 'and', 'dermatomyositis', 'patients', 'who', 'were', 'not', 'responsive', 'to', 'traditional', 'immunosuppressive', 'and/or', 'corticosteroid', 'therapy', '.', 'The', 'study', 'consisted', 'of', 'a', '12', 'week', ',', 'randomized', ',', 'placebo', 'controlled', 'period', ',', 'followed', 'by', 'another', '12', 'weeks', 'where', 'all', 'subjects', 'received', 'BAF312', 'treatment', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O']",NCT01148810,NCT01148810,"A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis | This study determined the efficacy, safety, tolerability and the PK profile of BAF312, a novel immunomodulator, in polymyositis and dermatomyositis patients who were not responsive to traditional immunosuppressive and/or corticosteroid therapy. The study consisted of a 12 week, randomized, placebo controlled period, followed by another 12 weeks where all subjects received BAF312 treatment.","[(30, 37, 'CONTROL', 'Placebo'), (118, 124, 'DRUG', 'BAF312'), (142, 154, 'CONDITION', 'Polymyositis'), (159, 174, 'CONDITION', 'Dermatomyositis'), (256, 262, 'DRUG', 'BAF312'), (292, 304, 'CONDITION', 'polymyositis'), (309, 324, 'CONDITION', 'dermatomyositis'), (468, 475, 'CONTROL', 'placebo'), (552, 558, 'DRUG', 'BAF312')]"
"['A', 'Pilot', 'Study', 'of', 'Exendin-4', 'in', 'Alzheimer', 's', 'Disease', '|', 'Background', ':', '\n\n', 'Exendin-4', '(', 'or', 'Exenatide', ')', 'is', 'a', 'medication', 'currently', 'used', 'to', 'treat', 'diabetes', 'that', 'has', 'shown', 'promising', 'results', 'in', 'animal', 'and', 'cellular', 'models', 'of', 'Alzheimer', ""'s"", 'disease', '.', 'It', 'is', 'possible', 'that', 'Exendin-4', 'may', 'be', 'a', 'treatment', 'for', 'Alzheimer', ""'s"", 'disease', ',', 'which', 'involves', 'the', 'gradual', 'deterioration', 'and', 'death', 'of', 'neurons', '.', 'Researchers', 'are', 'interested', 'in', 'studying', 'the', 'safety', 'and', 'comparing', 'the', 'effects', 'of', 'Exendin-4', 'with', 'placebo', 'on', 'cognitive', 'performance', ',', 'clinical', 'progression', 'of', 'dementia', ',', 'various', 'chemicals', 'measured', 'in', 'blood', 'and', 'cerebrospinal', 'fluid', ',', 'and', 'brain', 'MRI', ',', 'in', 'individuals', 'with', 'early', '-', 'stage', 'Alzheimer', ""'s"", 'disease', 'or', 'mild', 'cognitive', 'impairment', '.', '\n\n', 'Objectives', ':', '\n\n', 'To', 'determine', 'the', 'safety', 'and', 'tolerability', 'of', 'twice', 'daily', 'administration', 'of', 'Exendin-4', ',', 'as', 'well', 'as', 'to', 'acquire', 'preliminary', 'evidence', 'for', 'effects', 'on', 'cognitive', 'performance', ',', 'clinical', 'progression', 'of', 'dementia', ',', 'various', 'chemicals', 'measured', 'in', 'blood', 'and', 'cerebrospinal', 'fluid', ',', 'and', 'brain', 'MRI', ',', 'in', 'individuals', 'with', 'early', '-', 'stage', 'Alzheimer', ""'s"", 'disease', 'or', 'mild', 'cognitive', 'impairment', '.', '\n\n', 'Eligibility', ':', '\n\n', 'Individuals', 'at', 'least', '60', 'years', 'of', 'age', 'who', 'have', 'objective', 'evidence', 'of', 'early', '-', 'stage', 'Alzheimer', ""'s"", 'disease', 'or', 'mild', 'cognitive', 'impairment', 'in', 'screening', 'testing', '.', '\n\n', 'Design', ':', '\n\n', 'Participants', 'will', 'be', 'screened', '.', '\n', 'Following', 'the', 'telephone', 'screening', ',', 'two', 'in', '-', 'person', 'screening', 'visits', 'to', 'determine', 'eligibility', '.', '\n', 'The', 'screening', 'visit', 'will', 'involve', 'a', 'medical', 'history', 'and', 'neurological', 'examination', ',', 'tests', 'of', 'memory', 'and', 'cognition', ',', 'a', 'lumbar', 'puncture', ',', 'collection', 'of', 'blood', 'and', 'saliva', 'samples', ',', 'and', 'brain', 'Magnetic', 'Resonance', 'Imagine', '(', 'MRI', ')', 'studies', '.', 'Participants', 'will', 'be', 'required', 'to', 'appoint', 'a', 'Durable', 'Power', 'of', 'Attorney', 'for', 'research', 'and', 'medical', 'care', 'during', 'this', 'protocol', '.', '\n', 'Eligible', 'participants', 'will', 'be', 'divided', 'into', 'two', 'groups', '(', 'double', '-', 'blind', 'randomization', ')', '.', 'One', 'group', 'will', 'receive', 'Exendin-4', 'SC', 'twice', 'daily', ',', 'and', 'the', 'other', 'will', 'receive', 'a', 'placebo', '.', 'Participants', 'will', 'keep', 'a', 'medication', 'diary', 'and', 'will', 'be', 'scheduled', 'for', 'additional', 'study', 'visits', '1', 'and', '2', 'weeks', 'after', 'the', 'start', 'of', 'the', 'treatment', '.', '\n', 'Participants', 'will', 'have', 'regular', 'followup', 'visits', 'with', 'blood', 'tests', ',', 'cognitive', 'tests', ',', 'imaging', 'studies', ',', 'and', 'other', 'examinations', '6', ',', '12', ',', 'and', '18', 'months', 'after', 'the', 'start', 'of', 'the', 'treatment', '.', 'Another', 'lumbar', 'puncture', 'may', 'be', 'performed', 'optionally', 'at', 'the', '18', '-', 'month', 'followup', 'visit', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01255163,NCT01255163,"A Pilot Study of Exendin-4 in Alzheimer s Disease | Background:

Exendin-4 (or Exenatide) is a medication currently used to treat diabetes that has shown promising results in animal and cellular models of Alzheimer's disease. It is possible that Exendin-4 may be a treatment for Alzheimer's disease, which involves the gradual deterioration and death of neurons. Researchers are interested in studying the safety and comparing the effects of Exendin-4 with placebo on cognitive performance, clinical progression of dementia, various chemicals measured in blood and cerebrospinal fluid, and brain MRI, in individuals with early-stage Alzheimer's disease or mild cognitive impairment.

Objectives:

To determine the safety and tolerability of twice daily administration of Exendin-4, as well as to acquire preliminary evidence for effects on cognitive performance, clinical progression of dementia, various chemicals measured in blood and cerebrospinal fluid, and brain MRI, in individuals with early-stage Alzheimer's disease or mild cognitive impairment.

Eligibility:

Individuals at least 60 years of age who have objective evidence of early-stage Alzheimer's disease or mild cognitive impairment in screening testing.

Design:

Participants will be screened.
Following the telephone screening, two in-person screening visits to determine eligibility.
The screening visit will involve a medical history and neurological examination, tests of memory and cognition, a lumbar puncture, collection of blood and saliva samples, and brain Magnetic Resonance Imagine (MRI) studies. Participants will be required to appoint a Durable Power of Attorney for research and medical care during this protocol.
Eligible participants will be divided into two groups (double-blind randomization). One group will receive Exendin-4 SC twice daily, and the other will receive a placebo. Participants will keep a medication diary and will be scheduled for additional study visits 1 and 2 weeks after the start of the treatment.
Participants will have regular followup visits with blood tests, cognitive tests, imaging studies, and other examinations 6, 12, and 18 months after the start of the treatment. Another lumbar puncture may be performed optionally at the 18-month followup visit.","[(17, 26, 'DRUG', 'Exendin-4'), (30, 49, 'CONDITION', 'Alzheimer s Disease'), (65, 74, 'DRUG', 'Exendin-4'), (79, 88, 'DRUG', 'Exenatide'), (205, 224, 'CONDITION', ""Alzheimer's disease""), (246, 255, 'DRUG', 'Exendin-4'), (279, 298, 'CONDITION', ""Alzheimer's disease""), (442, 451, 'DRUG', 'Exendin-4'), (515, 523, 'CONDITION', 'dementia'), (621, 652, 'CONDITION', ""early-stage Alzheimer's disease""), (656, 681, 'CONDITION', 'mild cognitive impairment'), (771, 780, 'DRUG', 'Exendin-4'), (887, 895, 'CONDITION', 'dementia'), (993, 1024, 'CONDITION', ""early-stage Alzheimer's disease""), (1028, 1053, 'CONDITION', 'mild cognitive impairment'), (1138, 1169, 'CONDITION', ""early-stage Alzheimer's disease""), (1173, 1198, 'CONDITION', 'mild cognitive impairment'), (1805, 1814, 'DRUG', 'Exendin-4'), (1860, 1867, 'CONTROL', 'placebo')]"
"['Insulin', '-', 'like', 'Growth', 'Factor-1', 'in', 'Amyotrophic', 'Lateral', 'Sclerosis', '(', 'ALS', ')', '|', 'The', 'purpose', 'of', 'this', 'multicenter', 'study', 'is', 'to', 'determine', 'if', 'insulin', '-', 'like', 'growth', 'factor-1', '(', 'IGF', '-', 'I', ')', 'slows', 'the', 'progressive', 'weakness', 'in', 'amyotrophic', 'lateral', 'sclerosis', '(', 'ALS', ')', 'patients', '.', 'Study', 'participants', 'will', 'be', 'followed', 'for', '2', 'years', 'once', 'enrolled', '.', 'They', 'will', 'receive', 'either', 'placebo', 'or', 'the', 'active', 'IGF', '-', 'I.', 'Examinations', 'will', 'take', 'place', 'at', 'approximately', '6', '-', 'month', 'intervals', '.']","['B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00035815,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) | The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients. Study participants will be followed for 2 years once enrolled. They will receive either placebo or the active IGF-I. Examinations will take place at approximately 6-month intervals.,"[(0, 28, 'DRUG', 'Insulin-like Growth Factor-1'), (32, 61, 'CONDITION', 'Amyotrophic Lateral Sclerosis'), (63, 66, 'CONDITION', 'ALS'), (127, 155, 'DRUG', 'insulin-like growth factor-1'), (157, 162, 'DRUG', 'IGF-I'), (198, 227, 'CONDITION', 'amyotrophic lateral sclerosis'), (229, 232, 'CONDITION', 'ALS'), (332, 339, 'CONTROL', 'placebo'), (354, 360, 'DRUG', 'IGF-I.')]"
"['CANOPY', ':', 'Carotid', 'Artery', 'Stenting', 'Outcomes', 'in', 'the', 'Standard', 'Risk', 'Population', 'for', 'Carotid', 'Endarterectomy', '|', 'The', 'objective', 'of', 'the', 'CANOPY', 'trial', 'is', 'to', 'assess', 'the', 'continued', 'safety', 'and', 'effectiveness', 'of', 'the', 'RX', 'Acculink', 'Carotid', 'Stent', 'System', 'under', 'commercial', 'use', 'in', 'subjects', 'at', 'standard', 'risk', 'for', 'adverse', 'events', 'from', 'Carotid', 'Endarterectomy', '(', 'CEA', ')', 'enrolled', 'by', 'physicians', 'with', 'a', 'range', 'of', 'carotid', 'stenting', 'experience', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01445613,NCT01445613,CANOPY: Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy | The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA) enrolled by physicians with a range of carotid stenting experience.,"[(77, 99, 'SURGICAL', 'Carotid Endarterectomy'), (195, 227, 'SURGICAL', 'RX Acculink Carotid Stent System'), (302, 324, 'SURGICAL', 'Carotid Endarterectomy'), (326, 329, 'SURGICAL', 'CEA')]"
"['A', 'Phase', 'One', 'Treatment', 'Trial', 'of', 'the', 'Circadian', 'Sleep', 'Disturbance', 'in', 'Smith', '-', 'Magenis', 'Syndrome', '(', 'SMS', ')', '|', 'This', 'study', 'will', 'examine', 'the', 'effect', 'of', 'bright', 'light', 'or', 'melatonin', 'treatment', 'on', 'sleep', 'in', 'children', 'with', 'Smith', '-', 'Magenis', 'syndrome', '(', 'SMS', ')', ',', 'a', 'genetic', 'disorder', 'characterized', 'by', 'certain', 'physical', ',', 'behavioral', 'and', 'developmental', 'features', '.', 'Patients', 'have', 'a', 'disrupted', 'sleep', 'cycle', 'involving', 'early', 'waking', ',', 'frequent', 'daytime', 'napping', 'and', 'frequent', 'nighttime', 'awakenings', '.', 'Melatonin', 'is', 'a', 'hormone', 'normally', 'produced', 'at', 'night', 'in', 'healthy', 'people', '.', 'People', 'with', 'SMS', 'produce', 'high', 'levels', 'of', 'melatonin', 'during', 'the', 'daytime', 'and', 'very', 'low', 'levels', 'at', 'night', '.', 'This', 'may', 'affect', 'their', 'behavior', ',', 'mood', ',', 'attention', 'span', 'and', 'sleep', 'patterns', '.', '\n\n', 'Healthy', 'volunteers', 'between', '18', 'and', '45', 'years', 'of', 'age', 'and', 'children', 'with', 'SMS', 'who', 'are', 'between', '3', 'and', '16', 'years', 'of', 'age', 'may', 'be', 'eligible', 'for', 'this', 'study', '.', '\n\n', 'Healthy', 'subjects', 'are', 'admitted', 'to', 'the', 'NIH', 'Clinical', 'Center', 'overnight', '.', 'In', 'the', 'morning', 'they', 'take', 'one', 'dose', 'of', 'time', '-', 'release', 'melatonin', 'and', 'have', 'blood', 'and', 'saliva', 'samples', 'collected', 'hourly', 'from', '7:00', 'AM', 'to', '6:00', 'PM', '.', '\n\n', 'Children', 'with', 'SMS', 'participate', 'in', 'a', '2', '-', 'part', 'study', ',', 'as', 'follows', ':', '\n\n', 'Part', '1', 'Inpatient', 'Trial', '\n\n', 'Pre', '-', 'trial', 'at', '-', 'home', 'phase', ':', 'During', 'the', 'month', 'before', 'NIH', 'inpatient', 'admission', ',', 'participants', 'do', 'the', 'following', ':', '\n\n', 'Wear', 'an', 'actiwatch', 'device', 'or', 'keep', 'a', 'daily', 'sleep', 'diary', 'to', 'monitor', 'daytime', 'alertness', ',', 'mood', 'shifts', 'and', 'sleep', 'patterns', '.', '\n', 'Complete', 'a', 'behavior', 'assessment', 'survey', 'related', 'to', 'the', 'child', 's', 'behaviors', 'and', 'sleep', 'patterns', '.', '\n', 'Obtain', 'frequent', 'body', 'temperature', 'measurements', '.', '\n', 'Collect', 'several', 'saliva', 'samples', 'over', 'a', '24', '-', 'hour', 'period', '.', '\n\n', 'NIH', 'admission', 'phase', ':', '\n\n', 'Children', 'are', 'admitted', 'to', 'the', 'NIH', 'Clinical', 'Center', 'for', '2', '-', '3', 'nights', 'for', 'bright', 'light', 'treatment', '.', 'They', 'remain', 'in', 'their', 'rooms', 'for', 'alternating', 'periods', 'of', 'exposure', 'to', 'standard', 'dim', 'room', 'light', 'and', 'bright', 'light', ',', 'using', 'a', 'light', 'box', 'placed', 'within', '3', 'to', '5', 'feet', 'of', 'the', 'child', '.', 'An', 'electroencephalogram', '(', 'EEG', ')', 'with', 'additional', 'electrodes', 'to', 'track', 'eye', 'movements', 'is', 'used', 'to', 'monitor', 'the', 'child', 's', 'attention', '.', 'Between', '8AM', 'and', '6PM', 'serial', 'blood', 'samples', 'are', 'collected', 'to', 'measure', 'melatonin', 'levels', '.', 'A', 'parent', 'rates', 'the', 'child', 's', 'mood', 'and', 'behavior', 'during', 'the', '2', '-', 'day', 'test', 'period', '.', '\n', 'Children', 'are', 'admitted', 'to', 'the', 'NIH', 'Clinical', 'Center', 'for', '2', '-', '3', 'nights', 'for', 'melatonin', 'treatment', '.', 'They', 'take', 'a', 'single', 'dose', 'of', 'melatonin', 'or', 'placebo', 'tablet', 'at', 'bedtime', '.', 'During', 'the', 'daytime', ',', 'EEG', 'electrodes', 'are', 'placed', 'to', 'track', 'eye', 'movements', '.', 'Between', '7', 'PM', 'and', '7', 'AM', 'serial', 'blood', 'samples', 'are', 'collected', 'to', 'measure', 'melatonin', 'levels', '.', 'A', 'parent', 'rates', 'the', 'child', 's', 'behavior', 'and', 'mood', 'as', 'described', 'for', 'the', 'bright', 'light', 'study', '.', '\n', 'Children', 'may', 'receive', 'either', 'or', 'both', 'of', 'the', 'bright', 'light', 'and', 'melatonin', 'treatments', '.', '\n\n', 'Part', '2', 'Outpatient', 'Trial', '\n\n', 'Children', 'participate', 'in', 'a', 'combined', 'bright', 'light', 'with', 'melatonin', 'trial', 'at', 'home', '.', 'They', 'undergo', 'the', 'same', 'procedures', 'outlined', 'in', 'the', 'pre', '-', 'trial', 'at', '-', 'home', 'phase', 'of', 'Part', '1', '(', 'actiwatch', ',', 'behavior', 'assessments', ',', 'body', 'temperature', 'measurements', ',', 'saliva', 'samples', ')', 'over', 'an', '11', '-', 'week', 'period', '.', 'If', 'saliva', 'samples', 'can', 'not', 'be', 'collected', 'for', 'melatonin', 'testing', ',', '24', '-', 'hour', 'urine', 'samples', 'may', 'be', 'collected', 'instead', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00506259,NCT00506259,"A Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS) | This study will examine the effect of bright light or melatonin treatment on sleep in children with Smith-Magenis syndrome (SMS), a genetic disorder characterized by certain physical, behavioral and developmental features. Patients have a disrupted sleep cycle involving early waking, frequent daytime napping and frequent nighttime awakenings. Melatonin is a hormone normally produced at night in healthy people. People with SMS produce high levels of melatonin during the daytime and very low levels at night. This may affect their behavior, mood, attention span and sleep patterns.

Healthy volunteers between 18 and 45 years of age and children with SMS who are between 3 and 16 years of age may be eligible for this study.

Healthy subjects are admitted to the NIH Clinical Center overnight. In the morning they take one dose of time-release melatonin and have blood and saliva samples collected hourly from 7:00 AM to 6:00 PM.

Children with SMS participate in a 2-part study, as follows:

Part 1 Inpatient Trial

Pre-trial at-home phase: During the month before NIH inpatient admission, participants do the following:

Wear an actiwatch device or keep a daily sleep diary to monitor daytime alertness, mood shifts and sleep patterns.
Complete a behavior assessment survey related to the child s behaviors and sleep patterns.
Obtain frequent body temperature measurements.
Collect several saliva samples over a 24-hour period.

NIH admission phase:

Children are admitted to the NIH Clinical Center for 2-3 nights for bright light treatment. They remain in their rooms for alternating periods of exposure to standard dim room light and bright light, using a light box placed within 3 to 5 feet of the child. An electroencephalogram (EEG) with additional electrodes to track eye movements is used to monitor the child s attention. Between 8AM and 6PM serial blood samples are collected to measure melatonin levels. A parent rates the child s mood and behavior during the 2-day test period.
Children are admitted to the NIH Clinical Center for 2-3 nights for melatonin treatment. They take a single dose of melatonin or placebo tablet at bedtime. During the daytime, EEG electrodes are placed to track eye movements. Between 7 PM and 7 AM serial blood samples are collected to measure melatonin levels. A parent rates the child s behavior and mood as described for the bright light study.
Children may receive either or both of the bright light and melatonin treatments.

Part 2 Outpatient Trial

Children participate in a combined bright light with melatonin trial at home. They undergo the same procedures outlined in the pre-trial at-home phase of Part 1 (actiwatch, behavior assessments, body temperature measurements, saliva samples) over an 11-week period. If saliva samples cannot be collected for melatonin testing, 24-hour urine samples may be collected instead.","[(35, 62, 'CONDITION', 'Circadian Sleep Disturbance'), (66, 88, 'CONDITION', 'Smith-Magenis Syndrome'), (90, 93, 'CONDITION', 'SMS'), (135, 147, 'OTHER', 'bright light'), (151, 160, 'DRUG', 'melatonin'), (197, 219, 'CONDITION', 'Smith-Magenis syndrome'), (221, 224, 'CONDITION', 'SMS'), (336, 357, 'CONDITION', 'disrupted sleep cycle'), (442, 451, 'DRUG', 'Melatonin'), (523, 526, 'CONDITION', 'SMS'), (550, 559, 'DRUG', 'melatonin'), (751, 754, 'CONDITION', 'SMS'), (944, 953, 'DRUG', 'melatonin'), (1045, 1048, 'CONDITION', 'SMS'), (1621, 1643, 'OTHER', 'bright light treatment'), (1739, 1751, 'OTHER', 'bright light'), (1999, 2008, 'DRUG', 'melatonin'), (2160, 2169, 'DRUG', 'melatonin'), (2208, 2217, 'DRUG', 'melatonin'), (2221, 2228, 'CONTROL', 'placebo'), (2386, 2395, 'DRUG', 'melatonin'), (2533, 2545, 'OTHER', 'bright light'), (2550, 2559, 'DRUG', 'melatonin'), (2633, 2645, 'OTHER', 'bright light'), (2651, 2660, 'DRUG', 'melatonin'), (2906, 2915, 'DRUG', 'melatonin')]"
"['Virtual', 'Reality', 'in', 'Cognitive', 'Rehabilitation', 'of', 'Processing', 'Speed', 'for', 'Persons', 'With', 'Acquired', 'Brain', 'Injury', '|', 'One', 'hundred', 'participants', 'with', 'acquired', 'brain', 'injury', '(', 'ABI', ')', 'will', 'be', 'included', 'in', 'a', 'randomized', 'controlled', 'trial', ',', 'with', 'one', 'group', 'playing', 'a', 'commercially', 'available', 'VR', 'game', 'and', 'the', 'control', 'group', 'doing', 'activities', 'in', 'their', 'everyday', 'as', 'cognitive', 'training', '.', 'The', 'trial', 'aims', 'to', 'investigate', 'how', 'VR', 'can', 'affect', 'processing', 'speed', 'in', 'the', 'ABI', 'population', ',', 'and', 'if', 'these', 'effects', 'can', 'transfer', 'into', 'everyday', 'activities', '.', 'The', 'training', 'will', 'be', 'performed', 'in', 'the', 'participants', 'homes', ',', 'with', 'assistance', 'provided', 'by', 'the', 'project', 'group', 'via', 'phone', 'or', 'video', 'conference', '.', 'The', 'training', 'period', 'will', 'last', 'five', 'weeks', '.', 'Participant', ""'s"", 'cognitive', 'functions', 'will', 'be', 'measured', 'with', 'questionnaires', 'and', 'neuropsychological', 'tests', 'at', 'the', 'start', 'of', 'the', 'training', 'period', ',', 'at', 'the', 'end', 'of', 'training', 'and', 'sixteen', 'weeks', 'after', 'the', 'start', 'of', 'the', 'intervention', '.', 'In', 'depth', 'experiences', 'with', 'VR', 'as', 'a', 'training', 'method', 'will', 'be', 'gathered', 'through', 'performing', 'focus', 'group', 'interviews', 'with', 'some', 'of', 'the', 'participants', 'from', 'the', 'VR', 'group', ',', 'in', 'addition', 'to', 'self', '-', 'reported', 'questionnaires', 'from', 'all', 'the', 'participants', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05443542,NCT05443542,"Virtual Reality in Cognitive Rehabilitation of Processing Speed for Persons With Acquired Brain Injury | One hundred participants with acquired brain injury (ABI) will be included in a randomized controlled trial, with one group playing a commercially available VR game and the control group doing activities in their everyday as cognitive training. The trial aims to investigate how VR can affect processing speed in the ABI population, and if these effects can transfer into everyday activities. The training will be performed in the participants homes, with assistance provided by the project group via phone or video conference. The training period will last five weeks. Participant's cognitive functions will be measured with questionnaires and neuropsychological tests at the start of the training period, at the end of training and sixteen weeks after the start of the intervention. In depth experiences with VR as a training method will be gathered through performing focus group interviews with some of the participants from the VR group, in addition to self-reported questionnaires from all the participants.","[(0, 15, 'OTHER', 'Virtual Reality'), (81, 102, 'CONDITION', 'Acquired Brain Injury'), (135, 156, 'CONDITION', 'acquired brain injury'), (158, 161, 'CONDITION', 'ABI'), (239, 269, 'OTHER', 'commercially available VR game'), (298, 326, 'CONTROL', 'activities in their everyday'), (384, 386, 'OTHER', 'VR'), (422, 425, 'CONDITION', 'ABI'), (916, 918, 'OTHER', 'VR'), (1038, 1040, 'OTHER', 'VR')]"
"['Demonstration', 'of', 'mGluR5', 'Overexpression', 'in', 'Amish', 'and', 'Mennonite', 'CNTNAP2', 'Mutation', 'Carriers', '|', 'The', 'primary', 'goal', 'of', 'the', 'present', 'study', 'is', 'to', 'evaluate', 'the', 'utility', 'of', 'mGluR5', 'binding', 'as', 'measured', 'by', 'PET', 'as', 'a', 'biomarker', 'of', 'the', 'CNTNAP2', 'mutation', 'and', 'related', '/mTOR', 'kinase', 'pathway', 'dysregulation', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02572206,NCT02572206,Demonstration of mGluR5 Overexpression in Amish and Mennonite CNTNAP2 Mutation Carriers | The primary goal of the present study is to evaluate the utility of mGluR5 binding as measured by PET as a biomarker of the CNTNAP2 mutation and related /mTOR kinase pathway dysregulation.,"[(62, 87, 'CONDITION', 'CNTNAP2 Mutation Carriers')]"
"['A', 'Randomized', 'Controlled', 'Trial', 'Utilizing', 'the', 'Arts', 'to', 'Improve', 'Health', ',', 'Resilience', ',', 'and', 'Well', '-', 'Being', 'in', 'Individuals', 'With', 'Chronic', 'Health', 'Conditions', 'in', 'Underserved', 'Neighborhoods', '|', 'This', 'is', 'an', '8', '-', 'week', 'randomized', 'controlled', 'trial', 'to', 'help', 'address', 'health', ',', 'resilience', ',', 'and', 'well', '-', 'being', '.', 'Participants', 'are', 'randomized', 'into', 'either', 'a', 'health', 'education', 'group', 'or', 'an', 'arts', '-', 'based', 'health', 'education', 'group', '.', 'Both', 'groups', 'will', 'attend', 'for', '8', 'weeks', 'and', 'various', 'study', 'assessments', 'will', 'be', 'conducted', 'in', 'order', 'to', 'measure', 'the', 'experience', 'and', 'impact', 'of', 'the', 'program', '.', 'Anyone', '18', 'years', 'and', 'older', 'with', 'a', 'chronic', 'health', 'condition', '(', 'for', 'example', ',', 'diabetes', ',', 'hypertension', ',', 'congestive', 'heart', 'failure', ',', 'chronic', 'obstructive', 'pulmonary', 'disorder', ',', 'asthma', ',', 'weight', ',', 'anxiety', ',', 'depression', ',', 'cardiac', ',', 'arthritis', ',', 'multiple', 'sclerosis', ',', 'and', 'many', 'more', ')', 'are', 'eligible', 'to', 'participate', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04154579,NCT04154579,"A Randomized Controlled Trial Utilizing the Arts to Improve Health, Resilience, and Well-Being in Individuals With Chronic Health Conditions in Underserved Neighborhoods | This is an 8-week randomized controlled trial to help address health, resilience, and well-being. Participants are randomized into either a health education group or an arts-based health education group. Both groups will attend for 8 weeks and various study assessments will be conducted in order to measure the experience and impact of the program. Anyone 18 years and older with a chronic health condition (for example, diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disorder, asthma, weight, anxiety, depression, cardiac, arthritis, multiple sclerosis, and many more) are eligible to participate.","[(44, 48, 'OTHER', 'Arts'), (312, 328, 'CONTROL', 'health education'), (341, 368, 'OTHER', 'arts-based health education'), (594, 602, 'CONDITION', 'diabetes'), (604, 616, 'CONDITION', 'hypertension'), (618, 642, 'CONDITION', 'congestive heart failure'), (644, 682, 'CONDITION', 'chronic obstructive pulmonary disorder'), (684, 690, 'CONDITION', 'asthma'), (692, 698, 'CONDITION', 'weight'), (700, 707, 'CONDITION', 'anxiety'), (709, 719, 'CONDITION', 'depression'), (721, 728, 'CONDITION', 'cardiac'), (730, 739, 'CONDITION', 'arthritis'), (741, 759, 'CONDITION', 'multiple sclerosis')]"
"['Effectiveness', 'of', 'a', 'Short', '-', 'term', 'Mixed', 'Exercise', 'Program', 'for', 'Treating', 'Sarcopenia', 'in', 'Hospitalized', 'Patients', 'Aged', '80', 'Years', 'and', 'Older', '|', 'Most', 'previous', 'clinical', 'trials', 'that', 'addressed', 'exercise', 'for', 'sarcopenic', 'elderly', 'subjects', 'focused', 'on', 'community', '-', 'dwelling', 'older', 'adults', 'who', 'were', 'relatively', 'healthy', '.', 'There', 'is', 'a', 'notable', 'paucity', 'of', 'high', '-', 'quality', 'research', 'investigating', 'the', 'effects', 'and', 'feasibility', 'of', 'exercise', 'for', 'hospitalized', 'or', 'institutionalized', 'older', 'people', ',', 'who', 'are', 'generally', 'frailer', 'and', 'more', 'severe', 'in', 'functional', 'impairment', 'than', 'those', 'living', 'in', 'the', 'community', '.', 'Moreover', ',', 'most', 'reported', 'exercise', 'programs', 'were', 'of', 'long', '-', 'term', 'duration', ',', 'which', 'typically', 'lasted', '3', 'to', '6', 'months', 'with', 'two', 'sessions', 'per', 'week', '.', 'It', 'remains', 'unclear', 'whether', 'short', '-', 'term', 'exercise', 'would', 'be', 'effective', 'for', 'treating', 'sarcopenia', '.', 'Therefore', ',', 'the', 'investigators', 'aimed', 'to', 'assess', 'the', 'effectiveness', 'of', 'short', '-', 'term', 'exercise', 'for', 'treating', 'sarcopenia', 'in', 'hospitalized', 'older', 'patients', 'aged', '80', 'years', 'and', 'over', '.']","['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04355299,NCT04355299,"Effectiveness of a Short-term Mixed Exercise Program for Treating Sarcopenia in Hospitalized Patients Aged 80 Years and Older | Most previous clinical trials that addressed exercise for sarcopenic elderly subjects focused on community-dwelling older adults who were relatively healthy. There is a notable paucity of high-quality research investigating the effects and feasibility of exercise for hospitalized or institutionalized older people, who are generally frailer and more severe in functional impairment than those living in the community. Moreover, most reported exercise programs were of long-term duration, which typically lasted 3 to 6 months with two sessions per week. It remains unclear whether short-term exercise would be effective for treating sarcopenia. Therefore, the investigators aimed to assess the effectiveness of short-term exercise for treating sarcopenia in hospitalized older patients aged 80 years and over.","[(19, 52, 'PHYSICAL', 'Short-term Mixed Exercise Program'), (66, 76, 'CONDITION', 'Sarcopenia'), (186, 196, 'CONDITION', 'sarcopenic'), (383, 391, 'PHYSICAL', 'exercise'), (571, 588, 'PHYSICAL', 'exercise programs'), (709, 728, 'PHYSICAL', 'short-term exercise'), (761, 771, 'CONDITION', 'sarcopenia'), (839, 858, 'PHYSICAL', 'short-term exercise'), (872, 882, 'CONDITION', 'sarcopenia')]"
"['Comprehensive', 'Fall', 'Prevention', 'and', 'Detection', 'in', 'Multiple', 'Sclerosis', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'examine', 'whether', 'an', 'exercise', 'and', 'educational', 'classroom', 'program', 'can', 'help', 'reduce', 'falls', 'in', 'people', 'with', 'Multiple', 'Sclerosis', 'who', 'fall', 'frequently', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O']",NCT02583386,NCT02583386,Comprehensive Fall Prevention and Detection in Multiple Sclerosis | The purpose of this study is to examine whether an exercise and educational classroom program can help reduce falls in people with Multiple Sclerosis who fall frequently.,"[(0, 29, 'OTHER', 'Comprehensive Fall Prevention'), (47, 65, 'CONDITION', 'Multiple Sclerosis'), (119, 127, 'PHYSICAL', 'exercise'), (132, 161, 'BEHAVIOURAL', 'educational classroom program'), (199, 217, 'CONDITION', 'Multiple Sclerosis')]"
"['The', 'Effect', 'of', 'Functional', 'Electrical', 'Stimulation', 'and', 'Therapeutic', 'Exercise', 'on', 'Functional', 'Properties', 'of', 'Skeletal', 'Muscles', ',', 'Sitting', 'Postural', 'Stability', 'and', 'Quality', 'of', 'Life', 'in', 'Traumatic', 'Spinal', 'Cord', 'Injury', 'Patients', '|', 'Aim', 'of', 'the', 'current', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'functional', 'electrical', 'stimulation', 'and', 'therapeutic', 'exercise', 'on', 'traumatic', 'spinal', 'cord', 'injured', ""participants'skeletal"", 'muscle', 'characteristics', ',', 'sitting', 'balance', ',', 'lung', 'function', 'and', 'quality', 'of', 'life', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03517787,NCT03517787,"The Effect of Functional Electrical Stimulation and Therapeutic Exercise on Functional Properties of Skeletal Muscles, Sitting Postural Stability and Quality of Life in Traumatic Spinal Cord Injury Patients | Aim of the current study is to evaluate the effect functional electrical stimulation and therapeutic exercise on traumatic spinal cord injured participants'skeletal muscle characteristics, sitting balance, lung function and quality of life.","[(14, 47, 'OTHER', 'Functional Electrical Stimulation'), (52, 72, 'PHYSICAL', 'Therapeutic Exercise'), (169, 197, 'CONDITION', 'Traumatic Spinal Cord Injury'), (260, 293, 'OTHER', 'functional electrical stimulation'), (298, 318, 'PHYSICAL', 'therapeutic exercise'), (322, 351, 'CONDITION', 'traumatic spinal cord injured')]"
"['Effectiveness', 'Specific', 'Manual', 'Therapy', 'in', 'a', 'Multimodal', 'Physical', 'Therapy', 'Treatment', 'in', 'Patients', 'With', 'Tinnitus', 'and', 'Temporomandibular', 'Joint', 'Disorder', '.', '|', 'Tinnitus', 'is', 'one', 'of', 'the', 'most', 'prevalent', 'symptoms', 'that', 'causes', 'more', 'disability', 'in', 'patients', 'with', 'temporomandibular', 'disorder', '(', 'TMD', ')', '.', 'The', 'present', 'study', 'postulates', 'a', 'possible', 'link', 'between', 'temporomandibular', 'joint', '(', 'TMJ', ')', 'and', 'inner', 'ear', 'based', 'on', 'their', 'anatomical', ',', 'biomechanical', 'and', 'physiological', 'relationship', ',', 'proposing', 'a', 'physiotherapy', 'treatment', 'for', 'the', 'temporomandibular', 'joint', 'to', 'improve', 'tinnitus', '.', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'adding', 'specific', 'manual', 'therapy', 'to', 'a', 'multimodal', 'physiotherapy', 'treatment', 'in', 'patients', 'with', 'tinnitus', 'and', 'temporomandibular', 'disorder', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O']",NCT02850055,NCT02850055,"Effectiveness Specific Manual Therapy in a Multimodal Physical Therapy Treatment in Patients With Tinnitus and Temporomandibular Joint Disorder. | Tinnitus is one of the most prevalent symptoms that causes more disability in patients with temporomandibular disorder (TMD). The present study postulates a possible link between temporomandibular joint (TMJ) and inner ear based on their anatomical, biomechanical and physiological relationship, proposing a physiotherapy treatment for the temporomandibular joint to improve tinnitus. The aim of the study is to evaluate the effectiveness of adding specific manual therapy to a multimodal physiotherapy treatment in patients with tinnitus and temporomandibular disorder.","[(14, 37, 'OTHER', 'Specific Manual Therapy'), (43, 80, 'OTHER', 'Multimodal Physical Therapy Treatment'), (98, 106, 'CONDITION', 'Tinnitus'), (111, 143, 'CONDITION', 'Temporomandibular Joint Disorder'), (147, 155, 'CONDITION', 'Tinnitus'), (239, 265, 'CONDITION', 'temporomandibular disorder'), (267, 270, 'CONDITION', 'TMD'), (455, 510, 'OTHER', 'physiotherapy treatment for the temporomandibular joint'), (522, 530, 'CONDITION', 'tinnitus'), (596, 619, 'OTHER', 'specific manual therapy'), (625, 659, 'OTHER', 'multimodal physiotherapy treatment'), (677, 685, 'CONDITION', 'tinnitus'), (690, 716, 'CONDITION', 'temporomandibular disorder')]"
"['Evaluate', 'the', 'Safety', 'and', 'Immunogenicity', 'of', 'a', 'Vero', 'Cell', '-', 'Derived', 'Inactivated', 'Japanese', 'Encephalitis', 'Vaccine', '(', 'JECEVAX', ')', 'Produced', 'by', 'VABIOTECH', '(', 'Vietnam', ')', 'in', 'Vietnamese', 'Children', 'Aged', '9', '-', '24', 'Months', '|', 'A', 'study', 'of', 'the', 'study', 'vaccine', '(', 'JECEVAX-', 'VABIOTECH', '-', 'Vietnam', ')', 'and', 'a', 'licensed', 'vaccine', '(', 'JEVAX', '-', 'VABIOTECH', '-', 'Vietnam', ')', 'is', 'conducted', 'in', 'Vietnamese', 'children', ',', 'aged', '9', 'to', '24', 'months', 'to', 'assess', 'the', 'safety', 'of', 'the', 'study', 'vaccine', 'compares', 'to', 'licenced', 'vaccine', '.', 'Two', 'hundred', 'and', 'twenty', 'children', 'are', 'enrolled', 'and', 'randomly', 'assigned', 'into', '2', 'groups', '(', '110', 'children', '/', 'group', ')', ',', 'each', 'of', 'which', 'receive', '2', 'doses', 'of', 'study', '/', 'control', 'vaccine', 'subcutaneously', ',', 'at', '28', '-', '34', 'days', 'interval', '.', 'Safety', 'data', 'included', 'immediate', 'reaction', 'at', 'the', 'injection', 'site', 'and', 'systemic', 'reaction', 'within', '30', 'min', 'of', 'administration', ',', 'solicited', 'and', 'unsolicited', 'adverse', 'events', 'occurs', 'from', 'the', '1st', 'dose', 'to', '28', '-', '34', 'days', 'after', 'first', 'dose', 'and', 'from', 'the', 'second', 'dose', 'to', '28', '-', '34', 'days', 'after', '2nd', 'dose', '.', 'SAE', '(', 'from', 'start', 'of', 'first', 'dose', 'to', '28', '-', '34', 'days', 'after', 'second', 'dose', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03282370,NCT03282370,"Evaluate the Safety and Immunogenicity of a Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) Produced by VABIOTECH (Vietnam) in Vietnamese Children Aged 9-24 Months | A study of the study vaccine (JECEVAX- VABIOTECH-Vietnam) and a licensed vaccine (JEVAX-VABIOTECH-Vietnam) is conducted in Vietnamese children, aged 9 to 24 months to assess the safety of the study vaccine compares to licenced vaccine. Two hundred and twenty children are enrolled and randomly assigned into 2 groups (110 children/group), each of which receive 2 doses of study / control vaccine subcutaneously, at 28-34 days interval. Safety data included immediate reaction at the injection site and systemic reaction within 30 min of administration, solicited and unsolicited adverse events occurs from the 1st dose to 28-34 days after first dose and from the second dose to 28-34 days after 2nd dose. SAE (from start of first dose to 28-34 days after second dose).","[(44, 105, 'DRUG', 'Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine'), (107, 114, 'DRUG', 'JECEVAX'), (220, 228, 'DRUG', 'JECEVAX-'), (254, 270, 'CONTROL', 'licensed vaccine'), (272, 277, 'DRUG', 'JEVAX'), (408, 424, 'CONTROL', 'licenced vaccine')]"
"['A', 'Phase', '1', ',', 'Open', '-', 'Label', ',', '2', '-', 'Period', ',', 'Sequential', ',', 'Drug', '-', 'Drug', 'Interaction', 'Study', 'To', 'Determine', 'The', 'Effect', 'Of', 'Lithium', '600', 'Mg', 'BID', 'On', 'The', 'Safety', 'And', 'Pharmacokinetics', 'Of', 'Lurasidone', '120', 'Mg', 'QD', 'In', 'Patients', 'With', 'Schizophrenia', 'Or', 'Schizoaffective', 'Disorder', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'drug', '-', 'drug', 'interaction', 'effect', 'between', 'Lithium', 'and', 'Lurasidone', 'HCl', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O']",NCT01074073,NCT01074073,"A Phase 1, Open-Label, 2-Period, Sequential, Drug-Drug Interaction Study To Determine The Effect Of Lithium 600 Mg BID On The Safety And Pharmacokinetics Of Lurasidone 120 Mg QD In Patients With Schizophrenia Or Schizoaffective Disorder | The purpose of this study is to evaluate the drug-drug interaction effect between Lithium and Lurasidone HCl.","[(100, 107, 'DRUG', 'Lithium'), (157, 167, 'DRUG', 'Lurasidone'), (195, 208, 'CONDITION', 'Schizophrenia'), (212, 236, 'CONDITION', 'Schizoaffective Disorder'), (321, 328, 'DRUG', 'Lithium'), (333, 347, 'DRUG', 'Lurasidone HCl')]"
"['Emergence', 'Delirium', 'and', 'Recovery', 'Profile', 'in', 'Patients', 'Undergoing', 'Cleft', 'Lip', 'and', 'Palate', 'Repair', ':', 'Comparison', 'of', 'Combination', 'of', 'Morphine', 'and', 'Fentanyl', 'With', 'Fentanyl', 'Alone', '|', 'Emergence', 'Delirium', 'And', 'Recovery', 'Profile', 'In', 'Patients', 'Undergoing', 'Cleft', 'Lip', 'And', 'Cleft', 'Palate', 'Repair', 'With', 'Either', 'Combination', 'Of', 'Morphine', 'Plus', 'Fentanyl', 'Or', 'Fentanyl', 'Alone']","['O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O']",NCT03010540,NCT03010540,Emergence Delirium and Recovery Profile in Patients Undergoing Cleft Lip and Palate Repair: Comparison of Combination of Morphine and Fentanyl With Fentanyl Alone | Emergence Delirium And Recovery Profile In Patients Undergoing Cleft Lip And Cleft Palate Repair With Either Combination Of Morphine Plus Fentanyl Or Fentanyl Alone,"[(10, 18, 'CONDITION', 'Delirium'), (63, 72, 'CONDITION', 'Cleft Lip'), (77, 90, 'CONDITION', 'Palate Repair'), (121, 129, 'DRUG', 'Morphine'), (134, 142, 'DRUG', 'Fentanyl'), (148, 156, 'DRUG', 'Fentanyl'), (228, 237, 'CONDITION', 'Cleft Lip'), (242, 261, 'CONDITION', 'Cleft Palate Repair'), (289, 297, 'DRUG', 'Morphine'), (303, 311, 'DRUG', 'Fentanyl'), (315, 323, 'DRUG', 'Fentanyl')]"
"['Acute', 'Care', 'for', 'Elders', '(', 'ACE', ')', 'Program', 'at', 'OHSU', 'Hospital', '|', 'The', 'purpose', 'of', 'this', 'investigation', 'is', 'to', 'assess', 'the', 'effectiveness', 'of', 'a', 'multi', '-', 'disciplinary', 'Acute', 'Care', 'for', 'Elders', '(', 'ACE', ')', 'program', 'dedicated', 'to', 'the', 'care', 'of', 'patients', 'age', '70', 'and', 'older', 'admitted', 'to', 'Oregon', 'Health', '&', 'Science', 'University', ""'s"", 'hospital', 'medicine', 'service', '.', 'The', 'ACE', 'program', 'will', 'aim', 'to', 'improve', 'the', 'quality', 'of', 'care', 'of', 'older', 'patients', 'in', 'the', 'investigators', 'hospital', 'by', 'implementing', 'focused', 'interventions', 'and', 'recommendations', 'specific', 'to', 'geriatric', 'needs', 'and', 'syndromes', ',', 'including', ':', 'reduced', 'fall', 'rate', ',', 'decreased', 'incidence', 'and', 'duration', 'of', 'delirium', ',', 'early', 'recognition', 'and', 'treatment', 'of', 'impaired', 'mobility', 'and', 'function', ',', 'careful', 'minimization', 'of', 'medication', 'use', ',', 'prevention', 'of', 'unnecessary', 'catheter', 'and', 'restraint', 'use', ',', 'decreased', 'hospital', 'readmission', 'rates', ',', 'improved', 'transitional', 'care', 'following', 'hospital', 'discharge', ',', 'and', 'high', 'levels', 'of', 'patient', 'and', 'referring', 'physician', 'satisfaction', '.', 'Additionally', ',', 'the', 'ACE', 'program', 'aims', 'to', 'improve', 'resident', 'and', 'student', 'competence', 'in', 'treating', 'geriatric', 'syndromes', ',', 'and', 'to', 'improve', 'staff', 'and', 'learner', 'satisfaction', 'with', 'caring', 'for', 'older', 'adults', '.', 'ACE', 'programs', 'have', 'been', 'well', 'studied', 'at', 'other', 'institutions', ',', 'so', 'the', 'investigators', 'will', 'be', 'implementing', 'a', 'program', 'that', 'is', 'already', 'standard', 'of', 'care', ',', 'and', 'studying', 'the', 'elements', 'that', 'are', 'unique', 'to', 'OHSU', '.', '\n\n', 'This', 'will', 'be', 'a', 'quality', 'improvement', 'project', '.', 'Study', 'participants', 'will', 'be', 'a', 'convenience', 'sample', 'of', 'OHSU', 'faculty', ',', 'staff', ',', 'residents', 'and', 'students', 'who', 'are', 'employed', 'by', 'or', 'on', 'rotation', 'with', 'General', 'Medicine', 'Team', '1', 'of', 'the', 'Medicine', 'Teaching', 'Service', '.', 'Faculty', ',', 'staff', ',', 'and', 'learners', '(', 'ACE', 'team', 'members', ')', 'will', 'receive', 'the', 'ACE', 'training', '.', 'Study', 'personnel', 'will', 'conduct', 'prospective', 'and', 'retrospective', 'chart', 'review', 'of', 'patients', 'admitted', 'to', 'the', 'ACE', 'service', 'to', 'determine', 'outcomes', 'as', 'noted', 'above', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02119078,NCT02119078,"Acute Care for Elders (ACE) Program at OHSU Hospital | The purpose of this investigation is to assess the effectiveness of a multi-disciplinary Acute Care for Elders (ACE) program dedicated to the care of patients age 70 and older admitted to Oregon Health & Science University's hospital medicine service. The ACE program will aim to improve the quality of care of older patients in the investigators hospital by implementing focused interventions and recommendations specific to geriatric needs and syndromes, including: reduced fall rate, decreased incidence and duration of delirium, early recognition and treatment of impaired mobility and function, careful minimization of medication use, prevention of unnecessary catheter and restraint use, decreased hospital readmission rates, improved transitional care following hospital discharge, and high levels of patient and referring physician satisfaction. Additionally, the ACE program aims to improve resident and student competence in treating geriatric syndromes, and to improve staff and learner satisfaction with caring for older adults. ACE programs have been well studied at other institutions, so the investigators will be implementing a program that is already standard of care, and studying the elements that are unique to OHSU.

This will be a quality improvement project. Study participants will be a convenience sample of OHSU faculty, staff, residents and students who are employed by or on rotation with General Medicine Team 1 of the Medicine Teaching Service. Faculty, staff, and learners (ACE team members) will receive the ACE training. Study personnel will conduct prospective and retrospective chart review of patients admitted to the ACE service to determine outcomes as noted above.","[(0, 35, 'OTHER', 'Acute Care for Elders (ACE) Program'), (144, 179, 'OTHER', 'Acute Care for Elders (ACE) program'), (311, 322, 'OTHER', 'ACE program'), (927, 938, 'OTHER', 'ACE program'), (1096, 1108, 'OTHER', 'ACE programs'), (1560, 1563, 'OTHER', 'ACE'), (1595, 1607, 'OTHER', 'ACE training'), (1709, 1720, 'OTHER', 'ACE service')]"
"['TNF', '-', 'related', 'Weak', 'Inducer', 'of', 'Apoptosis', '(', 'TWEAK', ')', ',', 'a', 'New', 'Biomarker', 'Predicting', 'Inflammatory', 'Thrust', 'in', 'Multiple', 'Sclerosis', '|', 'A', 'significant', 'variation', 'in', 'the', 'serum', 'concentration', 'of', 'the', 'circulating', 'cytokine', 'TWEAK', 'is', 'associated', 'with', 'the', 'onset', 'of', 'an', 'inflammatory', 'attack', 'of', 'MS', '.', 'Study', 'the', 'concentration', 'variations', 'of', 'the', 'serum', 'soluble', 'form', 'of', 'cytokine', 'TWEAK', 'during', 'the', 'first', 'year', 'of', 'MS', 'and', 'to', 'analyze', 'their', 'correlation', 'with', 'the', 'occurrence', 'of', 'an', 'inflammatory', 'disease', 'outbreak', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03974997,NCT03974997,"TNF-related Weak Inducer of Apoptosis (TWEAK), a New Biomarker Predicting Inflammatory Thrust in Multiple Sclerosis | A significant variation in the serum concentration of the circulating cytokine TWEAK is associated with the onset of an inflammatory attack of MS. Study the concentration variations of the serum soluble form of cytokine TWEAK during the first year of MS and to analyze their correlation with the occurrence of an inflammatory disease outbreak.","[(97, 115, 'CONDITION', 'Multiple Sclerosis'), (261, 263, 'CONDITION', 'MS'), (369, 371, 'CONDITION', 'MS')]"
"['Binocular', 'Amblyopia', 'Treatment', '|', 'To', 'evaluate', 'the', 'effectiveness', 'of', 'enhanced', 'binocular', 'amblyopia', 'treatments', 'in', 'achieving', 'a', 'more', 'complete', 'and', 'stable', 'recovery', '.']","['B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03288948,NCT03288948,Binocular Amblyopia Treatment | To evaluate the effectiveness of enhanced binocular amblyopia treatments in achieving a more complete and stable recovery.,"[(0, 19, 'CONDITION', 'Binocular Amblyopia'), (74, 93, 'CONDITION', 'binocular amblyopia')]"
"['Sleep', 'Disordered', 'Breathing', 'and', 'Its', 'Impact', 'on', 'Neuro', '-', 'cognitive', 'Performance', 'and', 'Quality', 'of', 'Life', 'in', 'Parkinson', 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'impact', 'of', 'sleep', 'and', 'breathing', 'problems', 'during', 'sleep', 'on', 'memory', ',', 'attention', ',', 'and', 'general', 'well', 'being', '(', 'quality', 'of', 'life', ')', 'in', 'people', 'with', 'Parkinson', 'Disease', '.']","['B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT02034357,NCT02034357,"Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease | The purpose of this study is to determine the impact of sleep and breathing problems during sleep on memory, attention, and general well being (quality of life) in people with Parkinson Disease.","[(0, 26, 'CONDITION', 'Sleep Disordered Breathing'), (96, 113, 'CONDITION', 'Parkinson Disease'), (172, 200, 'CONDITION', 'sleep and breathing problems'), (292, 309, 'CONDITION', 'Parkinson Disease')]"
"['Study', 'of', 'Evaluating', 'Quetiapine', 'in', 'Improving', 'Sleep', 'Quality', 'of', 'Schizophrenia', '|', 'This', 'study', 'will', 'apply', 'polysomnography', '(', 'PSG', ')', 'to', 'evaluate', 'the', 'effect', 'of', 'quetiapine', 'fumarate', 'on', 'sleep', 'architecture', '.', 'Most', 'of', 'previous', 'studies', 'evaluated', 'sleep', 'by', 'self', '-', 'reported', 'questionnaires', 'during', 'the', 'antipsychotic', 'treatment', '(', 'clozapine', ',', 'risperidone', ',', 'olanzapine', ',', 'et', 'al', ')', ',', 'while', 'only', 'a', 'few', 'studies', 'with', 'PSG', 'evaluation', 'had', 'some', 'limitation', ',', 'such', 'as', ':', 'small', 'sample', 'size', ',', 'respective', 'or', 'cross', '-', 'sectional', ',', 'potential', 'sleep', 'disorders', ',', 'et', 'al', '.', 'In', 'this', 'study', ',', 'we', 'will', 'investigate', 'both', 'subjective', 'and', 'objective', 'effect', 'of', 'quetiapine', 'fumarate', 'in', 'improving', 'sleep', 'quality', 'in', 'schizophrenic', 'patients', 'by', 'PSG', 'as', 'well', 'as', 'psychiatric', 'scales', '.', 'The', 'control', 'drug', 'in', 'this', 'study', 'is', 'the', 'typical', 'antipsychotic', '-', 'haloperidol', '.', 'It', 'could', 'increase', 'sleep', 'duration', 'and', 'efficiency', 'by', 'mostly', 'increasing', 'the', 'S2', 'without', 'effect', 'on', 'rapid', 'eye', 'movement', '(', 'REM', ')', 'sleep', 'and', 'slow', 'wave', 'sleep', '(', 'SWS', ')', '.', 'The', 'patients', 'will', 'be', 'randomised', 'into', 'two', 'groups', 'as', 'a', 'parallel', 'design', '.', 'This', 'study', 'is', 'designed', 'as', 'rater', 'blinded', 'to', 'reduce', 'the', 'bias', 'in', 'evaluation', '.', 'It', 'is', 'suggested', 'that', 'the', 'sedative', 'effect', 'of', 'quetiapine', 'fumarate', 'could', 'diminish', 'in', '2', 'weeks', ',', 'therefore', ',', 'we', 'use', '4', 'weeks', 'to', 'ensure', 'the', 'change', 'of', 'sleep', 'quality', 'in', 'this', 'study', ',', 'which', 'could', 'be', 'helpful', 'for', 'the', 'evaluation', 'of', 'relative', 'short', 'and', 'middle', 'term', 'effect', 'of', 'quetiapine', 'fumarate', 'on', 'sleep', 'quality', '.']","['O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O']",NCT00642369,NCT00642369,"Study of Evaluating Quetiapine in Improving Sleep Quality of Schizophrenia | This study will apply polysomnography (PSG) to evaluate the effect of quetiapine fumarate on sleep architecture. Most of previous studies evaluated sleep by self-reported questionnaires during the antipsychotic treatment (clozapine, risperidone, olanzapine, et al), while only a few studies with PSG evaluation had some limitation, such as: small sample size, respective or cross-sectional, potential sleep disorders, et al. In this study, we will investigate both subjective and objective effect of quetiapine fumarate in improving sleep quality in schizophrenic patients by PSG as well as psychiatric scales. The control drug in this study is the typical antipsychotic - haloperidol. It could increase sleep duration and efficiency by mostly increasing the S2 without effect on rapid eye movement (REM) sleep and slow wave sleep (SWS). The patients will be randomised into two groups as a parallel design. This study is designed as rater blinded to reduce the bias in evaluation. It is suggested that the sedative effect of quetiapine fumarate could diminish in 2 weeks, therefore, we use 4 weeks to ensure the change of sleep quality in this study, which could be helpful for the evaluation of relative short and middle term effect of quetiapine fumarate on sleep quality.","[(20, 30, 'DRUG', 'Quetiapine'), (61, 74, 'CONDITION', 'Schizophrenia'), (147, 166, 'DRUG', 'quetiapine fumarate'), (577, 596, 'DRUG', 'quetiapine fumarate'), (627, 640, 'CONDITION', 'schizophrenic'), (750, 761, 'DRUG', 'haloperidol'), (1103, 1122, 'DRUG', 'quetiapine fumarate'), (1315, 1334, 'DRUG', 'quetiapine fumarate')]"
"['A', 'Phase', 'IIIb', 'Multicenter', ',', 'Open', '-', 'label', ',', 'Single', 'Arm', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Pasireotide', 'in', 'Patients', 'With', 'Acromegaly', 'Inadequately', 'Controlled', 'With', 'First', 'Generation', 'Somatostatin', 'Analogues', '|', 'This', 'is', 'a', 'phase', 'IIIb', 'multicenter', ',', 'open', '-', 'label', ';', 'single', 'arm', 'study', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'pasireotide', 'LAR', '40', 'mg', 'and', '60', 'mg', 'in', 'patients', 'with', 'inadequately', 'controlled', 'acromegaly', 'with', 'maximal', 'approved', 'doses', 'of', 'first', 'generation', 'somatostatin', 'analogues', '.', 'The', 'study', 'will', 'enroll', 'inadequately', 'controlled', 'patients', 'by', 'high', 'doses', '(', 'maximal', 'approved', ')', 'of', 'first', '-', 'generation', 'somatostatin', 'analogues', 'given', 'for', 'at', 'least', '3', 'months', '.', 'Patients', 'will', 'receive', 'pasireotide', 'LAR', '40', 'mg', 'or', '60', 'mg', 'during', 'the', '36', 'week', 'core', 'study', 'phase', '.', 'Patients', 'who', 'have', 'completed', 'all', 'visits', 'of', 'core', 'phase', 'and', 'have', 'completed', 'all', 'the', 'assessments', 'at', 'the', 'core', 'phase', 'completion', 'visit', 'can', 'move', 'into', 'the', '32', '-', 'week', 'extension', 'phase', '.', 'Patients', 'can', 'continue', 'with', 'study', 'treatment', 'until', 'pasireotide', 'LAR', 'is', 'commercially', 'available', 'and', 'reimbursed', 'in', 'their', 'respective', 'country', 'or', 'until', 'the', 'end', 'of', 'the', 'extension', 'phase', 'whichever', 'occurs', 'first', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02354508,NCT02354508,"A Phase IIIb Multicenter, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues | This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly with maximal approved doses of first generation somatostatin analogues. The study will enroll inadequately controlled patients by high doses (maximal approved) of first-generation somatostatin analogues given for at least 3 months. Patients will receive pasireotide LAR 40 mg or 60 mg during the 36 week core study phase. Patients who have completed all visits of core phase and have completed all the assessments at the core phase completion visit can move into the 32-week extension phase. Patients can continue with study treatment until pasireotide LAR is commercially available and reimbursed in their respective country or until the end of the extension phase whichever occurs first.","[(94, 105, 'DRUG', 'Pasireotide'), (123, 157, 'CONDITION', 'Acromegaly Inadequately Controlled'), (180, 202, 'DRUG', 'Somatostatin Analogues'), (307, 318, 'DRUG', 'pasireotide'), (356, 390, 'CONDITION', 'inadequately controlled acromegaly'), (439, 461, 'DRUG', 'somatostatin analogues'), (571, 593, 'DRUG', 'somatostatin analogues'), (645, 656, 'DRUG', 'pasireotide'), (932, 943, 'DRUG', 'pasireotide')]"
"['The', 'Effect', 'of', 'Plantar', 'Vibration', 'on', 'the', 'Progression', 'of', 'Peripheral', 'Neuropathy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'effect', 'of', 'vibration', 'of', 'the', 'plantar', 'surface', 'of', 'the', 'foot', 'on', 'peripheral', 'neuropathy', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O']",NCT00822198,NCT00822198,The Effect of Plantar Vibration on the Progression of Peripheral Neuropathy | The purpose of this study is to assess the effect of vibration of the plantar surface of the foot on peripheral neuropathy.,"[(14, 31, 'OTHER', 'Plantar Vibration'), (54, 75, 'CONDITION', 'Peripheral Neuropathy'), (131, 175, 'OTHER', 'vibration of the plantar surface of the foot'), (179, 200, 'CONDITION', 'peripheral neuropathy')]"
"['Comparison', 'of', 'the', 'Effectiveness', 'of', 'Low', '-', 'intensity', 'Laser', 'and', 'ESWT', 'Treatments', 'in', 'Carpal', 'Tunnel', 'Syndrome', '|', 'Carpal', 'tunnel', 'syndrome', 'is', 'the', 'most', 'common', 'neuropathy', 'of', 'the', 'median', 'nerve', '.', 'Conservative', 'methods', 'are', 'used', 'in', 'mild', 'and', 'moderate', 'CTS', 'in', 'the', 'treatment', '.', 'In', 'this', 'study', ',', 'we', 'aimed', 'to', 'compare', 'the', 'effectiveness', 'of', 'low', '-', 'intensity', 'laser', 'and', 'ESWT', 'treatments', 'in', 'patients', 'with', 'mild', 'and', 'moderate', 'carpal', 'tunnel', 'syndrome', 'diagnosed', 'with', 'EMG', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O']",NCT05589805,NCT05589805,"Comparison of the Effectiveness of Low-intensity Laser and ESWT Treatments in Carpal Tunnel Syndrome | Carpal tunnel syndrome is the most common neuropathy of the median nerve. Conservative methods are used in mild and moderate CTS in the treatment. In this study, we aimed to compare the effectiveness of low-intensity laser and ESWT treatments in patients with mild and moderate carpal tunnel syndrome diagnosed with EMG.","[(35, 54, 'OTHER', 'Low-intensity Laser'), (59, 63, 'OTHER', 'ESWT'), (78, 100, 'CONDITION', 'Carpal Tunnel Syndrome'), (103, 125, 'CONDITION', 'Carpal tunnel syndrome'), (210, 231, 'CONDITION', 'mild and moderate CTS'), (306, 325, 'OTHER', 'low-intensity laser'), (330, 334, 'OTHER', 'ESWT'), (363, 403, 'CONDITION', 'mild and moderate carpal tunnel syndrome')]"
"['Anticoagulation', 'for', 'New', '-', 'Onset', 'Post', '-', 'Operative', 'Atrial', 'Fibrillation', 'After', 'CABG', '|', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', '(', 'prevention', 'of', 'thromboembolic', 'events', ')', 'and', 'safety', '(', 'major', 'bleeding', ')', 'of', 'adding', 'oral', 'anticoagulation', '(', 'OAC', ')', 'to', 'background', 'antiplatelet', 'therapy', 'in', 'patients', 'who', 'develop', 'new', '-', 'onset', 'post', '-', 'operative', 'atrial', 'fibrillation', '(', 'POAF', ')', 'after', 'isolated', 'coronary', 'artery', 'bypass', 'graft', '(', 'CABG', ')', 'surgery', '.', '\n\n', 'All', 'patients', 'with', 'a', 'qualifying', 'POAF', 'event', ',', 'who', 'decline', 'randomization', ',', 'will', 'be', 'offered', 'the', 'option', 'of', 'enrollment', 'in', 'a', 'parallel', 'registry', 'that', 'captures', 'their', 'baseline', 'risk', 'profile', 'and', 'their', 'treatment', 'strategy', 'in', 'terms', 'of', 'anticoagulants', 'or', 'antiplatelets', 'received', '.', 'These', 'patients', 'will', 'also', 'be', 'asked', 'to', 'fill', 'out', 'a', 'brief', 'decliner', 'survey', '.']","['B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04045665,NCT04045665,"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.

All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.","[(0, 15, 'DRUG', 'Anticoagulation'), (20, 64, 'CONDITION', 'New-Onset Post-Operative Atrial Fibrillation'), (71, 75, 'CONDITION', 'CABG'), (223, 243, 'DRUG', 'oral anticoagulation'), (245, 248, 'DRUG', 'OAC'), (264, 284, 'DRUG', 'antiplatelet therapy'), (309, 353, 'CONDITION', 'new-onset post-operative atrial fibrillation'), (355, 359, 'CONDITION', 'POAF'), (367, 419, 'CONDITION', 'isolated coronary artery bypass graft (CABG) surgery'), (453, 457, 'CONDITION', 'POAF'), (639, 653, 'DRUG', 'anticoagulants'), (657, 670, 'DRUG', 'antiplatelets')]"
"['The', 'Effect', 'of', 'Vitamin', 'C', 'and', 'E', 'Therapy', 'on', 'Restless', 'Leg', 'Syndrome', 'in', 'Patients', 'With', 'End', 'Stage', 'Renal', 'Disease', 'on', 'Haemodialysis', '|', 'This', 'study', 'aims', 'to', 'measure', 'the', 'effectiveness', 'of', 'vitamins', 'C', 'and', 'E', 'on', 'relieving', 'RLS', 'symptoms', 'in', 'end', 'stage', 'renal', 'disease', 'patients', 'on', 'HD']","['O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND']",NCT05350124,NCT05350124,The Effect of Vitamin C and E Therapy on Restless Leg Syndrome in Patients With End Stage Renal Disease on Haemodialysis | This study aims to measure the effectiveness of vitamins C and E on relieving RLS symptoms in end stage renal disease patients on HD,"[(14, 29, 'DRUG', 'Vitamin C and E'), (41, 62, 'CONDITION', 'Restless Leg Syndrome'), (80, 103, 'CONDITION', 'End Stage Renal Disease'), (107, 120, 'CONDITION', 'Haemodialysis'), (171, 187, 'DRUG', 'vitamins C and E'), (201, 204, 'CONDITION', 'RLS'), (217, 240, 'CONDITION', 'end stage renal disease'), (253, 255, 'CONDITION', 'HD')]"
"['A', 'Phase', 'III', 'Trial', 'of', 'BUN', '/', 'Cr', '-', 'based', 'Hydration', 'Therapy', 'to', 'Reduce', 'Stroke', '-', 'in', '-', 'evolution', 'and', 'Improve', 'Short', '-', 'term', 'Functional', 'Outcomes', 'for', 'Dehydrated', 'Patients', 'With', 'Acute', 'Ischemic', 'Stroke', '|', 'The', 'investigators', ""'"", 'preliminary', 'findings', 'suggest', 'that', 'providing', 'patients', 'with', 'acute', 'ischemic', 'stroke', 'hydration', 'therapy', 'on', 'the', 'basis', 'of', 'their', 'presenting', 'BUN', '/', 'Cr', 'ratio', 'may', 'help', 'reduce', 'the', 'occurrence', 'of', 'stroke', '-', 'in', '-', 'evolution(SIE', ')', 'and', 'therefore', 'improve', 'prognosis', '.', '\n\n', 'The', 'trial', 'will', 'be', 'carried', 'out', 'in', 'two', 'parts', '.', 'Part', '1', 'assesses', 'the', 'rate', 'of', 'stroke', '-', 'in', '-', 'evolution', '72', 'hours', 'after', 'the', 'onset', 'of', 'stroke', 'as', 'a', 'measure', 'of', 'the', 'activity', 'of', 'BUN', '/', 'Cr', 'ratio', 'based', 'hydration', 'therapy', '.', 'Part', '2', ',', 'The', 'investigators', 'use', 'two', 'outcome', 'measures', ',', 'including', 'Barthel', 'index', ',', 'and', 'modified', 'Rankin', 'scale', 'for', 'neurological', 'evaluation', 'to', 'assess', 'whether', 'BUN', '/', 'Cr', 'ratio', 'based', 'hydration', 'therapy', 'results', 'in', 'sustained', 'clinical', 'benefit', 'at', 'three', 'months', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02099383,NCT02099383,"A Phase III Trial of BUN/Cr-based Hydration Therapy to Reduce Stroke-in-evolution and Improve Short-term Functional Outcomes for Dehydrated Patients With Acute Ischemic Stroke | The investigators' preliminary findings suggest that providing patients with acute ischemic stroke hydration therapy on the basis of their presenting BUN/Cr ratio may help reduce the occurrence of stroke-in-evolution(SIE) and therefore improve prognosis.

The trial will be carried out in two parts. Part 1 assesses the rate of stroke-in-evolution 72 hours after the onset of stroke as a measure of the activity of BUN/Cr ratio based hydration therapy. Part 2, The investigators use two outcome measures, including Barthel index, and modified Rankin scale for neurological evaluation to assess whether BUN/Cr ratio based hydration therapy results in sustained clinical benefit at three months.","[(21, 51, 'OTHER', 'BUN/Cr-based Hydration Therapy'), (62, 81, 'CONDITION', 'Stroke-in-evolution'), (129, 139, 'CONDITION', 'Dehydrated'), (154, 175, 'CONDITION', 'Acute Ischemic Stroke'), (255, 276, 'CONDITION', 'acute ischemic stroke'), (277, 340, 'OTHER', 'hydration therapy on the basis of their presenting BUN/Cr ratio'), (375, 398, 'CONDITION', 'stroke-in-evolution(SIE'), (506, 525, 'CONDITION', 'stroke-in-evolution'), (554, 560, 'CONDITION', 'stroke'), (593, 629, 'OTHER', 'BUN/Cr ratio based hydration therapy'), (780, 816, 'OTHER', 'BUN/Cr ratio based hydration therapy')]"
"['Behavioral', 'Treatment', 'of', 'Drug', 'Abuse', 'in', 'SPMI', 'Patients', '|', 'The', 'main', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'the', 'multifaceted', 'treatment', 'for', 'substance', 'abuse', 'in', 'dual', 'disordered', 'patients', 'is', 'more', 'effective', 'in', 'reducing', 'drug', 'use', 'than', 'a', 'supportive', 'control', 'treatment', '.', 'The', 'researchers', 'will', 'also', 'determine', 'if', 'adding', 'a', 'case', 'management', 'component', '(', 'Critical', 'Time', 'Intervention', ';', 'CTI', ')', 'to', 'the', 'intervention', 'will', 'increase', 'treatment', 'engagement', 'and', 'retention', '.']","['B-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00295139,NCT00295139,Behavioral Treatment of Drug Abuse in SPMI Patients | The main purpose of this study is to determine if the multifaceted treatment for substance abuse in dual disordered patients is more effective in reducing drug use than a supportive control treatment. The researchers will also determine if adding a case management component (Critical Time Intervention; CTI) to the intervention will increase treatment engagement and retention.,"[(0, 20, 'BEHAVIOURAL', 'Behavioral Treatment'), (24, 34, 'CONDITION', 'Drug Abuse'), (38, 42, 'CONDITION', 'SPMI'), (108, 150, 'BEHAVIOURAL', 'multifaceted treatment for substance abuse'), (225, 253, 'CONTROL', 'supportive control treatment'), (303, 328, 'BEHAVIOURAL', 'case management component'), (330, 356, 'BEHAVIOURAL', 'Critical Time Intervention'), (358, 361, 'BEHAVIOURAL', 'CTI')]"
"['The', 'Feasibility', 'and', 'Efficacy', 'of', 'Baduanjin', 'Exercise', 'on', 'Cognition', 'and', 'Physical', 'Fitness', 'Among', 'Patients', 'With', 'Schizophrenia', ':', 'Randomized', 'Controlled', 'Trial', '|', 'As', 'an', 'ancient', ',', 'popular', 'Chinese', 'exercise', ',', 'Baduanjin', 'is', 'characterized', 'by', 'symmetrical', 'posture', ',', 'deep', 'breathing', 'and', 'meditation', 'and', 'easy', 'to', 'learn', '.', 'Previous', 'studies', 'showed', 'immediate', 'effect', 'of', 'Baduanjin', 'on', 'cognition', 'in', 'patients', 'with', 'schizophrenia', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'immediate', 'effect', 'and', 'chronic', 'effect', 'of', 'Baduanjin', 'exercise', 'on', 'physical', 'fitness', ',', 'cognition', 'and', 'daily', 'functions', 'in', 'middle', '-', 'aged', 'and', 'older', 'adults', 'with', 'schizophrenia', '.']","['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04430309,NCT04430309,"The Feasibility and Efficacy of Baduanjin Exercise on Cognition and Physical Fitness Among Patients With Schizophrenia:Randomized Controlled Trial | As an ancient, popular Chinese exercise, Baduanjin is characterized by symmetrical posture, deep breathing and meditation and easy to learn. Previous studies showed immediate effect of Baduanjin on cognition in patients with schizophrenia.The purpose of this study is to investigate the immediate effect and chronic effect of Baduanjin exercise on physical fitness, cognition and daily functions in middle-aged and older adults with schizophrenia.","[(32, 41, 'PHYSICAL', 'Baduanjin'), (105, 118, 'CONDITION', 'Schizophrenia'), (190, 199, 'PHYSICAL', 'Baduanjin'), (334, 343, 'PHYSICAL', 'Baduanjin'), (374, 387, 'CONDITION', 'schizophrenia'), (475, 484, 'PHYSICAL', 'Baduanjin'), (582, 595, 'CONDITION', 'schizophrenia')]"
"['Impact', 'of', 'Early', 'and', 'Intensive', 'Bimanual', 'Stimulation', 'on', 'the', 'Evolution', 'of', 'Bimanual', 'Function', 'in', 'Infants', 'With', 'Clinical', 'Findings', 'Suggesting', 'Unilateral', 'Cerebral', 'Palsy', '(', 'BB', '-', 'BIM', ')', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'measure', 'the', 'impact', 'of', 'early', 'bimanual', 'stimulation', 'in', 'babies', 'with', 'clinical', 'signs', 'of', 'underuse', 'of', 'one', 'hand', '.', 'The', 'observation', 'focuses', 'on', 'the', 'developmental', 'curve', 'of', 'hands', 'use', '.', 'The', 'intervention', 'is', 'provided', 'by', 'the', 'family', 'environment', 'and', 'takes', 'place', 'in', 'the', 'child', ""'s"", 'familiar', 'surroundings', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04899284,NCT04899284,Impact of Early and Intensive Bimanual Stimulation on the Evolution of Bimanual Function in Infants With Clinical Findings Suggesting Unilateral Cerebral Palsy (BB-BIM) | The aim of this study is to measure the impact of early bimanual stimulation in babies with clinical signs of underuse of one hand. The observation focuses on the developmental curve of hands use. The intervention is provided by the family environment and takes place in the child's familiar surroundings.,"[(10, 50, 'OTHER', 'Early and Intensive Bimanual Stimulation'), (134, 159, 'CONDITION', 'Unilateral Cerebral Palsy'), (221, 247, 'OTHER', 'early bimanual stimulation')]"
"['Assessing', 'Outcomes', 'of', 'Enhanced', 'Chronic', 'Disease', 'Care', 'Through', 'Patient', 'Education', 'and', 'a', 'Value', '-', 'based', 'Formulary', 'Study', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'effect', 'of', 'two', 'novel', 'interventions', ';', '(', '1', ')', 'a', 'value', '-', 'based', 'formulary', 'which', 'eliminates', 'copayment', 'for', 'selected', 'high', '-', 'value', 'medications', '(', 'proven', 'to', 'prevent', 'heart', 'attacks', ',', 'stroke', ',', 'and', 'hospitalizations', ')', ';', 'and', '(', '2', ')', 'a', 'comprehensive', 'patient', 'education', 'program', 'aimed', 'at', 'lifestyle', 'modification', 'and', 'optimal', 'drug', 'use', ',', 'combined', 'with', 'relay', 'of', 'information', 'on', 'medication', 'use', ',', 'on', 'the', 'risk', 'of', 'adverse', 'clinical', 'outcomes', '(', 'mortality', ',', 'heart', 'attack', ',', 'stroke', ',', 'need', 'for', 'coronary', 'revascularization', ',', 'and', 'chronic', 'disease', 'related', 'hospitalizations', ')', 'in', 'low', '-', 'income', 'seniors', 'with', 'chronic', 'conditions', 'over', 'three', 'years', 'of', 'follow', '-', 'up', 'or', 'until', 'March', '31', ',', '2021', '(', 'whichever', 'comes', 'first', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02579655,NCT02579655,"Assessing Outcomes of Enhanced Chronic Disease Care Through Patient Education and a Value-based Formulary Study | The purpose of this study is to determine the effect of two novel interventions; (1) a value-based formulary which eliminates copayment for selected high-value medications (proven to prevent heart attacks, stroke, and hospitalizations); and (2) a comprehensive patient education program aimed at lifestyle modification and optimal drug use, combined with relay of information on medication use, on the risk of adverse clinical outcomes (mortality, heart attack, stroke, need for coronary revascularization, and chronic disease related hospitalizations) in low-income seniors with chronic conditions over three years of follow-up or until March 31, 2021 (whichever comes first).","[(60, 77, 'BEHAVIOURAL', 'Patient Education'), (84, 105, 'OTHER', 'Value-based Formulary'), (201, 222, 'OTHER', 'value-based formulary'), (375, 392, 'BEHAVIOURAL', 'patient education'), (562, 574, 'CONDITION', 'heart attack'), (576, 582, 'CONDITION', 'stroke')]"
"['A', 'Double', 'Blind', ',', 'Placebo', '-', 'controlled', 'Study', 'for', 'the', 'Effect', 'of', 'IV', 'Amantadine', 'on', 'Freezing', 'of', 'Gait', '(', 'FOG', ')', 'Resistant', 'to', 'Dopaminergic', 'Therapy', '|', 'Tp', 'determine', 'the', 'effect', 'of', 'IV', 'amantadine', 'on', 'dopaminergic', '-', 'drug', '-', 'resistant', 'freezing', 'of', 'gait(FOG)in', 'patients', 'with', 'Parkinson', ""'s"", 'disease']","['O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT01313819,NCT01313819,"A Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy | Tp determine the effect of IV amantadine on dopaminergic-drug-resistant freezing of gait(FOG)in patients with Parkinson's disease","[(16, 23, 'CONTROL', 'Placebo'), (59, 72, 'DRUG', 'IV Amantadine'), (76, 92, 'CONDITION', 'Freezing of Gait'), (94, 97, 'CONDITION', 'FOG'), (99, 132, 'CONDITION', 'Resistant to Dopaminergic Therapy'), (162, 175, 'DRUG', 'IV amantadine'), (245, 264, 'CONDITION', ""Parkinson's disease"")]"
"['Optimizing', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'for', 'Motor', 'Recovery', 'From', 'Severe', 'Post', '-', 'stroke', 'Hemiparesis', '|', 'This', 'study', 'will', 'compare', 'the', 'effectiveness', 'of', 'different', 'polarities', 'of', 'transcranial', 'direct', 'current', 'stimulation', 'paired', 'with', 'intensive', 'motor', 'training', 'in', 'recovery', 'of', 'upper', 'extremity', 'function', 'in', 'individuals', 'with', 'severe', 'post', '-', 'stroke', 'hemiparesis', '.', 'The', 'hypothesis', 'is', 'that', 'more', 'severely', 'impaired', 'individuals', 'will', 'derive', 'greater', 'benefit', 'from', 'anodal', 'stimulation', 'of', 'the', 'ipsilesional', 'hemisphere', 'or', 'cathodal', 'stimulation', 'of', 'the', 'contralesional', 'hemisphere', 'than', 'dual', 'stimulation', '(', 'anodal', 'applied', 'to', 'the', 'ipsilesional', 'hemisphere', 'and', 'cathodal', 'applied', 'to', 'the', 'contralesional', 'hemisphere', '.', ')']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03124147,NCT03124147,Optimizing Transcranial Direct Current Stimulation for Motor Recovery From Severe Post-stroke Hemiparesis | This study will compare the effectiveness of different polarities of transcranial direct current stimulation paired with intensive motor training in recovery of upper extremity function in individuals with severe post-stroke hemiparesis. The hypothesis is that more severely impaired individuals will derive greater benefit from anodal stimulation of the ipsilesional hemisphere or cathodal stimulation of the contralesional hemisphere than dual stimulation (anodal applied to the ipsilesional hemisphere and cathodal applied to the contralesional hemisphere.),"[(11, 50, 'OTHER', 'Transcranial Direct Current Stimulation'), (75, 105, 'CONDITION', 'Severe Post-stroke Hemiparesis'), (177, 216, 'OTHER', 'transcranial direct current stimulation'), (229, 253, 'PHYSICAL', 'intensive motor training'), (314, 344, 'CONDITION', 'severe post-stroke hemiparesis'), (437, 486, 'OTHER', 'anodal stimulation of the ipsilesional hemisphere'), (490, 543, 'OTHER', 'cathodal stimulation of the contralesional hemisphere'), (549, 565, 'CONTROL', 'dual stimulation')]"
"['Testing', 'of', 'a', 'Tool', 'to', 'Elicit', 'Patient', 'Preferences', 'for', 'CTS', '|', 'This', 'study', 'will', 'complete', 'a', 'randomized', 'controlled', 'trial', 'to', 'quantitatively', 'measure', 'patient', 'decisional', 'conflict', '(', 'Decisional', 'Conflict', 'Scale', ')', 'in', '150', 'patients', 'treated', 'for', 'CTS', 'with', 'the', 'tool', 'compared', 'to', '150', 'patients', 'treated', 'with', 'standard', 'care', '.', 'The', 'investigators', 'hypothesize', 'patients', 'treated', 'for', 'CTS', 'will', 'have', 'lower', 'decisional', 'conflict', 'with', 'the', 'tool', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03532373,NCT03532373,Testing of a Tool to Elicit Patient Preferences for CTS | This study will complete a randomized controlled trial to quantitatively measure patient decisional conflict (Decisional Conflict Scale) in 150 patients treated for CTS with the tool compared to 150 patients treated with standard care. The investigators hypothesize patients treated for CTS will have lower decisional conflict with the tool.,[]
"['The', 'Relationship', 'Between', 'Post', 'Dural', 'Puncture', 'Headache', 'and', 'Joint', 'Laxity', '|', 'Post', '-', 'spinal', 'headache', 'is', 'divided', 'into', '3', 'according', 'to', 'the', 'severity', 'scale', '.', 'It', 'is', 'divided', 'into', '3', 'groups', 'as', 'mild', ',', 'moderate', 'and', 'severe', 'according', 'to', 'the', 'presence', 'of', 'symptoms', 'such', 'as', 'nausea', ',', 'vomiting', ',', 'and', 'dizziness', 'that', 'prevent', 'daily', 'activity', '.', '\n\n', 'It', 'has', 'been', 'reported', 'that', 'CSF', 'leakage', 'may', 'be', 'higher', 'due', 'to', 'the', 'weakness', 'of', 'the', 'regional', 'dural', 'sac', 'in', 'primary', 'connective', 'tissue', 'diseases', 'with', 'joint', 'laxity', 'and', 'isolated', 'joint', 'hypermobility', '.', 'Joint', 'laxity', 'is', 'scored', 'according', 'to', 'the', 'level', 'of', 'motion', 'in', '5', 'different', 'joints', 'and', 'a', 'maximum', 'of', '9', 'points', 'is', 'obtained', '.', '\n\n', 'In', 'this', 'study', ',', 'it', 'was', 'aimed', 'to', 'investigate', 'whether', 'joint', 'laxity', 'contributes', 'to', 'the', 'development', 'of', 'post', '-', 'spinal', 'headache', 'by', 'questioning', 'the', 'correlation', 'between', 'joint', 'laxity', 'examination', 'score', 'and', 'postspinal', 'headache', 'in', 'patients', 'with', 'post', '-', 'spinal', 'headache', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT05212194,NCT05212194,"The Relationship Between Post Dural Puncture Headache and Joint Laxity | Post-spinal headache is divided into 3 according to the severity scale. It is divided into 3 groups as mild, moderate and severe according to the presence of symptoms such as nausea, vomiting, and dizziness that prevent daily activity.

It has been reported that CSF leakage may be higher due to the weakness of the regional dural sac in primary connective tissue diseases with joint laxity and isolated joint hypermobility. Joint laxity is scored according to the level of motion in 5 different joints and a maximum of 9 points is obtained.

In this study, it was aimed to investigate whether joint laxity contributes to the development of post-spinal headache by questioning the correlation between joint laxity examination score and postspinal headache in patients with post-spinal headache.","[(25, 53, 'CONDITION', 'Post Dural Puncture Headache'), (58, 70, 'CONDITION', 'Joint Laxity'), (73, 93, 'CONDITION', 'Post-spinal headache'), (451, 463, 'CONDITION', 'joint laxity'), (477, 496, 'CONDITION', 'joint hypermobility'), (498, 510, 'CONDITION', 'Joint laxity'), (667, 679, 'CONDITION', 'joint laxity'), (714, 734, 'CONDITION', 'post-spinal headache'), (774, 786, 'CONDITION', 'joint laxity'), (809, 828, 'CONDITION', 'postspinal headache'), (846, 866, 'CONDITION', 'post-spinal headache')]"
"['Investigation', 'of', 'the', 'Efficacy', 'of', 'Virtual', 'Reality', 'Mediated', 'Neurodynamic', 'Exercises', 'in', 'Carpal', 'Tunnel', 'Syndrome', ':', 'A', 'Prospective', 'Randomized', 'Controlled', 'Clinical', 'Study', '|', 'Carpal', 'tunnel', 'syndrome', '(', 'CTS', ')', 'is', 'the', 'most', 'common', 'nerve', 'entrapment', 'syndrome', '.', 'It', 'occurs', 'as', 'a', 'result', 'of', 'compression', 'of', 'the', 'median', 'nerve', 'as', 'it', 'passes', 'through', 'a', 'restricted', 'osteofibrous', 'canal', 'in', 'the', 'wrist', '.', 'Known', 'as', 'the', 'carpal', 'tunnel', ',', 'this', 'canal', 'contains', 'the', 'wrist', 'bones', ',', 'transverse', 'carpal', 'ligament', ',', 'median', 'nerve', ',', 'and', 'digital', 'flexor', 'tendons', '.', 'Edema', ',', 'tendon', 'inflammation', ',', 'hormonal', 'changes', ',', 'and', 'manual', 'activity', 'can', 'contribute', 'to', 'increased', 'nerve', 'compression', 'and', 'sometimes', 'cause', 'pain', '.', '\n\n', 'In', 'this', 'research', ',', 'the', 'investigators', 'aim', 'to', 'present', 'the', 'virtual', 'reality', '-', 'mediated', 'exercise', 'program', 'to', 'patients', 'non', '-', 'immersive', '.', 'It', 'is', 'planned', 'to', 'use', 'the', 'Leap', 'Motion', 'motion', 'sensor', 'to', 'detect', 'hand', 'and', 'wrist', 'movements', 'and', 'to', 'monitor', 'the', 'gamified', 'setup', 'on', 'the', 'computer', 'screen', '.', '\n\n', 'In', 'the', 'system', 'that', 'will', 'be', 'presented', 'via', 'computer', 'and', 'hand', 'motion', 'sensor', ',', 'the', 'patient', 'will', 'be', 'asked', 'to', 'perform', 'therapeutic', 'exercises', 'for', 'the', 'diagnosis', 'of', 'CTS', 'in', 'a', 'scenario', 'developed', 'through', 'virtual', 'reality', '.', 'The', 'investigators', 'predict', 'that', 'patients', 'will', 'actively', 'participate', 'in', 'virtual', 'reality', '-', 'mediated', 'therapeutic', 'exercise', 'program', 'with', 'high', 'motivation', 'and', 'their', 'functional', 'results', 'will', 'be', 'better', 'than', 'classical', 'exercise', 'programs', '.', '\n\n', 'In', 'our', 'research', ',', 'the', 'investigators', 'aim', 'to', 'present', 'the', 'tendon', 'and', 'nerve', 'gliding', 'exercises', 'with', 'proven', 'effectiveness', 'in', 'patients', 'with', 'CTS', ',', 'with', 'non', '-', 'immersive', 'virtual', 'reality', 'systems', ',', 'and', 'to', 'compare', 'their', 'effectiveness', 'with', 'the', 'classical', 'exercise', 'program', '.']","['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT05563909,NCT05563909,"Investigation of the Efficacy of Virtual Reality Mediated Neurodynamic Exercises in Carpal Tunnel Syndrome: A Prospective Randomized Controlled Clinical Study | Carpal tunnel syndrome (CTS) is the most common nerve entrapment syndrome. It occurs as a result of compression of the median nerve as it passes through a restricted osteofibrous canal in the wrist. Known as the carpal tunnel, this canal contains the wrist bones, transverse carpal ligament, median nerve, and digital flexor tendons. Edema, tendon inflammation, hormonal changes, and manual activity can contribute to increased nerve compression and sometimes cause pain.

In this research, the investigators aim to present the virtual reality-mediated exercise program to patients non-immersive. It is planned to use the Leap Motion motion sensor to detect hand and wrist movements and to monitor the gamified setup on the computer screen.

In the system that will be presented via computer and hand motion sensor, the patient will be asked to perform therapeutic exercises for the diagnosis of CTS in a scenario developed through virtual reality. The investigators predict that patients will actively participate in virtual reality-mediated therapeutic exercise program with high motivation and their functional results will be better than classical exercise programs.

In our research, the investigators aim to present the tendon and nerve gliding exercises with proven effectiveness in patients with CTS, with non-immersive virtual reality systems, and to compare their effectiveness with the classical exercise program.","[(33, 80, 'PHYSICAL', 'Virtual Reality Mediated Neurodynamic Exercises'), (84, 106, 'CONDITION', 'Carpal Tunnel Syndrome'), (161, 183, 'CONDITION', 'Carpal tunnel syndrome'), (185, 188, 'CONDITION', 'CTS'), (689, 730, 'PHYSICAL', 'virtual reality-mediated exercise program'), (1057, 1060, 'CONDITION', 'CTS'), (1093, 1108, 'PHYSICAL', 'virtual reality'), (1179, 1232, 'PHYSICAL', 'virtual reality-mediated therapeutic exercise program'), (1303, 1330, 'CONTROL', 'classical exercise programs'), (1387, 1421, 'PHYSICAL', 'tendon and nerve gliding exercises'), (1465, 1468, 'CONDITION', 'CTS'), (1475, 1512, 'OTHER', 'non-immersive virtual reality systems'), (1558, 1584, 'CONTROL', 'classical exercise program')]"
"['A', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Study', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Efficacy', 'of', 'NA-831', 'in', 'Alzheimer', 'Patients', 'With', 'Mild', 'Cognitive', 'Impairment', '|', 'This', 'study', 'seeks', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'NA-83', 'in', 'subjects', 'with', 'mild', 'cognitive', 'impairment', 'due', 'to', 'Alzheimer', ""'s"", 'Disease']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT03538522,NCT03538522,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment | This study seeks to evaluate the efficacy and safety of NA-83 in subjects with mild cognitive impairment due to Alzheimer's Disease","[(28, 35, 'CONTROL', 'Placebo'), (105, 111, 'DRUG', 'NA-831'), (115, 124, 'CONDITION', 'Alzheimer'), (139, 164, 'CONDITION', 'Mild Cognitive Impairment'), (223, 228, 'DRUG', 'NA-83'), (246, 271, 'CONDITION', 'mild cognitive impairment'), (279, 298, 'CONDITION', ""Alzheimer's Disease"")]"
"['Anger', 'Control', 'Training', 'for', 'Youth', 'With', 'Tourette', 'Syndrome', '|', 'This', 'is', 'a', 'clinical', 'study', 'of', 'a', 'cognitive', '-', 'behavioral', 'therapy', 'known', 'as', 'anger', 'control', 'training', 'in', 'adolescents', 'with', 'Tourette', 'Syndrome', 'and', 'explosive', ',', 'disruptive', 'behavior', '.', 'ACT', 'is', 'compared', 'to', 'treatment', 'as', 'usual', '(', 'TAU', ')', 'in', 'a', 'randomized', 'clinical', 'trial', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-BEH', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00486551,NCT00486551,"Anger Control Training for Youth With Tourette Syndrome | This is a clinical study of a cognitive-behavioral therapy known as anger control training in adolescents with Tourette Syndrome and explosive, disruptive behavior. ACT is compared to treatment as usual (TAU) in a randomized clinical trial.","[(0, 22, 'BEHAVIOURAL', 'Anger Control Training'), (38, 55, 'CONDITION', 'Tourette Syndrome'), (88, 116, 'BEHAVIOURAL', 'cognitive-behavioral therapy'), (126, 148, 'BEHAVIOURAL', 'anger control training'), (169, 186, 'CONDITION', 'Tourette Syndrome'), (191, 221, 'CONDITION', 'explosive, disruptive behavior'), (223, 226, 'BEHAVIOURAL', 'ACT'), (242, 260, 'CONTROL', 'treatment as usual'), (262, 265, 'CONTROL', 'TAU')]"
